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Chronic cerebral hypoperfusion resulting from cerebrovascular disease is associated with the 
development of white matter damage, cognitive impairment and dementia. Although 
incompletely understood, recent studies suggest neuroinflammation is a key mechanism 
driving vascular pathology, white matter damage and cognitive decline. Neuroinflammation is 
observed in various neurological conditions and is implicated in both the initiation and 
progression of dementia. Mutations in the microglial immunoreceptor triggering receptor 
expressed on myeloid cells 2 (TREM2) increase susceptibility to neurodegenerative 
conditions and dementia providing key evidence for the role of microglial dysfunction in 
dementia pathogenesis. Precisely how TREM2 dysfunction contributes to neurodegeneration 
and dementia remains to be established, particularly in relation to cerebrovascular causes of 
degeneration.  
To investigate the contribution of TREM2 to cerebrovascular-mediated white matter damage, 
the bilateral common carotid artery stenosis (BCAS) model of chronic cerebral hypoperfusion 
was implemented in wild type (WT) and TREM2-/- C57BL/6Ntac mice. Initial studies 
demonstrated 0.18 mm internal diameter microcoils failed to induce sufficient white matter 
pathology or neuroinflammatory changes in WT C57BL/6Ntac mice. However, implementation 
of microcoils with smaller internal diameters (0.16 mm) precipitated robust myelin damage 
associated with neuroinflammation. In the absence of TREM2 expression, myelin damage 
was exacerbated and microglial responses to BCAS were blunted as assessed by 
immunohistochemistry and flow cytometric analysis.  
Collectively, the data presented in this thesis suggest TREM2 plays a key role in regulating 
microglial responses to chronic cerebral hypoperfusion. Given that TREM2 deficiency 
exacerbated myelin damage, it appears TREM2 confers protection to cerebrovascular 
dysfunction. However, the precise mechanisms remain unclear. Furthermore, the effects of 
TREM2 deficiency on white matter function and cognition remain unknown. Future studies 
investigating the impact of chronic cerebral hypoperfusion on the microglial transcriptome will 
advance our understanding of microglial function and neuroinflammation in the context of 
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vascular cognitive impairment (VCI) and dementia. Such studies may reveal novel TREM2-





















Despite constituting only 2 % of total body mass, the brain requires 20 % of energy intake. As 
the brain has a high energy demand, efficient delivery of oxygen and other nutrients via the 
blood stream is crucial to maintain normal brain function. Ageing as well as vascular risk 
factors such as high blood pressure and diabetes cause damage to the brain’s blood vessels 
over time impairing blood flow to the brain, also known as chronic cerebral hypoperfusion. If 
blood flow to the brain is compromised, brain cells are starved of nutrients and this can result 
in tissue damage and lead to memory loss and dementia.  
The term ‘vascular cognitive impairment’ (VCI) is used to describe a loss of memory and 
thinking skills caused by damage to the brain’s blood vessels. VCI is the second most common 
cause of dementia and as yet, no effective treatment exists. Given that the number of people 
suffering from dementia is rising, it is crucial to gain a better understanding of the disease 
mechanisms to identify potential drug treatments. 
Recent experimental studies suggest brain inflammation, also known as neuroinflammation, 
may play a role in vascular-mediated brain damage and dementia. Within the brain, immune 
cells called microglia are primary drivers of neuroinflammation through the release of 
inflammatory molecules. Although neuroinflammation is usually initiated to protect the brain 
from damage or infection, if prolonged or dysregulated it can do more harm than good.  
Mutations in immune genes expressed by microglia such as triggering receptor expressed on 
myeloid cells 2 (TREM2) increase the risk of developing dementia providing key evidence that 
microglial dysfunction can contribute to dementia. Increased numbers of microglia are 
observed in areas of vascular-mediated brain damage. However, the precise function of 
microglia and whether they contribute to or protect from brain damage remains unclear. 





To understand how neuroinflammation and TREM2 contribute to vascular-mediated brain 
damage, chronic cerebral hypoperfusion was induced in mice which lack the TREM2 gene 
and resultant microglial responses and brain damage were investigated. Chronically reducing 
blood flow to the brain resulted in widespread damage associated with increased numbers of 
microglia. Interestingly, brain damage was worsened and microglial responses were 
dampened in mice which did not have the TREM2 gene.  
The results suggest TREM2 plays an important role in regulating microglial responses to 
chronically reduced brain blood flow and vascular-mediated brain damage. As mice lacking 
TREM2 had increased brain damage this suggests TREM2 regulates protective microglial 
processes. However, it remains unclear precisely what processes TREM2 may regulate to 
prevent brain damage. Furthermore, although mice without the TREM2 gene had increased 
brain damage, the impact on memory function has not yet been measured. Overall, this 
research demonstrates TREM2 regulated microglial functions play a key role in vascular 
mediated brain damage, however further work is necessary as understanding of these 
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 The cerebrovasculature 
Although the brain constitutes just 2 % of total body mass, 20-25 % of total oxygen and glucose 
intake is required for normal brain function (Clarke & Sokoloff, 1999). The cerebrovasculature 
is therefore crucial for the delivery of nutrients and removal of waste products to support 
normal brain function. The cerebrovasculature originates from the carotid and vertebral 
arteries in the neck joining the circle of Willis at the base of the brain (fig.1.1A). From the circle 
of Willis, the posterior, middle and anterior cerebral arteries extend across the brain surface 
providing a rich anastomotic network of pial arteries and arterioles. Pial vessels penetrating 
the cortical surface give rise to smaller penetrating arterioles and capillaries before reaching 
deeper subcortical white matter regions (fig.1.1B). Given that the brain is critically dependant 
on cerebral blood flow, the correct regulation of cerebral blood flow by cells of the 














Figure 1.1: The human cerebrovasculature. (A) The circle of Willis. (B) The cerebrovascular supply 
of the deep subcortical white matter. The middle and anterior cerebral arteries arise from the internal 
carotid at the circle of Willis and supply the cortical surface before penetrating the brain parenchyma 
and supplying deep subcortical structures. Adapted from: Iadecola, 2013. 
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 The neurogliovascular unit  
Within the brain, endothelial cells, pericytes, vascular smooth muscle cells (VSMCs), glia and 
neurons form the neurogliovascular unit (fig. 1.2A). Together these cells orchestrate 
coordinated responses to ensure cerebral blood flow is sufficient for the brain’s metabolic 
needs (Iadecola, 2010). Endothelial cells, astrocytes and mural cells (VSMCs and pericytes) 
form the blood brain barrier (BBB). Endothelial cells lacking fenestrae form the blood vessel 
wall providing a unique physical barrier limiting paracellular movement of solutes from the 
blood stream into the brain parenchyma and vice versa due to interconnecting tight junctions 
and adherens junctions. Low rates of endothelial transcytosis limits vesicle-mediated 
transcellular movement of solutes and expression of specialised transporters on luminal and 
abluminal membranes enables the selective influx or efflux of solutes across the endothelium. 
Whilst transporters such as glucose transport 1 (GLUT1) and amino acid transporters on the 
luminal membrane enable the influx of glucose and amino acids from the blood stream into 
the brain parenchyma, efflux transporters on the abluminal surface such as adenosine 
triphosphate (ATP) binding cassette transporters (ABC transporters) play a key role in the 
removal of waste or metabolic bi-products (Abbott et al., 2010). Endothelial cells also regulate 
vascular tone through the release of vasoactive factors in response to mechanical or chemical 
stimuli (Iadecola, 2010).  
Mural cells including VSMCs and pericytes envelop the abluminal portion of endothelial cells. 
While VSMCs surround the endothelium in larger arteries and arterioles, these are replaced 
by pericytes at the capillary level (fig. 1.2B). VSMCs react to a range of vasoactive agents and 
mediate blood vessel constriction or dilation via contractile proteins to ensure cerebral blood 
flow is maintained at 50 ml per 100 g of brain tissue per minute within a range of pressures 
(60-160 mmHg) (van Beek et al., 2008). This protective mechanism, known as cerebral 
autoregulation, minimises potentially damaging perfusion pressure fluctuations associated 
with daily living. In response to low perfusion pressure, VSMCs trigger arterial dilation resulting 
in reduced vascular resistance, increased cerebral blood flow and vice versa.  
 


















Figure 1.2: The neurogliovascular unit. A) The neurogliovascular unit consisting of the 
cerebrovasculature, glia (astrocytes, microglia and oligodendrocytes) and neurons. (B) Anatomy of the 
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At the level of the capillary, platelet derived growth factor β (PDGFβ) secreted by endothelial 
cells recruits pericytes to the vascular wall via platelet derived growth factor β receptor 
(PDGFβR). PDGFβ null mice demonstrate reduced pericyte coverage, microvessel 
abnormalities, microaneurysm and embryonic lethality (Lindahl et al., 1997). Pericyte deficient 
mice similarly demonstrate impaired capillary perfusion associated with BBB breakdown (Bell 
et al., 2010). In addition to maintenance of the BBB and cerebral blood flow, pericytes are also 
implicated in clearance of debris via phagocytosis, angiogenesis and regulation of leucocyte 
recruitment (Proebstl et al., 2012, Winkler, Sagare and Zlokovic, 2014). 
Astrocyte end feet contacting nodes of Ranvier and neuronal synapses detect neuronal activity 
and ensure metabolic need is matched with sufficient blood flow by releasing vasoactive 
factors at end feet contacting blood vessels, a process known as neurovascular coupling 
(Gordon, Howarth and MacVicar, 2016). Astrocytic end feet contacting the cerebrovasculature 
also play key roles in development and maintenance of the BBB (Cabezas et al. 2014). 
Neurons also directly contact blood vessels and regulate vascular tone through release of 
vasoactive factors (Hamel, 2006).  
Through the release of inflammatory mediators, microglia, the resident immune cells of the 
central nervous system (CNS), impact on neurovascular function by modulating BBB integrity, 
endothelial function and leucocyte recruitment (Thurgur and Pinteaux, 2019). Perivascular 
macrophage (PVMs) located within the perivascular space surrounding the basement 
membrane of penetrating arterioles also regulate neurovascular unit (NVU) integrity with 
suggested roles in waste clearance, antigen presentation and inflammatory cell recruitment in 
response to damage or infection (Polfliet et al., 2001, Hawkes and McLaurin, 2009, Zhang et 
al., 2011b). Given that the orchestrated interaction between multiple cell types of the NVU is 
crucial for the maintenance of cerebral blood flow and CNS homeostasis, damage to individual 
components can functionally impair the NVU and cerebrovascular integrity. If cerebral blood 
flow is compromised and autoregulation fails the brain attempts to compensate by increasing 
blood oxygen extraction (Cipolla, 2009). However, if the brain’s metabolic need continues to 
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exceed the ability to extract oxygen from the bloodstream ischaemia ensues leading to cell 
loss and tissue damage 
 Vascular cognitive impairment  
The term vascular cognitive impairment (VCI) was devised to encompass all forms of cognitive 
impairment primarily resulting from cerebrovascular dysfunction and accounts for 20 % of 
dementia cases (Farooq and Gorelick, 2013). Pathologies associated with VCI are highly 
heterogeneous and manifest as a spectrum of vascular lesions predominantly affecting the 
white matter. These pathologies include single (strategic) or multiple infarcts, lacunar infarcts, 
microinfarcts, white matter lesions, haemorrhage, microbleeds, enlarged perivascular spaces 












Figure 1.3: Pathological features of VCI. Pathologies associated with VCI are highly 
hetereogenous predominantly affecting the white matter of the brain consisting of cortical and 
subcortical infarcts, microinfarcts, enlarged perivascular spaces, haemorrhage and white matter 
lesions. In addition to local tissue damage, vascular injury can cause secondary neurodegeneration 
and cortical thinning resulting in brain atrophy.  
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Cerebral small vessel disease (cSVD), in which the small arteries, arterioles, capillaries and 
venules of the brain are damaged, is a primary cause of VCI. Whilst in vivo imaging of the 
brain’s microvasculature is not yet possible, detection of damage to the surrounding 
parenchyma enables diagnosis of cSVD. White matter hyperintensities, characterised 
pathologically by demyelination and axonal damage, in addition to lacunar infarcts, 
microbleeds, enlarged perivascular spaces and brain atrophy are common radiological 
features of cSVD (ter Telgte et al., 2018). Post-mortem studies demonstrate vascular 
pathologies including deposition of hyaline in vessel walls, arteriosclerosis, atherosclerosis, 
fibrinoid necrosis and venous collagenosis (Iadecola, 2013). The progressive accumulation of 
amyloid β (Aβ) in cerebrovasculature, known as cerebral amyloid angiopathy (CAA) is also 
associated with cSVD. Although highly prevalent in Alzheimer’s disease (AD) patients, CAA is 
frequently observed in the elderly in the absence of AD pathology (Vinters and Gilbert, 1983).  
The white matter of the brain is particularly susceptible to cerebrovascular dysfunction due to 
lack of collateral vessels and non-overlapping vascular territories (Iadecola, 2013). The brain’s 
white matter constitutes 50 % of total human brain volume containing glial cells including 
oligodendrocytes, astrocytes and microglia in addition to myelinated axons and blood vessels. 
Lipid rich oligodendrocyte processes extend and wrap around surrounding axons to form an 
insulating myelin sheath enabling saltatory conduction of action potentials limiting energy 
expenditure by restricting membrane depolarisation to nodes of Ranvier. Oligodendrocytes 
also provide support to axons through the release of trophic factors including insulin growth 
factor 1 (IGF-1) and glial cell derived neurotrophic factor (GDNF) (Wilkins et al., 2003). If 
myelin integrity is compromised, trophic support is lost impairing axon health. 
 As myelin is lost, the axon surface is increasingly exposed to neurotoxic stimuli in the 
surrounding microenvironment exacerbating damage. It is theorised damage to the white 
matter impairs cortical-cortical and cortical-subcortical connections within the brain leading to 
disruption of brain networks associated with VCI including processing speed and executive 
function (Lawrence et al., 2014). Studies have demonstrated key radiological features of cSVD 
including brain atrophy, lacunar infarction and white matter ultrastructural damage detected 
 
  8 
by diffusion tensor imaging (DTI) are associated with poorer processing speed and executive 
function (Lawrence et al., 2013, Nitkunan et al., 2008, Nitkunan et al., 2011). Furthermore, 
white matter damage on DTI predicts cognitive decline and progression to dementia 
(Zeestraten et al., 2017). As the lesions associated with VCI are highly diverse and often 
coexist in the same brain the extent of cognitive impairment can vary. This is particularly true 
in patients exhibiting strategic or multiple infarcts in which the degree of cognitive impairment 
can depend on lesion size and location. 
The incidence of cSVD is strongly influenced by aging and vascular risk factors including 
hypercholesterolaemia, smoking, hyperhomocysteinaemia, hypertension and diabetes 
(Dichgans and Leys, 2017). Importantly, many risk factors associated with cSVD can be 
treated or modified offering a potential strategy to reduce disease prevalence. Hereditary 
forms of cSVD include cerebral autosomal-dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL), caused by mutations in the neurogenic locus notch 
homolog protein 3 (NOTCH3) gene. Post-mortem studies demonstrate accumulation of 
granular osmiophilic deposits containing NOTCH3 protein in the cerebrovascular wall and 
vessel wall thickening in addition to VSMC loss (Sondergaard et al., 2017).  
On the other hand, cerebral autosomal-recessive arteriopathy with subcortical infarcts and 
leukoencephalopathy (CARASIL) is caused by mutations in the high temperature requirement 
A serine protease 1 (HTRA1) gene leading to defective transforming growth factor β (TGFβ) 
signalling and VSMC loss (Oide et al., 2008). Additional genetic causes of cSVD are caused 
by collagen alpha-1 (IV) chain (COL4A1) and collagen alpha-2 (IV) chain (COL4A2) gene 
mutations resulting in basement membrane defects and vessel wall thickening in addition to 
three prime repair exonuclease 1 (TREX1) gene mutations which cause autosomal dominant 
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Although VCI is suggested to account for 20 % of dementia cases it is now recognised there 
is substantial overlap with other dementias including AD. Neuropathological studies 
demonstrate up to 80 % of AD patients have cerebrovascular pathology (Toledo et al., 2013). 
The presence of vascular pathology lowers the threshold for cognitive impairment and 
dementia in AD (Esiri et al., 1999, Riekse et al., 2004, Snowdon et al., 1997). CSVD risk factors 
including hypertension, diabetes and hyperlipidaemia are similarly associated with AD and 
increase amyloid β (Aβ) and tau burden (Langbaum et al., 2012, Vemuri et al., 2017). 
Furthermore, VCI risk factors have been suggested to act synergistically with Aβ to induce tau 
deposition and cognitive impairment (Rabin et al., 2018, Rabin et al., 2019). Neuroimaging 
studies demonstrate cerebrovascular dysfunction occurs early during disease trajectory prior 
to Aβ deposition and may predict disease progression (Iturria-Medina et al., 2016, Yew, Nation 
and Alzheimer's Dis, 2017).  White matter changes are also observed years prior to symptom 
onset in familial forms of AD suggesting that vascular dysfunction and white matter injury has 
a causal role in AD pathogenesis (Lee et al., 2016, Caballero et al., 2018).   
Although cerebrovascular dysfunction plays a key role in cognitive impairment and dementia, 
the precise pathological mechanisms remain unclear. It is suggested that aging and vascular 
risk factors cause damage to the cerebrovasculature through several mechanisms including 
BBB breakdown, oxidative stress and neuroinflammation leading to the development of 
pathological lesions. Determining the mechanisms by which cSVD contributes to white matter 
damage and VCI in humans is difficult due to the presence of several confounding variables 
including age, gender and vascular risk factors. Numerous animal models have therefore been 
developed to recapitulate aspects of cSVD to investigate potential pathogenic mechanisms 
which contribute to white matter damage and cognitive decline. In addition to models which 
manipulate cerebral blood flow, several models have been developed which investigate how 
environmental and genetic risk factors contribute to white matter damage and cognitive 
impairment. 
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 Animal models of VCI 
 Bilateral common carotid artery occlusion 
Bilateral common carotid artery occlusion (BCCAO) by permanent occlusion or ligation of the 
carotid arteries was originally developed in rats to induce chronic cerebral hypoperfusion and 
precipitate white matter damage and cognitive impairment. Following vessel occlusion, 
animals demonstrate a 70 % reduction in cerebral blood flow immediately following surgery 
which gradually recovers to 40-50 % after 28 d (Tomimoto et al., 2003). Animals demonstrate 
disruption of the optic tract within the first 3 d with damage extending to other white matter 
regions such as the corpus callosum and internal capsule with longer durations of 
hypoperfusion (Otori et al., 2003, Wakita et al., 2002). Animals also demonstrate progressive 
hippocampal degeneration from as early as 2 w following surgery (Bennett et al., 1998, Farkas 
et al., 2006, Ohtaki et al., 2006). In addition to this, behavioural studies demonstrate increased 
escape latencies in the Morris water maze and increased errors in the radial arm maze 
compared to sham animals (Pappas et al., 1996, Bennett et al., 1998, Sopala and Danysz, 
2001).  
Although this model precipitates white matter damage and cognitive impairment, occlusion or 
ligation of the carotid arteries induces severe hypoperfusion associated with hippocampal 
neurodegeneration. Furthermore, the optic tract is highly susceptible to hypoperfusion-
mediated damage which may impact on cognitive assessments utilising visual cues. BCCAO 
is also limited to rats as they have a fully developed circle of Willis whilst certain mouse strains 
have under-developed posterior communicating arteries (Yang et al., 1997). Therefore, whilst 
carotid occlusion is compensated by the vertebral circulation in rats, carotid occlusion induces 
extensive ischaemic damage in mice (Kitagawa et al., 1998, Yang et al., 1997).  
 Bilateral common carotid artery stenosis  
The BCCAO model was therefore refined leading to development of the bilateral common 
carotid artery stenosis (BCAS) model. Placement of microcoils on the carotid arteries leads to 
partial, rather than complete occlusion of the carotid arteries meaning this model can be 
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implemented in mouse strains with underdeveloped posterior communicating arteries 
(Shibata, et al. 2004). Furthermore, the acute reduction in cerebral blood flow following 
microcoil placement is less severe than that caused by BCCAO. Application of 0.18 mm 
internal diameter microcoils induces an initial 30 - 40 % reduction in cerebral blood flow which 
gradually recovers to 15- 30 % of baseline 1 – 3 months following surgery in young mice. 
(Shibata et al., 2004, Nishio et al., 2010, McQueen et al., 2014).  
Myelin disruption characterised by nodal/ paranodal breakdown is observed 3 d after BCAS 
and microarray analysis of white matter demonstrates alterations in various cell processes 
including cell proliferation, angiogenesis and inflammation (Reimer et al., 2011). Diffuse white 
matter damage coinciding with astrocyte and microglial activation is observed 1 m after BCAS 
associated with working memory impairment in the absence of grey matter damage (Coltman 
et al., 2011, Reimer et al., 2011, Shibata et al., 2007, Shibata et al., 2004). With prolonged 
BCAS (6 - 8 m), further loss of white matter integrity is accompanied by BBB disruption, 
development of cortical and subcortical ischaemic and haemorrhagic lesions and additional 
spatial reference memory impairment coinciding with hippocampal atrophy (Holland et al., 
2015, Nishio et al., 2010).   
In addition to recapitulating various pathological features of cSVD, the BCAS model provides 
a platform to investigate how loss of white matter integrity contributes to cognitive impairment 
in the absence of neuronal perikarya damage. An additional advantage of the BCAS model is 
that the extent of hypoperfusion can be manipulated by using microcoils with different internal 
diameters ranging from 0.16 mm – 0.22 mm (Shibata et al., 2004).  
While use of 0.18 mm internal diameter microcoils induces diffuse white matter damage 
without overt neuronal perikaryal damage after 28 d, 0.16 mm internal diameter microcoils 
cause extensive white and grey matter damage associated with high mortality (75 %). To 
circumvent this, the BCAS model was modified so that a 0.18 mm microcoils is applied to the 
right carotid artery whilst a 0.16 mm microcoil is applied to the left carotid artery to induce 
greater cerebrovascular insufficiency and more definite white matter damage associated with 
reduced mortality (Miki et al., 2009). After 1 m, animals demonstrate widespread white matter 
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damage and neuronal perikarya damage in the hippocampus associated with 
neuroinflammation and spatial reference memory dysfunction (Miki et al., 2009). A more recent 
study similarly demonstrated robust white matter pathology and neuroinflammation after 1 w 
associated with impaired white matter conduction velocity (Fowler et al., 2018).  
However, a limitation of the BCAS model is that placement of microcoils causes an acute 
reduction in cerebral blood flow that does not mimic the gradual onset of hypoperfusion seen 
with aging. To address this, the gradual common carotid artery stenosis model (GCAS) was 
developed for use in rodents in which ameroid constrictors containing casein are placed 
around the carotid arteries (Kitamura et al., 2012, Hattori et al., 2016a). The casein within the 
devices absorb extracellular fluid over time and swell, gradually reducing cerebral blood flow. 
In rats, a gradual 30 % reduction in cerebral blood flow is observed after 3 d recovering to 15 
% after 28 d (Kitamura et al., 2012). In mice however, cerebral blood flow gradually decreases 
by 30 % without recovery up to 28 d following surgery (Hattori et al., 2016a).  
Similar to the BCAS model, GCAS causes diffuse white matter damage associated with 
neuroinflammation without hippocampal neurodegeneration (Hattori et al., 2016a). GCAS 
mice also demonstrate spatial working memory and motor coordination deficits in the absence 
of spatial reference memory impairment (Hattori et al., 2016a). Although the GCAS model 
circumvents acute reductions in cerebral blood flow caused by microcoil placement it remains 
unclear if devices can be left on for longer durations without causing complete occlusion of the 
carotid arteries.  
The GCAS model has also been adapted to induce greater cerebral hypoperfusion associated 
with more severe white matter pathology. In the asymmetric common carotid artery stenosis 
(ACAS) model, an ameroid constrictor is placed on the right carotid artery whilst a 0.16 mm 
internal diameter microcoil is placed on the left carotid artery (Hattori et al., 2015). While the 
right carotid artery becomes completely occluded 28 d after surgery, cerebral blood flow is 
reduced by 50 % in the left carotid. Mice develop numerous white matter infarcts in addition to 
frequent hippocampal damage associated with spatial working and reference impairment as 
well as impaired motor coordination (Hattori et al., 2015). 
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Although the above models enable investigation of how hypoperfusion contributes to CNS 
pathology, it must be noted that the above surgical models may directly impact autoregulation, 
vessel pulsatility or vessel stiffness independant of hypoperfusion. Furthermore, local 
inflammation resulting from surgery and application of devices may contribute to pathological 
or behavioural outcomes. Given that the above factors all contribute VCI pathogenesis it will 
be important characterise whether these factors are altered in hypoperfusion models.   
 Additional models of VCI 
In addition to models that manipulate cerebral blood flow, models have been developed which 
investigate the contribution of environmental or genetic risk factors to VCI pathogenesis. 
Spontaneously hypertensive stroke prone (SHRSP) rats demonstrate spontaneous and 
progressive increases in mean arterial blood pressure from 4 w of age reaching 220 mmHg 
by early adulthood (Yamori et al., 1976). Neuropathological studies identify a range of vascular 
pathologies including vessel wall thickening, loss of BBB integrity and enlarged perivascular 
spaces which progress over time affecting 80 % by 30 w of age (Okamoto, Yamori and 
Nagaoka, 1974, HartHeistad and Brody, 1980, Fredriksson et al., 1985). Early endothelial 
dysfunction has recently been suggested as a key mechanism contributing to impaired 
oligodendrocyte maturation and white matter vulnerability (Rajani et al., 2018).  By 9-12 m of 
age SHRSP rats exhibit stroke lesions varying in severity and location and 90 % mortality by 
12 m of age (Madigan, Wilcock and Hainsworth, 2016). As the severity and location of 
cerebrovascular pathology can vary, the impact on cognitive function is unpredictable 
(Madigan et al., 2016).  
Hyperhomocysteinaemia, a risk factor for VCI, can be induced by providing rodents a diet 
lacking vitamin B6, B9-folate and B12 with or without homocysteine precursor methionine 
supplementation (Sudduth et al., 2013). Hyperhomocysteinaemia leads to cerebrovascular 
abnormalities including reduced capillary density and microhaemorrhage associated with 
neuroinflammation in addition to impaired performance on the Morris water maze (Sudduth et 
al. 2013). 
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Transgenic mice harbouring mutations in NOTCH3 have also been utilised to investigate the 
pathological mechanisms of CADASIL, the most common genetic cause of VCI.  Notch3R169C 
mice exhibit increased Notch3 aggregation in the cerebrovasculature and demonstrate 
cerebrovascular abnormalities with increasing age including loss of BBB integrity, reduced 
pericyte coverage and impaired cerebrovascular reactivity (Ghosh, et al. 2015). At older ages 
Notch3R169C mice demonstrate reduced cerebral blood flow and white matter damage 
associated with reactive gliosis and impaired myelin clearance (Joutel et al., 2010, Cognat et 
al., 2014, Ghosh et al., 2015). Although the precise mechanisms remain unclear, abnormal 
accumulation of vitronectin and TIMP3 is suggested to contribute to loss of cerebrovascular 
reactivity and subsequent white matter damage downstream of Notch3 deposition. While 
Timp3 haploinsufficiency ameliorates impairments in functional hyperaemia and 
autoregulation, Vtn haploinsufficiency reduces white matter damage without impacting 
cerebral blood flow responses in notch3R169C mice (Capone et al., 2015). Although notch3R169C 
mice develop various pathological features of cSVD the impact on cognition remains unclear.  
Whilst a model does not exist which fully recapitulates the heterogeneity of pathology observed 
in cSVD, utilisation of these models has led to the identification of several mechanisms which 
contribute to loss of white matter integrity and cognitive decline including chronic cerebral 
hypoperfusion, BBB breakdown, neuroinflammation and oxidative stress.  
 Mechanisms contributing to VCI 
 Chronic cerebral hypoperfusion 
Chronic cerebral hypoperfusion, defined as a chronic reduction in cerebral blood flow, is 
increasingly implicated as a key mechanism contributing to white matter damage and cognitive 
impairment in the elderly. Lower cerebral blood flow is associated with greater prevalence of 
cognitive impairment and dementia (Ruitenberg et al., 2005, Chao et al., 2010). Furthermore, 
individuals with severe carotid stenosis demonstrate greater cognitive deterioration and faster 
transition from mild cognitive impairment to dementia (Balestrini et al., 2013, Buratti et al., 
2014). 
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Aging, one of the biggest risk factors for cSVD, is associated with reduced cerebral blood flow 
and increased capillary loss (Brown and Thore, 2011). Indeed, between 20 – 80 years of age 
cerebral blood flow is reduced by 0.5 % a year (Leenders et al., 1990). Individuals with vascular 
diseases such hypertension and diabetes also have reduced cerebral blood flow associated 
with worsened cerebrovascular reactivity compared to healthy controls (Kim et al., 2008, 
Beason-Held et al., 2007). Hypertension is associated with vascular remodelling resulting in 
vessel wall thickening, lumen narrowing and reduced cerebral blood flow. Damage to the NVU, 
loss of BBB integrity and impaired vessel elasticity also disrupts neurovascular coupling thus 
contributing to cerebral hypoperfusion. 
As stated earlier, the white matter of the brain is more susceptible to damage caused by 
cerebral hypoperfusion. Although larger arteries and arterioles provide a rich anastomotic 
network on the cortical surface, penetrating arterioles supplying subcortical structures lack 
collateral vessels. In addition to this, the subcortical white matter is supplied by non-
overlapping distal branches of the middle and anterior cerebral arteries, known as watershed 
regions. Therefore, reductions in cerebral blood flow cannot be effectively compensated in 
deeper subcortical white matter regions increasing susceptibility to damage.  
Preclinical animal models have demonstrated chronic cerebral hypoperfusion is a key driver 
of white matter damage and cognitive impairment. However, the precise contribution in 
humans remains unclear. White matter hyperintensities are associated with reduced cerebral 
blood flow and cerebrovascular reactivity and elderly individuals with lower cerebral blood flow 
demonstrate increased white matter burden (O'Sullivan et al., 2002, Schuff et al., 2009, 
Promjunyakul et al., 2015, van Dalen et al., 2016, Sam et al., 2016).  Neuropathological studies 
have also demonstrated areas of white matter damage are associated with upregulation of 
hypoxia-related proteins including hypoxia inducible factor (HIF) 1 and 2 and matrix 
metalloproteinase (MMP) 7 suggestive of an ischaemic environment (Fernando et al., 2006). 
Furthermore, neuroimaging studies suggest reduced cerebral blood flow or cerebrovascular 
reactivity precedes the development of white matter hyperintensities suggesting chronic 
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cerebral hypoperfusion plays a causal role in white matter damage (O'Sullivan et al., 2002, 
Bernbaum et al., 2015, Sam et al., 2016). 
However, a longitudinal study investigating the relationship between cerebral blood flow and 
white matter hyperintensities in patients with arterial disease demonstrated changes in 
parenchymal cerebral blood flow were not associated with progression of white matter damage 
(van der Veen et al., 2015). Furthermore, a recent meta-analysis of longitudinal studies 
demonstrated individuals with lower cerebral blood flow have greater white matter burden. 
However, evidence was insufficient to support chronic cerebral hypoperfusion occurs prior to 
development of white matter damage (Shi et al., 2016). It is therefore suggested hypoperfusion 
reflects reduced activity and metabolic requirement of damaged white matter and that factors 
other than chronic cerebral hypoperfusion such as impaired vessel pulsation and vessel 
stiffness contribute white matter damage.  
 Loss of blood brain barrier integrity  
Endothelial dysfunction and loss of BBB integrity are also considered as key early mechanisms 
contributing to VCI. CSVD patients demonstrate increased albumin in cerebrospinal fluid 
(CSF) and neuropathological studies demonstrate extravasation of plasma proteins in areas 
of vascular pathology (Alafuzoff et al., 1985, Tomimoto et al., 2003, Akiguchi et al., 1998, 
Candelario-Jalil et al., 2011). Neuroimaging studies have also demonstrated increased BBB 
permeability with aging which is further exacerbated in patients with VCI or AD (Farrall and 
Wardlaw, 2009, Topakian et al., 2010, Maniega et al., 2017). A recent neuroimaging study 
also demonstrated white matter hyperintensities are associated with increased BBB 
permeability (Wardlaw et al., 2017). Furthermore, such areas predicted subsequent cognitive 
impairment suggesting loss of BBB integrity is an early pathological event which contributes 
to white matter damage and cognitive decline (Wardlaw et al., 2017).  
Endothelial dysfunction and loss of BBB integrity are also frequently observed in preclinical 
models of VCI. Kitamura et al. (2017) reported gradual upregulation of endothelial adhesion 
molecules intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 
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(VCAM1) 3 months after BCAS thus promoting immune cell attachment to the endothelial wall 
(Kitamura et al., 2017). In support of this, recent in vivo two photon imaging demonstrated 
leucocyte attachment and rolling across the cerebrovascular wall in response to BCAS (Yata 
et al., 2014).  
In contrast, Liu et al. (2019) demonstrated a much more rapid loss of BBB integrity 3 days 
after BCAS concomitant with reduced pericyte coverage prior to onset of white matter injury 
(Liu et al., 2019). Rajani et al. (2018) similarly demonstrated early endothelial dysfunction and 
impaired oligodendrocyte precursor cell (OPC) maturation in SHRSP rats. Importantly, such 
findings were also observed in pre-symptomatic cSVD patient post-mortem tissue suggesting 
loss of BBB integrity is an early mechanism contributing to white matter damage and cognitive 
impairment (Rajani et al., 2018). 
In addition to promoting infiltration of immune cells into the brain parenchyma, BBB breakdown 
also permits entry of plasma proteins including fibrinogen, complement and immunoglobulins 
all of which activate microglia contributing to neuroinflammation. In addition to this, endothelial 
dysfunction and BBB leakiness impair neurovascular coupling contributing to cerebral 
hypoperfusion. Importantly, therapeutic reversal of endothelial dysfunction ameliorates white 
matter vulnerability suggesting targeting endothelial dysfunction and BBB integrity may 
provide a potential therapeutic strategy for cSVD (Kitamura et al., 2017, Rajani et al., 2018).  
 Neuroinflammation 
Neuropathological studies in the elderly demonstrate areas of white matter damage are 
associated with activated microglia in addition to markers of oxidative stress and inflammation 
(Akiguchi et al., 1998, Rosenberg, Sullivan and Esiri, 2001, Simpson et al., 2007, Back et al., 
2011). Neuroinflammation coinciding with areas of white matter damage has also been 
demonstrated in preclinical models of VCI. Microarray analysis of white matter demonstrates 
alterations in biological pathways associated with cytokine-cytokine receptor interactions and 
inflammatory responses 72 h after BCAS (Reimer et al., 2011). Furthermore, microglial 
number closely correlates with loss of white matter structure and function (Manso et al., 2018). 
 
  18 
Importantly, various studies have suggested immunomodulatory drugs reduce microglial 
activation and improve white matter structure and function (Wakita et al., 1995, Cho et al., 
2006, Manso et al., 2018, Fowler et al., 2018). Genetic manipulation of inflammatory genes 
similarly alters disease trajectory further supporting the role of neuroinflammation in VCI (Liu 
et al., 2015, Miyanohara et al., 2018). In addition to microglia, reactive astrocytes are observed 
surrounding areas of white matter damage. Specific inhibition of astrocyte nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) attenuates reactive gliosis, white 
matter pathology and cognitive deficits suggesting astrocytes also contribute to 
neuroinflammation (Saggu et al., 2016).  
Precisely how neuroinflammation contributes to white matter injury and VCI remains unclear. 
Upregulation of various cytokines including interleukin (IL)-1β, IL-6 and tumour necrosis factor 
α (TNF-α) is observed in preclinical modes of cSVD (Tsai et al., 2015, Lee et al., 2015). 
Cytokines themselves can further activate microglia resulting in a feed forward loop of 
microglial activation and production of inflammatory mediators which in excess may cause 
damage to surrounding cells.  
In vitro stimulation of microglia and subsequent cytokine release impairs OPC maturation and 
promotes death (Sherwin and Fern, 2005). IL-1β upregulation following intracerebral injection 
of lipopolysaccharide (LPS) and is also associated with impaired oligodendrocyte maturation 
and hypomyelination in neonatal rats (Xie et al., 2016). Furthermore, exposure of primary 
OPCs to IL-1β impairs proliferation and maturation (Xie, et al., 2016). TNF-α overexpression 
also causes a chronic inflammatory demyelinating disease and early mortality in mice (Probert 
et al., 1995). Interferon-γ (IFN-γ) has also been demonstrated to suppress remyelination and 
delay functional recovery in cuprizone and experimental autoimmune encephalomyelitis (EAE) 
models of multiple sclerosis (MS) (Lin et al., 2006).  IL-1β and TNF-α also influence BBB 
permeability and expression of endothelial adhesion molecules promoting infiltration of plasma 
proteins and attachment of circulating leucocytes thus amplifying inflammation (Wu et al., 
2010, Yamagata et al., 2004, Mark and Miller, 1999, Wong, Prameya and Dorovini-Zis, 2007).  
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Activated microglia also secrete MMPs which degrade endothelial tight junctions, extracellular 
matrix and myelin thus contributing to BBB breakdown and white matter damage. In response 
to chronic cerebral hypoperfusion, increased MMP-2 expression is associated with BBB 
breakdown prior to the onset of white matter damage (Ihara et al., 2001). Furthermore, MMP-
2 inhibition or genetic depletion attenuates BBB breakdown and white matter damage (Nakaji 
et al., 2006). MMP inhibition also reverses myelin loss following ischaemic reperfusion injury 
suggesting MMPs play a key role in mediating white matter damage (Walker and Rosenberg, 
2010).  
Microglia are also a key source of reactive oxygen species (ROS) thus contributing to oxidative 
stress. ROS also activate microglia perpetuating further microglial activation. ROS generation 
also impairs endothelial function and cerebral blood flow regulation by reducing nitric oxide 
availability thus contributing to cerebral hypoperfusion. Oligodendrocytes are suggested to be 
particularly susceptible to oxidative stress due to having a high metabolic rate and iron content 
coupled with low expression of antioxidants such as glutathione (Thorburne and Juurlink, 
1996). Oxidative stress is observed in areas of white matter damage in the elderly and 
preclinical models of chronic cerebral hypoperfusion (Ueno et al., 2009, Washida et al., 2010, 
Back et al., 2011, Zhang et al., 2011a). Furthermore, use of the free radical scavenger 
edaravone reduces oligodendrocyte loss in vitro and in vivo and ameliorates cognitive deficits 
caused by chronic cerebral hypoperfusion (Miyamoto et al., 2013). Dong, et al. (2014) similarly 
demonstrated use of the superoxide scavenger tempol ameliorates oxidative stress, white 
matter damage and cognitive deficits resulting from chronic cerebral hypoperfusion (Dong et 
al., 2011). Overexpression of the anti-oxidant Nrf2 in astrocytes also protects white matter 
structure and function in response to chronic cerebral hypoperfusion through repression of 
inflammatory genes (Sigfridsson et al., 2018).  
Vascular risk factors associated with cSVD such as hypertension and diabetes are also 
associated with chronic inflammation and increased expression of circulating pro-inflammatory 
cytokines (Lee et al., 2013, Krishnan et al., 2014).  Furthermore, ageing, a major risk factor for 
cSVD and other neurodegenerative diseases, is associated with increased expression of 
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inflammatory genes and microglial dysfunction (Primiani et al., 2014). Recent analysis of the 
microglial transcriptome revealed upregulation of immune amplifying genes in aged mice 
compared to young mice (Grabert et al., 2016). Microglia derived from aged mice demonstrate 
a dystrophic-like morphology, impaired phagocytosis and exaggerated inflammatory 
responses to stimuli characterised by increased ROS and pro-inflammatory cytokine release 
(Matt and Johnson, 2016). In response to chronic cerebral hypoperfusion, aged mice 
demonstrate greater microglial activation, white matter damage and cognitive impairment 
compared to young mice (Wolf et al., 2017). Safaiyan et al. (2016) recently demonstrated 
myelin uptake leads to the accumulation of undegradable lysosomal aggregates contributing 
to microglial senescence and immune dysfunction (Safaiyan et al., 2016). It could therefore be 
postulated chronic non-resolving injury such as hypoxia, inflammation and white matter 
damage may overwhelm microglia leading to functional impairment, neuroimmune dysfunction 
and exacerbation of damage.  
Additonal evidence for the contribution of microglia in dementia causing white matter disease 
derives from the identification of microgliopathies caused by mutations in microglial-enriched 
genes. Nasu Hakola disease (NHD) (TREM2) and adult-onset leukoencephalopathy with 
axonal spheroids and pigmented glia (CSF1R) are characterised by extensive demyelination, 
axonal loss and the development of pre-senile dementia during mid-life (Schuburth,Bianchin 
et al., 2004). Although the pathophysiological mechanisms remain unknown, these diseases 
demonstrate microglial dysfunction actively contributes to white matter degeneration and 
dementia.  
However, microglia play a key role in various homeostatic processes throughout development 
and adult life including synaptic pruning, synaptic plasticity, neurogenesis and myelogenesis. 
Whilst inflammatory mediators released by microglia may contribute to neurodegenerative 
process such factors are also required for homeostatic or regenerative processes. For 
example, mice lacking TNF-α or IL-1β demonstrate decreased differentiation of OPCs into 
mature oligodendrocytes and delayed remyelination in the cuprizone model of demyelination 
(Arnett et al., 2001, Mason et al., 2001). Microglia are also a source of various trophic 
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mediators including brain derived neurotrophic factor (BDNF), IGF-1 and leukaemia inhibitory 
factor (LIF) (Goldstein et al., 2016). Lastly, microglial mediated clearance of debris is 
necessary to initiate regenerative processes such as remyelination (Lampron et al., 2015). 
Therefore, fine tuning of microglial function to amplify neuroprotective mechanisms whilst 
limiting potentially neurotoxic neuroinflammation may provide a promising therapeutic strategy 
for the treatment of VCI and other dementia causing diseases. 
 Microglia  
Microglia are tissue resident macrophages of the CNS constituting 5-12 % of cells in the adult 
brain (Lawson et al., 1990). As innate immune cells of the CNS, microglia rapidly respond to 
CNS perturbation so to resolve damage and maintain CNS homeostasis. Under steady state 
conditions, microglia have small cell somas with thin branching processes which continuously 
survey the local microenvironment. Microglia mediate host defence against CNS injury and 
infectious agents through a range of receptors including Fc receptors, viral receptors and toll-
like receptors (TLR). These receptors recognise a broad range of pathogen associated 
molecular patterns (PAMPS) such as LPS or damage associated molecular patterns (DAMPS) 
associated with cell damage or death (Olson and Miller, 2004).  In response to CNS 
perturbation, microglial activation ensues during which microglia increase in size and retract 
processes adopting an amoeboid morphology (Ransohoff and Perry, 2009). Activated 
microglia migrate to the area of interest, proliferate, secrete pro-inflammatory mediators and 
increase their phagocytic ability in an attempt to remove pathogen, debris and dead cells to 
protect the CNS.  
In addition to demonstrating robust morphological adaptations in response to CNS 
perturbation, microglia also exhibit functionally diverse phenotypes influenced by type and 
duration of stimuli. Previously, attempts were made to categorise microglial activation as pro- 
or anti-inflammatory based on in vitro classification devised for macrophages (Mantovani et 
al., 2004). It was initially hypothesised that macrophage activation could be categorised and 
and distinguished as classical (M1) or alternative (M2) based on expression of cytokines and 
other inflammatory molecules. Inflammatory mediators including TNF-α, IFN-γ, LPS or 
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granulocyte macrophage colony stimulating factor (GM-CSF) trigger M1 activation. This 
results in the upregulation of various pro-inflammatory mediators including IL-1β, TNF-α, IL-
12, IL-23, chemokines, ROS and various immunoreceptors (Zhang et al., 2017).  
In contrast, M2 activation is triggered by IL-4, IL-13, IL-10, TGF-β or glucocorticoids resulting 
in the release of anti-inflammatory mediators such as TGF-β, IL-10 and trophic factors 
promoting wound repair and resolution of inflammation (Zhang et al., 2017). Whilst this may 
be observed in vitro, various in vivo studies investigating macrophage and microglial 
phenotype fail to definitively characterise microglia as M1 or M2 (Mabbott et al., 2010, Chiu et 
al., 2013, Kim, Nakamura and Hsieh, 2016). Therefore, the M1/ M2 characterisation of 
microglial phenotype is deemed too simplistic and microglial phenotypes are suggested to be 
‘multi-dimensional’ (Ransohoff, 2016). This concept is supported by recent single cell 
sequencing studies identifying diverse microglia activation states distinct from those induced 
by polarising stimuli including LPS and IL4 throughout development and disease (Hammond 
et al., 2019, Masuda et al., 2019). 
 Microglia origin 
Although the precise origin of microglia remained enigmatic for many years, recent lineage 
tracing and parabiosis studies suggest microglia derive from RUNX1+, CD45-, c-kit+ 
erythromyeloid progenitors of the yolk sac (Kierdorf et al., 2013, Ginhoux et al., 2010). These 
cells colonise the developing CNS on embryonic day 9.5 via the bloodstream and mature into 
microglia via a Myb independent, PU.1, interferon regulatory factor (IRF) 8 dependant 
mechanism (Kierdorf et al., 2013, Ginhoux et al., 2010). Microglia continue to colonise the 
CNS until formation of the BBB on embryonic day 13.5. Whilst initially amoeboid, microglia 
adopt a ramified morphology on embryonic day 14.5 and remain highly proliferative until birth 
at which point they acquire a unique microglial TGF-β-dependant gene signature (Kierdorf et 
al., 2013, Butovsky et al., 2014). Tightly coupled apoptosis and proliferation maintain microglial 
populations throughout life (Askew et al., 2017). Recent single cell imaging also suggests 
microglia have a slow turnover with a median lifespan of over 15 months (Fueger et al., 2017).  
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Microglial differentiation and post-natal survival are critically dependant on colony stimulatory 
factor 1 receptor (CSF1R) function. Microglia are absent in Csf1r-/- mice and antibodies 
blocking CSF1R activity deplete developing microglia and macrophages (Ginhoux et al., 2010, 
Erblich et al., 2011, Hoeffel et al., 2015). Csf1r-/- mice also demonstrate brain abnormalities 
including ventricle enlargement, cortical thinning and olfactory hollowing (Erblich et al., 2011).  
Furthermore, mice carrying a mutation in colony stimulatory factor 1 (CSF1) (Csf1op/op), a key 
ligand for CSF1R also demonstrate microglial depletion although less profound (Wegiel et al., 
1998, Kondo, Lemere and Seabrook, 2007). This observation led to the suggestion that 
another CSF1R ligand exists resulting in the identification of IL-34. Il-34-/- mice similarly 
demonstrate less microglia however the impact of Il-34 deficiency is region dependant 
suggesting IL-34 expression may differ spatially (Wang and Colonna, 2014).  
In addition to CSF1 and IL-34, recent studies suggest TGF-β also plays a crucial role in 
microglial development. CNS TGFβ-/- mice demonstrate impaired microglial development 
from embryonic day 14.5 onwards with adult mice exhibiting reduced numbers of microglia 
with an amoeboid morphology (Butovsky et al., 2014). More recently, Buttgereit et al. (2016) 
demonstrated targeted deletion of microglial TGF-βR did not impact on microglial number but 
enhanced microglial reactivity suggesting TGF β signalling plays a key role in mainta ining a 
microglial homeostatic phenotype rather than survival (Buttgereit et al., 2016). The 
transcription factor SALL1 is similarly suggested to be important for maintenance of 
homeostatic microglia as ablation of the Sall1 gene locus induces an inflammatory phenotype 
associated with disturbed neurogenesis (Buttgereit et al., 2016).  
 Microglia in health and disease  
It is becoming increasingly clear microglia play key roles in various homeostatic processes 
throughout development and adult life. Even though microglia are described as ‘resting’ under 
steady state conditions, in vivo two photon microscopy demonstrates microglia have highly 
motile processes which continuously contact astrocytes, blood vessels, axons, dendritic 
spines and neuronal cell bodies (Nimmerjahn, Kirchhoff and Helmchen, 2005, Wake et al., 
2009, Tremblay, Lowery and Majewska, 2010). 
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Within the developing brain, microglia are suggested to play key roles in modelling of neuronal 
circuitry via synaptic pruning, a process in which synaptic structures are cleared by microglial 
phagocytosis. Using electron microscopy and two-photon imaging, Trembley et al. (2010) 
demonstrated microglial processes dynamically interact with synapses in the visual cortex in 
an activity dependent manner (Tremblay et al., 2010). Furthermore, microglia demonstrated 
increased cellular inclusions and phagocytosis of synaptic elements in response to sensory 
deprivation (Tremblay et al., 2010). Paolicelli et al. (2011) also demonstrated microglial 
mediated synapse engulfment and elimination in the hippocampus during development via 
STED and electron microscopy (Paolicelli et al., 2011). Furthermore, mice lacking Cx3cr1 
expression demonstrate defective synaptic pruning, excess excitatory synapses, impaired 
neural circuit maturation in addition to defective brain connectivity and behavioural 
abnormalities (Zhan et al., 2014, Paolicelli et al., 2011). 
The classical complement cascade plays a key role in microglial-mediated synaptic pruning. 
Post-natal mice exhibit C1q and C3 deposition at synapses in the developing CNS and 
attenuated synapse elimination in the absence of C1q or C3 expression (Stevens, 2008). 
Signalling via microglial complement receptor 3 (CR3) is a key mechanism mediating synapse 
elimination during development as CR3 deficient mice demonstrate defective synaptic 
remodelling (Schafer et al., 2012). In addition to synapse elimination, microglia are also 
suggested to be crucial for learning- dependant synapse formation via release of BDNF 
(Parkhurst et al., 2013). 
Microglia also regulate neuronal apoptosis and clearance throughout development. Microglial-
derived ROS triggers neuronal apoptosis via a CD11B, DNAX activation protein of 12kD 
(DAP12) dependant pathway in the developing hippocampus (Wakselman et al., 2008). Marin-
Teva et al. (2004) similarly demonstrated microglia actively induce Purkinje cell apoptosis in 
the developing cerebellum via ROS release (Marin-Teva et al., 2004). Furthermore, liposome 
and tetracycline- mediated depletion of fetal microglia in utero enhances the number of neural 
precursor cells in the developing cortex whilst maternal immune challenge and subsequent 
microglial activation attenuates the number of neural precursor cells providing key evidence 
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for microglia-mediated regulation of the neural precursor pool during neurogenesis 
(Cunningham, Martinez-Cerdeno and Noctor, 2013). Microglia also regulate adult 
neurogenesis via apoptosis coupled phagocytosis in the subgranular zone of the hippocampus 
(Sierra et al., 2010).  
Recent studies suggest microglia are also important for myelogenesis. Following 
pharmacological depletion of microglia, OPCs are substantially reduced impacting subsequent 
myelogenesis during early postnatal development (Hagemeyer et al., 2017). Microglial 
depletion in the adult brain similarly reduces OPC number suggesting microglia also play a 
key role in OPC maintenance throughout development and adult life (Hagemeyer et al., 2017). 
Given that microglia play numerous roles in maintenance of CNS homeostasis their 
dysfunction is suggested to contribute to a range of neurological conditions. Activated 
microglia are observed across all neurodegenerative diseases. However, it remains unclear 
whether neuroinflammation is a cause or consequence of neurodegenerative processes. 
Although it was originally believed neuroinflammation was mainly secondary to 
neurodegeneration, recent genome wide association studies (GWAS) identifying variants in 
several innate immune genes which increase susceptibility to neurodegenerative diseases 
provides key evidence for the role of neuroimmune dysfunction as a driver of 
neurodegenerative disease and dementia.  
Amongst identified genes, mutations in triggering receptor expressed on myeloid cells 2 
(TREM2) significantly increases the risk of developing AD similar to having one 
apolipoproteinE4 (APOE4) allele (Karch and Goate, 2015). In addition to increasing 
susceptibility to AD, TREM2 variants are also suggested to increase susceptibility to 
Parkinson’s, frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) 
(Guerreiro et al., 2013a, Rayaprolu et al., 2013, Cady et al., 2014). Furthermore, 
microgliopathies caused by homozygous loss of function mutations in microglial-enriched 
genes such as CSF1R in addition to TREM2 cause leukodystrophies associated with 
demyelination, axonal pathology and pre-senile dementia providing key evidence that 
microglial dysfunction and neuroinflammation actively contribute to dementia pathogenesis. 
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 TREM2  
The importance of TREM2 in CNS homeostasis was first demonstrated by studies identifying 
homozygous loss of function mutations in TREM2 or its adaptor protein DAP12 causing NHD 
in which patients develop bone abnormalities and pre-senile dementia (Nasu, Tsukahara and 
Terayama, 1973, Kaneko et al., 2010, Hakola, 1972). Post-mortem studies report severe white 
matter degeneration characterised by extensive demyelination and axonal loss in addition to 
cortical atrophy associated with reactive gliosis. Mutations in TREM2 were first linked to NHD 
by Paloneva et al. (2003) and have since been replicated in several genetic studies (Paloneva, 
2003, Soragna et al., 2003, Klunemann et al., 2006, Bock et al., 2013). NHD can also develop 
in the absence of bone abnormalities (Yamazaki et al., 2015). Furthermore, homozygous or 
heterozygous mutations associated with NHD can also cause FTD or frontotemporal lobar 
dementia (FTLD) (Le Ber et al., 2014, Guerreiro et al., 2013b, Giraldo et al., 2013). 
Following this, genetic studies identified several rare TREM2 variants which increase the risk 
of developing AD. The R47H TREM2 variant has been repeatedly associated with increased 
AD risk and other variants have also been identified including R62H, D87N and H157Y 
(Guerreiro et al., 2013a, Jin et al., 2014, Jiang et al., 2016a, Ghani et al., 2016). Although the 
R47H TREM2 variant is consistently associated with AD risk it remains unclear how this 
contributes to clinical phenotype. While some studies suggest TREM2 R47H carriers 
demonstrate accelerated disease progression this has not always been replicated (Korvatska 
et al., 2015, Rajagopalan, Hibar and Thompson, 2013, Slattery et al., 2014). Similarly, studies 
have suggested TREM2 R47H is associated with premature disease onset whilst others have 
reported no association (Ruiz et al., 2014, Rosenthal et al., 2015). As the TREM2 R47H variant 
only occurs in a very small percentage of the population such studies are limited by small 
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TREM2 is located on human chromosome 6p21 and mouse chromosome 17C3 as part of a 
gene locus containing various TREM and TREM-like genes (Ford and McVicar, 2009). 
Although some genes within the TREM locus are highly conserved between humans and mice 
(e.g. Trem1/TREM1 and Trem2/ TREM2), others including Trem3, Trem5 and Treml6 are 
exclusively expressed by mice whilst expression of TREML3 is limited to humans. Of the many 
genes within the TREM gene locus, triggering receptor expressed on myeloid cells 1 (TREM1) 
and TREM2 are best characterised. Whilst TREM1 is expressed by neutrophils, monocytes 
and microglia, TREM2 is expressed by dendritic cells, macrophages, microglia and osteoclasts 
(Bouchon, Dietrich and Colonna, 2000, Bouchon et al., 2001, Schmid et al., 2002, Turnbull et 
al., 2006).  
Within the CNS, TREM2 expression is highly enriched on microglia. During development, 
TREM2 is detected as early as embryonic day 14 and continues to be expressed throughout 
adulthood. TREM2 expression fluctuates during early postnatal development in an age and 
region dependant manner (Chertoff et al., 2013). Furthermore, regional heterogeneity has also 
been detected in the adult CNS in both mice and humans with highest expression reported in 
the white matter and hippocampus (Chertoff et al., 2013, Forabosco et al., 2013).  
Under steady state conditions, TREM2 is localised intracellularly on exocytotic vesicles and 
membranes of the Golgi network continuously shuttling between the cell membrane and 
cytoplasm in a beclin-1, Vps35 dependant manner (Prada et al., 2006, Lucin et al., 2013, Yin 
et al., 2016). Ionomycin stimulation and subsequent intracellular Ca2+ accumulation 
mimicking cell activation results in rapid redistribution of TREM2 to the cell membrane. TREM2 
gene expression is also tightly modulated by inflammatory stimuli or damage. Treatment of 
human or murine microglia with inflammatory mediators such as LPS downregulates TREM2 
expression whilst anti-inflammatory mediators such as IL-4 increase TREM2 expression 
(Owens et al., 2017). In vivo, TREM2 is downregulated in response to acute cerebral 
inflammatory challenges, whilst increased expression is observed in response to chronic CNS 
damage, inflammation and aging (Forabosco et al., 2013, Jiang et al., 2014b, Owens et al., 
2017, Raha et al., 2017).  
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 TREM2 protein structure and signalling  
TREM2 exists as a single pass transmembrane protein with an extracellular V-type 
immunoglobulin (Ig) domain containing N-linked glycosylation sites followed by a short stork 
leading to a transmembrane helix and short cytoplasmic domain. A lysine residue in the 
transmembrane region of TREM2 associates with an aspartate residue on adaptor protein 
DAP12 via electrostatic interaction. DAP12 exists as a homodimer and contains an 
immunoreceptor tyrosine-based activation motif (ITAM) in its intracellular domain enabling 
downstream signalling upon receptor activation (Bouchon et al., 2000). In response to ligand 
binding, tyrosine residues in the ITAM motif of DAP12 are phosphorylated by Src kinases 
enabling binding of spleen tyrosine kinase (SYK) via SH2 domains. This initiates various 
downstream signalling cascades including mitogen-activated protein kinase (MAPK) 
activation, protein tyrosine phosphorylation, Ca2+ mobilisation and phosphoinositide 3 – 
kinase (PI3K) activation contributing to various cell processes including actin remodelling, 
proliferation, survival, phagocytosis and release of inflammatory mediators (fig. 1.4) (Colonna 
and Wang, 2016).   
In addition to the membrane-bound form, a soluble form of TREM2 (sTREM2) is generated by 
proteolytic cleavage or alternative splicing. Membrane bound TREM2 is proteolytically cleaved 
in a sequential two step event. The ectodomain is first shed by a disintegrin and 
metalloproteinase domain-containing protein 17 (ADAM17) or ADAM10 producing sTREM2 
and the remaining intracellular domain is subsequently cleaved by γ-secretase to produce C-
terminal fragments (CTF) (Feuerbach et al., 2017). The precise role of sTREM2 remains 
controversial. It was originally suggested sTREM2 may act as a decoy receptor to attenuate 
TREM2 signalling. In support of this, Kim et al. (2005) demonstrated use of a chimeric TREM-
Fc protein to model sTREM2 inhibited TREM2 mediated osteoclastogenesis (Kim et al., 2005). 
sTREM2 is also suggested to regulate additional biological functions including 
immunomodulation and microglial survival (Wu et al., 2015, Zhong et al., 2017).  
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In addition to sTREM2, recent studies propose TREM2 CTF may also regulate microglial 
function. In the absence of γ-secretase-mediated cleavage of TREM2, TREM2 CTF 
accumulates at the plasma membrane and sequesters DAP12 preventing interaction with full 
length TREM2 leading to reduced DAP12 phosphorylation and phospholipase Cγ (PLCγ) 
signalling (Wunderlich et al., 2013, Glebov et al., 2016). Glebov et al. (2016) subsequently 
demonstrated this was also associated with reduced microglial phagocytosis (Glebov, et al., 
2016). Overexpressing TREM2 CTF in BV2 cells also reduces pro-inflammatory cytokine 
release following LPS stimulation suggesting TREM2 CTF contributes to immunomodulation 
























Figure 1.4: TREM2 signalling and cleavage. Upon ligand binding, DAP12 immunoreceptor 
tyrosine based activation motifs (ITAMs) are phosphorylated by Src kinases provided a binding 
site for SH2 domains of SYK resulting in various downstream signalling cascades (PI3K 
activation, Ca2+ mobilisation, MAPK activation) which regulate various cell processes including 
migration, proliferation, survival, phagocytosis and immunomodulation. sTREM2 is generated by 
ADAM10/ ADAM17 cleavage of the ectodomain while TREM2 CTF is generated by γ secretase-
mediated cleavage of the transmembrane domain. 
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 TREM2 ligands  
TREM2 binds to a range of lipoproteins including ApoE, ApoA, low density lipoprotein (LDL) 
and clusterin. Bailey et al. (2015) first demonstrated TREM2 Ig fusion protein precipitates 
ApoE and ApoA from serum and cerebrospinal fluid (Bailey De Vaux and Farzan, 2015). ApoE 
was also shown to induce TREM2 signalling in a reporter cell line (Jendresen et al., 2017). 
Since discovering the interaction between ApoE and TREM2 it is suggested ApoE enables 
indirect TREM2-mediated recognition of CNS damage as ApoE binds to apoptotic cells and 
Aβ plaques. Subsequently, Yeh et al. (2016) demonstrated TREM2 also binds clusterin, ApoA, 
ApoB as well as low density lipoprotein via protein microarray (Yeh et al., 2016).  
TREM2 is also suggested to bind a range of anionic molecules including phosphatidic acid, 
phosphatidylserine and cardiolipin (Cannon O'Driscoll and Litman, 2012, Kober et al., 2016). 
Studies utilising reporter cells also demonstrated lipids including sulfatide, sphingomyelin, 
phosphatidic acid, phosphatidylinositol, phosphatidylcholine and phosphatidyl stimulate 
TREM2 signalling (Wang et al., 2015, Poliani et al., 2015). Kawabori et al. (2015) also 
demonstrated TREM2 fusion protein binds to high molecular weight nucleic acids in the 
ischaemic brain via chromatin immunoprecipitation (Kawabori et al., 2015). Furthermore, 
treatment of reporter cells with purified deoxyribonucleic acid (DNA) induces TREM2 signalling 
(Kawabori, et al., 2015).  
Mammalian cells and bacteria are also sources of TREM2 ligands. Initial studies demonstrated 
TREM2 fusion protein binds to a range of Gram-negative (Staphylococcus aureus, Proteus 
mirabilis) and Gram-positive (Escherichia coli, Streptococcus pyogenes) bacteria (Daws et al., 
2003). Such binding was disrupted in the presence of LPS, dextran sulfate, peptidoglycan and 
lipoteichoic acid demonstrating TREM2 binds to a range of bacterial products (Daws et al., 
2003, Phongsisay et al., 2015). Furthermore, TREM2 has also shown to bind to Pertussis toxin 
and cholera toxin (Phongsisay et al., 2015, Phongsisay et al., 2017).  
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Various mammalian cells including macrophages, THP-1 monocytes, dendritic cells, 
astrocytes and neurons are suggested to express endogenous TREM2 ligands (Hamerman et 
al., 2006, Hsieh et al., 2009, Ito and Hamerman, 2012, Kober et al., 2016, Daws et al., 2003). 
It was additionally shown induction of apoptosis increased TREM2 ligand expression on 
neuronal and non-neuronal cells. In response to apoptosis, TREM2 signalling and microglial 
phagocytosis were enhanced while this response was attenuated following treatment with an 
anti-TREM2 monoclonal antibody (Hsieh et al., 2009).   
 TREM2 function 
 Cell survival and proliferation  
Various studies suggest TREM2 plays a key role in promoting cell survival and proliferation. 
Wang et al. (2016) demonstrated TREM2 knockdown induces S-phase cell cycle arrest and 
increased apoptosis in glioma cell lines and suppressed tumorigenesis in vivo (Wang et al., 
2016a). Similar findings were also observed in a liver cancer cell line (Zhang et al., 2016). 
TREM2-/- cells also demonstrate reduced invasive and migratory ability suggesting TREM2 
may regulate migration (Wang et al., 2016a). Otero et al. (2012) demonstrated TREM2 
deficiency impairs CSF1-mediated activation and proliferation of osteoclast precursors via 
defective β-catenin signalling suggesting CSF1R and TREM2 signalling synergise to promote 
cell proliferation and survival (Otero et al., 2012). Otero, et al (2009) also showed that DAP12-
/- macrophages demonstrate defective CSF1-mediated activation and proliferation in vitro 
associated with reduced β-catenin stabilisation (Otero et al., 2009). More recently, Zheng at 
al. (2017) demonstrated TREM2 deficiency prevents β-catenin stabilisation resulting in its 
degradation via RAC-alpha serine/threonine-protein kinase (AKT)/ glycogen synthase kinase 
3 β (GSK3β) signalling leading to microglial cell cycle arrest, reduced proliferation and survival 




  33 
Reduced proliferation has also been demonstrated in animal models of demyelination and AD 
(Cantoni et al., 2015, Jay et al., 2017, Wang et al., 2016b). Furthermore, TREM2-/- microglia 
surrounding Aβ plaques demonstrate increased apoptosis (Wang et al., 2015). Decreased 
microglial clustering in areas of pathology is commonly observed in many TREM2-/- models 
of neurodegeneration highlighting the importance of TREM2 in maintaining microglial 
responses to noxious stimuli. However, it remains unclear if reduced microglial number is 
predominantly due to increased apoptosis or reduced survival.  
 Phagocytosis  
Numerous studies suggest TREM2 plays a key role in modulating phagocytic capacity. 
Impaired phagocytosis of a wide range of substrates including apoptotic cells, pathogens and 
lipids has been demonstrated in the absence of TREM2 expression in vitro (Takahashi, 
Rochford and Neumann, 2005, Hsieh et al., 2009, Kleinberger et al., 2014, Yeh et al., 2016). 
Similarly, TREM2 is suggested to be important for clearance of myelin debris in response to 
demyelination and tissue resorption following middle cerebral artery occlusion (MCAO) in vivo 
(Takahashi et al., 2007, Kawabori et al., 2015, Poliani et al., 2015). TREM2 is also implicated 
in the uptake of Aβ as TREM2 knockdown or overexpression correlates with Aβ phagocytosis 
in vitro (Melchior et al., 2010, Jiang et al., 2014a). Similar findings have also been observed in 
vivo as TREM2-/- AD microglia demonstrate worsened Aβ burden (Wang et al., 2016b, Yuan 
et al., 2016). However, studies have also demonstrated no effect or reduced Aβ burden in the 
absence of TREM2 expression (Ulrich et al., 2014, Jay et al., 2015). Therefore, the precise 
role of TREM2 regulation of Aβ uptake remains unclear. 
Interestingly, the impact of TREM2-mediated phagocytosis may be cell type specific. TREM2-
/- bone marrow derived macrophages (BMDMs) demonstrated impaired uptake of S. 
pneumoniae, yet TREM2-/- alveolar macrophages demonstrated increased phagocytosis both 
in vitro and in vivo (Sharif et al., 2014). Furthermore, TREM2-mediated clearance may be 
influenced by mediators within the local microenvironment. While injection of BMDMs 
overexpressing TREM2 reduced mortality in response to polymicrobial sepsis, no such effect 
was observed in response to LPS challenge in vitro (Chen et al., 2013). Similarly, a similar 
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study showed that TREM2 expression positively correlates to Aβ phagocytosis and that this 
was greatly reduced by pre-treating TREM2 overexpressing microglia with LPS (Melchior et 
al., 2010).   
Studies have also demonstrated TREM2 variants impact microglial phagocytosis. R47H 
impairs phagocytosis of fluorescent beads by BV2s (Yin et al., 2016). Furthermore, monocyte-
derived macrophages expressing the R62H variant demonstrate reduced Aβ-LDL uptake in 
vitro (Yeh et al., 2016). Interestingly, it is suggested TREM2 variants may differentially impact 
recognition of different substrates. Although Y38C, R47H and T66M variants all impair 
phagocytosis of latex beads, R47H does not impair E.coli clearance (Kleinberger et al., 2014). 
In addition to phagocytosis recent studies suggest TREM2 may also regulate lysosomal 
function. Cantoni et al. (2015) reported TREM2-/- microglia do not show defects in myelin 
uptake but instead demonstrate impaired degradation of internalised myelin (Cantoni et al., 
2015). Similarly, Zhu et al. (2014) showed TREM2 deficiency did not impact internalisation of 
Pseudomonas aeruginosa but impaired bacterial killing via ROS release (Zhu et al., 2014). 
More recently, single cell sequencing of microglia from various disease models identified that 
TREM2 is required for the upregulation of lysosomal genes. Separate gene network analysis 
also demonstrated lysosome activity is associated with TREM2 in all human brain regions 
(Forabosco et al., 2013). 
 Immunomodulation 
TREM2 is suggested to play a key role in modulation of inflammatory pathways in response 
to injury or infection. Although TREM2 is regularly described as ‘anti-inflammatory’ this is not 
always the case as both pro- and anti-inflammatory effect have been described. In vitro 
TREM2 knockdown generally enhances pro-inflammatory cytokine in response to a range of 
stimuli including Aβ, apoptotic cells, LPS and other TLR ligands such as zymosan and CpG 
(Turnbull et al., 2006). Furthermore, BV2 cells expressing the R47H variant demonstrate 
increased expression of pro inflammatory cytokines including IL-6 and TNF-α. In contrast, 
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overexpressing TREM2 reduces transcription of pro-inflammatory mediators (Jiang et al., 
2016b, Jiang et al., 2014a). 
In vivo studies also suggested TREM2 attenuates neuroinflammation however several studies 
suggest TREM2 actually amplifies neuroinflammation (Takahashi et al., 2007, Seno et al., 
2009, Jiang et al., 2014b, Jiang et al., 2014a, Ren et al., 2018). TREM2-/- AD mice 
demonstrate reduced pro-inflammatory gene expression in the brain (Jay et al., 2017, Jay et 
al., 2015). Transcriptional analysis of TREM2-/- microglia demonstrate reduced transcription 
of several proinflammatory cytokines (Wang et al., 2015). Similar reductions in pro-
inflammatory cytokine production have also been reported in models of stroke, MS, traumatic 
brain injury, lung infection and colonic mucosal injury (Sieber et al., 2013, Correale et al., 2013, 
Poliani et al., 2015, Sharif et al., 2014, Wu et al., 2015, Saber et al., 2017). In addition to gene 
expression, in vivo and in vitro studies have demonstrated TREM2-/- microglia exhibit an 
altered morphology with reduced cell somas and increased process length characteristic of 
microglia in their resting state (Kawabori et al., 2015, Wang et al., 2015).  
In addition to modulation of microglia and macrophage responses, studies have demonstrated 
TREM2 also appears to modulate responses of other inflammatory cell types including T cells 
and astrocytes. TREM2-/- animals demonstrate reduced astrocyte coverage as assessed by 
glial fibrillary acid protein (GFAP) in models of AD and demyelination (Cantoni et al., 2015, 
Jay et al., 2017, Jay et al., 2015, Leyns et al., 2017). In contrast, Saber et al.(2017) found 
TREM2 deficiency did not impact GFAP coverage in a model of traumatic brain injury (Saber 
et al., 2017). Similarly, Kawabori et al. (2015) demonstrated a modest reduction in GFAP 
coverage in TREM2-/- mice in response to MCAO suggesting TREM2-mediated regulation of 
astrocytes may be context dependant (Kawabori et al., 2015). 
A separate study investigating the impact of TREM2 deficiency on neuroinflammatory 
responses after MCAO demonstrated reduced infiltration of peripheral T cells suggesting 
TREM2 may regulate leucocyte recruitment to the CNS (Sieber et al., 2013). Although unclear, 
TREM2 may also regulate microglial antigen presentation. Bouchon et al. (2001) 
demonstrated TREM2 activation upregulates expression of various antigen presentation 
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molecules on immature dendritic cells required for T cell activation following LPS stimulation 
including major histocompability complex class II (MHCII), CD40, B7.1, B7.2 CCR7 (Bouchon 
et al., 2001). Microglia demonstrate upregulation of MHCII but no other antigen presentation 
molecules upon TREM2 stimulation in vitro suggesting TREM2 may initiate distinct antigen 
presenting functions in microglia compared to peripherally derived myeloid cells (Melchior, 
Puntambekar and Carson, 2006). By coculturing BV2 cells with CD4+ T cells, Melchior et al. 
(2010) also demonstrated TREM2 expression correlated with enhanced T cell proliferation and 
cytokine production in vitro suggesting TREM2 may play a key role in initiating adaptive 
responses (Melchior et al., 2010). However, whether this is observed in vivo is yet to be 
established. 
 Metabolic adaptation 
In addition to immunomodulation, TREM2 was recently shown to play a key role in metabolic 
adaption. Using a combination of ribonucleic acid (RNA) sequencing and metabolomics, 
Ulland et al. (2017) demonstrated TREM2 deficiency impairs BMDM ATP generation, 
glycolysis and anabolic metabolism particularly following growth factor withdrawal via 
attenuated mammalian target of rapamycin (mTOR) signalling resulting in increased 
autophagy (Ulland et al., 2017). Confocal and electron microscopy also demonstrated 
increased autophagic vesicles in microglia surrounding Aβ plaques in TREM2-/- AD mice as 
well as AD patients with R47H or R62H variants characteristic of metabolic stress (Ulland et 
al., 2017). It is therefore postulated TREM2-mediated mTOR activation is required for 
maintenance of microglia in a high metabolic state following cell activation. In its absence, 
microglia cannot initiate an appropriate response to stimuli due to impaired energy production. 
TREM2 regulation of metabolism is further supported from neuroimaging studies 
demonstrating NHD patients exhibit reduced glucose metabolism (Ueki et al., 2000). 
Furthermore, TREM2 T66M mice lacking cell surface TREM2 expression demonstrate fewer 
microglia compared to wild type (WT) controls associated with reduced glucose metabolism 
(Kleinberger et al., 2017). 
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 TREM2 during basal conditions  
Given that TREM2 causes NHD in humans, characterised by bone abnormalities, severe 
demyelination and pre-senile dementia, TREM2-mediated microglial reactivity clearly plays an 
important role in maintenance of CNS homeostasis. Although few studies have been 
conducted investigating the impact of TREM2 deficiency in the brain during basal conditions, 
current data suggests TREM2 deficient mice do not develop CNS pathology akin to humans 
with NHD.  
Unpublished data from the McColl lab has demonstrated TREM2 deficient mice show no overt 
difference in gross white or grey matter integrity or differences in microglial/ astrocyte number 
across several brain regions compared to WT mice. In addition, Kang et al. (2018) 
demonstrated TREM2 deficiency does not alter behavioural or cognitive performance in 6 
month old mice during basal conditions. However, RNA sequencing of hippocampal tissue 
demonstrated alterations in pathways relating to inflammation and chemotaxis of immune cells 
(Kang, et al., 2018). In a separate study, Filipello, et al. (2018) demonstrated TREM2 appears 
to play an important role in early brain development. Young TREM2-/- mice exhibit reduced 
ionised calcium binding adaptor protein 1 (IBA1)+ cell density in the hippocampus associated 
with impaired synapse elimination. Interestingly, this was associated with impaired functional 
connectivity between brain regions and decreased sociability in the absense of cognitive 
deficits (Filipello, et al., 2018). Therefore, whilst TREM2 deficiency appears to alter impact 
synaptic elimination during development and alter inflammatory pathways at the transcriptomic 
level, this is not associated with overt CNS pathology comparable to that observed in Nasu 
Hakola disease.  
Given that the mouse life span is much shorter than that of humans it could be postulated mice 
do not live long enough to develop pathology comparable to that observed in NHD.  
Furthermore, as mice used in the above studies were relatively young, it could be argued 
pathology develops at much later stages. Therefore, future studies phenotyping TREM2 
deficient aged mice are required.  
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 TREM2 in neurodegenerative disease 
As TREM2 variants have been demonstrated to increase the risk of dementia, various models 
of neurodegenerative disease have been implemented in animals in which TREM2 expression 
has been manipulated to understand how TREM2 regulates microglial function in the context 
of disease.  
 Alzheimer’s disease 
The role of TREM2 in neurodegenerative disease has most frequently been investigated in 
animal models which develop amyloid or tau pathology mimicking AD. Studies investigating 
the impact of TREM2 deficiency on Aβ plaque burden have yielded mixed finding with studies 
demonstrating reduced, increased or no change in amyloid pathology. While the reasons for 
observed discrepancies were originally unclear it is suggested use of different animal models 
and time of analysis may explain contrasting observations. Wang et al. (2015) demonstrated 
TREM2 deficiency increased plaque burden in 8 month 5XFAD while Jay et al. (2015) 
demonstrated reduced plaque burden in 4 month APP/PS1 (Jay et al., 2015, Wang et al., 
2015). Subsequent studies in 8 month APP/PS1 mice demonstrated worsened Aβ plaque 
burden demonstrating TREM2 may play divergent roles at early and late stages of disease 
(Jay et al., 2017). Furthermore, while in vivo over expression of TREM2 is associated with 
reduced Aβ plaque load, neuropathology and cognitive impairment in 7 month APP/PS1 mice 
this effect is lost in older 18 month mice (Jiang et al., 2017b, Jiang et al., 2014a). Microglia 
from aged mice showed diminished phagocytosis of Aβ attributed to reduced expression of 
Aβ-binding receptors which could not be rescued by TREM2 overexpression in vitro (Jiang et 
al., 2017b). Given that the effects of TREM2 on Aβ appear to be somewhat dependant on 
microglial phagocytic function such studies suggest potential therapeutic interventions 
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Although studies investigating the impact of TREM2 on Aβ burden report inconsistent results, 
reduced clustering of microglia around Aβ plaques is commonly observed suggesting TREM2 
is required for microglia to detect and contain Aβ plaques. TREM2 is suggested to play a key 
role in enabling microglia to detect and surround Aβ plaques forming a barrier-like structure. 
Using high resolution confocal and super resolution microscopy, Yuan et al. (2016) observed 
TREM2-enriched microglial processes enveloping amyloid fibrils and early-stage Aβ plaques 
preventing outward extension. In TREM2 or DAP12 haploinsufficient mice this barrier function 
was impaired resulting in reduced plaque compaction associated with greater neuronal 
dystrophy and tau hyperphosphorylation (Yuan et al., 2016).  Importantly, AD patients carrying 
R47H variants similarly demonstrate reduced plaque compaction associated with increased 
neuronal dystrophy compared to control AD patients (Yuan et al., 2016). It is therefore 
suggested TREM2 serves a neuroprotective function by reducing surface area of neurotoxic 
amyloid fibrils and exposure to surrounding neurons. 
Although impact of TREM2 deficiency on tau pathology is less well studied similar 
discrepancies have been observed. In response to TREM2 deficiency, both increases and 
decreases in phosphorylated tau accumulation have been observed in dystrophic neurites 
surrounding Aβ plaques in AD mouse models (Jay et al., 2015, Wang et al., 2015, Wang et 
al., 2016). TREM2 knockdown exacerbates tau pathology in P301S mice whilst 
overexpression attenuates pathology suggesting TREM2 confers neuroprotection to tau-
related pathology (Jiang et al., 2015, Jiang et al., 2016). Although the precise mechanisms by 
which TREM2 confers protection to tau require further study, protective effects are attributed 
to attenuation of neuroinflammation and suppression of tau kinases cyclin dependant kinase 
5 (CDK5) and GSK3β. In a separate tauopathy model (PS19), Leyns et al. (2017) 
demonstrated TREM2 deficiency had no impact of tau accumulation but reduced 
neuroinflammation and neurodegeneration (Leyns et al., 2017). Similarly, Sayed et al. (2018) 
demonstrated TREM2 deficiency had no impact on tau pathology and protected from brain 
atrophy due to reduced neuroinflammation (Sayed et al., 2018). Interestingly however, TREM2 
haploinsufficiency increased tau pathology and was associated with worsened 
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neuroinflammation and brain atrophy suggesting TREM2 deficiency or haploinsufficiency yield 
differential effects on microglial function and tau pathology (Sayed et al., 2018). 
 Demyelination/ remyelination 
Studies investigating the role of TREM2 in the context of MS similarly demonstrate attenuated 
microgliosis in areas of white matter damage in TREM2-/- mice. In the cuprizone model of 
demyelination, Poliani et al. (2015) demonstrated TREM2 deficiency impaired clearance of 
myelin debris and subsequent remyelination leading to persistent demyelination (Poliani et al., 
2015). Immunohistochemical analysis revealed that the extent of microgliosis was dampened 
and failed to resolve most likely due to accumulating myelin debris (Poliani, et al., 2015). 
Investigation of the microglial transcriptome revealed reduced expression of transcripts 
associated with microglial activation, lipid metabolism and phagocytosis (Poliani, et al., 2015). 
Similarly, Cantoni et al., (2015) demonstrated exacerbated white matter pathology in response 
to cuprizone treatment in TREM2-/- mice associated with defective microgliosis. 
Investigation of white matter gene expression revealed TREM2 deficient mice failed to 
upregulate genes associated with lipid metabolism (Poliani et al., 2015). Interestingly, TREM2 
deficiency did not impact myelin uptake by primary microglia. Instead it was suggested 
microglial degradation of internalised myelin was impaired as TREM2-/- microglia 
demonstrated accumulations of myelin debris containing phagosomes by electron microscopy 
(Cantoni et al., 2015). In a separate study, blocking TREM2 function in EAE similarly 
exacerbated CNS pathology whilst intravenous injection of TREM2 transduced BMDMs 
enhanced removal of degraded myelin, and ameliorated myelin and axonal pathology (Piccio 
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 Stroke 
Several studies have also suggested TREM2 plays a key role in mediating microglial 
responses to cerebral ischaemia. Kawabori et al. (2015) demonstrated reduced tissue 
resorption and poorer functional recovery in TREM2-/- mice in response to MCAO (Kawabori, 
et al., 2015). Reduced microgliosis and phagocytosis of apoptotic cells were observed in areas 
of injury in addition to reduced microvessel density suggesting TREM2 may also play a key 
role in angiogenesis (Kawabori, et al., 2015). While Sieber et al. (2013) did not observe any 
difference in ischaemic lesion severity, microgliosis was reduced and investigation of pro-
inflammatory genes demonstrated TREM2 deficiency attenuated inflammation in the sub-
acute phase following MCAO associated with reduced CD3+ T cell infiltration (Sieber, et al., 
2013). In contrast, Wu et al. (2017) demonstrated TREM2 gene silencing exacerbated 
neuroinflammation in vitro and in vivo whilst TREM2 overexpression attenuated 
neuroinflammation and limited neuronal apoptosis (Wu et al., 2017). More recently, Kurisu et 
al. (2018) demonstrated TREM2-/- mice exhibit impaired myeloid cell activation associated 
with greater infarct volume and reduced functional recovery (Kurisu et al., 2018). Interestingly, 
transplantation with WT bone marrow failed to ameliorate deficits associated with TREM2 
deficiency suggesting TREM2 expression on CNS resident microglia plays a key role in 
mediating recovery following MCAO (Kurisu, et al., 2018).  
 Disease associated microglia 
Recent single cell RNA sequencing in models of AD, ALS and aging identified a subset of 
microglia named disease associated microglia (DAM). DAM are characterised by 
downregulation of homeostatic genes including P2ry12, Tmem119, Cx3cr1, Cst3 and 
upregulation of genes associated with lysosomal function, phagocytosis and lipid metabolism 
such as Lpl, Apoe, Axl and Trem2 (fig. 1.5) (Keren-Shaul et al., 2017). DAM are observed 
surrounding areas of pathology but are absent in unaffected regions. Microglia demonstrate 
similar DAM-like gene expression profiles across models of tauopathy and demyelination 
(Krasemann et al., 2017, Friedman et al., 2018). Furthermore, DAM markers are also observed 
in post-mortem AD brain suggesting the DAM phenotype may represent a conserved 
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microglial signature adopted in response to certain forms of CNS damage (Keren-Shaul et al., 
2017). However, further work is required to conclude if microglia exhibit a similar phenotype 
across other contexts of neurodegenerative disease and determine whether this subset is 
beneficial or detrimental. 
Importantly, recent findings demonstrate TREM2 signalling is necessary for microglia to fully 
acquire a DAM phenotype via ApoE signalling (Krasemann et al., 2017). In the absence of 
TREM2, microglia do not exhibit a DAM phenotype but instead display an intermediate 
phenotype suggesting TREM2 plays a key role in sustaining microglial activation (Keren-Shaul 
et al., 2017, Krasemann et al., 2017). Although future work is crucial for elucidating the precise 
function of DAM in the context of neurodegeneration, amplifying DAM function via TREM2 may 






Figure 1.5: DAM induction. Microglia respond to CNS perturbation via a TREM2 independent 
mechanism of which the current signal is unknown, resulting in downregulation of homeostatic 
genes and upregulation of TREM2 adaptor/ regulator genes. A subsequent TREM2 dependant 
pathway ensues in which microglia upregulate several genes associated with phagocytosis, lipid 
metabolism and lysosomal pathways. Adapted from Keren-Shaul et al. 2017. 
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 Summary and aims of thesis  
Given that neuroinflammation and cerebrovascular dysfunction are suggested to play key roles 
in dementia pathogenesis it is crucial to determine how these processes converge to mediate 
neurodegeneration and cognitive impairment. Although neuroinflammation is implicated in 
VCI, the precise function of microglia and how they contribute to loss of white matter integrity 
and cognitive impairment remains unclear. Furthermore, it remains unknown if microglia 
exclusively contribute to the neuroinflammatory response or if peripherally derived leucocytes 
also play a role. It is therefore crucial to characterise the cellular and molecular 
neuroinflammatory profile and elucidate how this may contribute to disease pathogenesis.  
As neuroinflammation is suggested as a key mechanism contributing to white matter damage 
and cognitive impairment modulation of the neuroinflammatory profile could influence disease 
trajectory. TREM2 regulates several microglial functions including sensing of CNS 
perturbation, immunomodulation as well as clearance of damage and debris across various 
neurodegenerative disease settings. However, it is currently unknown how TREM2 functions 
in the context of chronic cerebrovascular dysfunction. As treatments are currently lacking for 
the treatment of cSVD and other dementias, modulation of TREM2 activity offers a promising 
therapeutic strategy. It is therefore crucial to gain a better understanding of TREM2 function 
to identify potential mechanisms which could be modulated to promote pro-regenerative 
functions whilst limiting detrimental neuroinflammation in the context of cSVD as well as other 
causes of cognitive impairment and dementia.  
The overall aim of this thesis was therefore to define key elements of the temporal cellular and 
molecular neuroinflammatory profile in an experimental model of chronic cerebral 
hypoperfusion. Using this model, we also aimed to investigate how TREM2 deficiency impacts 
neuroinflammation and white matter damage. It was hypothesised chronic cerebral 
hypoperfusion would impact detrimentally on myelin integrity and induce inflammation. It was 
further hypothesised that TREM2 deficiency would affect this response and exacerbate white 
matter damage.  
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 Aims  
To address the above hypothesis, the thesis investigated the following aims:  
1. Develop and optimise the BCAS model of chronic cerebral hypoperfusion to 
precipitate robust white matter pathology.  
2. To characterise the temporal cellular and molecular neuroinflammatory profile 
resulting from chronic cerebral hypoperfusion.  
3. To determine the impact of TREM2 deficiency on white and grey matter pathology 
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 Mice 
Male mice were used throughout (ages are provided in relevant results chapters). Wild type 
and TREM2-/- C57Bl/6Ntac mice were bred in house, and imported C57Bl/6J mice (Charles 
Rivers, UK) were housed in cages of up to five under temperature (19-24 oC) and humidity (55 
% ± 10 %) controlled conditions. Mice were on a 12 h light (7:00 – 19:00) dark (19:00-7:00) 
cycle and given ad libitum access to food and water. All procedures were carried out at the 
University of Edinburgh under the authority of UK Home Office project and personal licenses 
and in accordance with the Animals (scientific procedures) Act 1986 and European Directive 
2010/ 63/ EU.  
 Generation of TREM2 deficient mice 
TREM2-/- mice (Trem2tm1(KOMP)Vlcg) were generated on a C57BL/6Ntac background and 
imported from the UC- Davis Knock-Out Mouse Project (KOMP) and bred in-house. Litters 
derived from TREM2+/- mice were utilised to generate TREM2+/+ and TREM2-/- breeding 
pairs to maintain genetic diversity and subsequent litters were used for experiments. Loss of 
TREM2 expression was achieved by introducing a velocigene ZEN-Ub1 reporter cassette into 
the TREM2 locus via homologous recombination creating a deletion size of 5485 base pairs 
in chromosome 17 between 48485765 and 4849349 replacing exons 2 and 3, as well as the 









Figure 2.1: Method of gene deletion to generate TREM2-/- mice. The ZEN-Ub1 reporter cassette is 
inserted into the Trem2 gene locus via homologous recombination creating a deletion size of 5485 base 
pairs in chromosome 17 replacing exons 2 and 3 and the majority of exon 4. 
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 Genotyping of the TREM2 colony 
Ear notches were obtained from litters derived from TREM2+/- breeding pairs to conduct 
genotyping and distinguish TREM2+/+, TREM2+/- and TREM2-/- mice for subsequent 
breeding pair generation and colony management. DNA was isolated using a DNeasy Blood 
and Tissue kit (Qiagen) following manufacturer’s instructions. Firstly, tissues were digested in 
180 µl buffer RLT and 20 µl proteinase K overnight on a shaker at 55 oC. Digested samples 
were then combined with 200 µl buffer AL and vortexed before adding 200 µl 100 % ethanol. 
Samples were vortexed again and transferred to a DNeasy Mini spin column placed in a 2 ml 
collection tube and centrifuged at 6000 g for 1 min at room temperature (RT). The flow through 
and collection tube were discarded and the spin column was placed in a new 2 ml collection 
tube. 500 μl buffer AW1 was added to the spin column and samples were centrifuged for 1 
min at 6000 g at RT. The flow through and collection tube were again discarded and the spin 
column was placed in a new 2 ml collection tube and 500 µl buffer AW2 was added to the spin 
column and samples centrifuged at 20,000 g for 3 min at RT. The flow through and collection 
tube were discarded and the spin column was placed in a sterile 1.5 ml eppendorf and 200 µl 
buffer AE added to the spin column. Spin columns were incubated for 1 min at RT and 
centrifuged for 1 min at 6000 g at RT to elute DNA. The flow through was then re-added to the 
spin column and centrifugation repeated to maximise DNA yield. DNA samples were then 
stored at 4 oC prior to amplifying via polymerase chain reaction (PCR). For the PCR reaction, 
previously designed primers (Sigma) (table 2.1) were utilised to detect and amplify TREM2+/+, 
TREM2+/- and TREM2-/- DNA segments.  
Per sample, 1 µl DNA was combined with 48 µl JAX megamix blue (Clent Life Science) and 
0.5 µl forward and 0.5 µl reverse primer. A water only control was also included to ensure 
reagents were not contaminated with DNA. Samples were then briefly centrifuged and added 

































Stage Temperature ( oC) Time Cycles 
Initial denaturation 95 3 min 1 
Denaturation 95 30 sec  
Annealing 60 30 sec  
Elongation 72 45 sec 1 
Final extension 68 10 min 1 
Table 2.1: Oligonucleotide sequences of primers used to identify WT, TREM2+/- and TREM2-
/- mice. 
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Once the PCR had finished DNA expression of TREM2 or the inserted reporter cassette in 
TREM2-/- mice was detected based on fragment size distinction via gel electrophoresis (fig. 
2.2). A 1.5 % agarose gel was created by combining molecular grade agarose (Bioline) with 
1X TBE buffer and heating in a microwave. Once the agarose had dissolved 1X DNA 
SYBRsafe (Cambridge Bioscience) was added to visualise DNA bands. The solution was then 
poured into an electrophoresis tank containing fitted combs to create sample chambers and 
left to set. Once set, combs were removed and the gel was submerged in 1X TBE buffer. 
Sample was then added to each well and a 100 bp DNA ladder (New England BioLabs) was 
included to determine band size. Sixty volts was applied and DNA samples were allowed to 
migrate across the gel for 45 minutes. Gels were then placed in a D-DiGit™ gel scanner (Li-



















Figure 2.2: Gel electrophoresis of TREM2+/+, TREM2+/-, TREM2-/- DNA. TREM2+/+ mice are 
identified by a single 200 bp product in lanes detecting the Trem2 gene only. In TREM2+/- mice, an 
additional 598 bp product is observed in lanes detecting the inserted reporter cassette. In TREM2-/- 
mice, a single 598bp band is observed only in lanes detecting the inserted reporter cassette.  
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 Surgical Procedures 
 Bilateral common carotid artery stenosis 
BCAS was conducted to induce chronic cerebral hypoperfusion in mice (fig. 2.3). Mice were 
anaesthetised in an induction chamber with 5 % isoflurane in O2 (200 ml/ min) and N2O (500 
ml/ min) and then transferred to a face mask where anaesthesia was maintained at 2 % 
isoflurane in O2 (200 ml/ min) and N2O (500 ml/ min). The neck region of mice was shaved 
and treated with iodine, and a drape was placed over mice to maintain sterility. Temperature 
was maintained between 36.5 – 37.5 oC using a rectal probe and heat mat. A midline cervical 
incision was first made and each common carotid artery was dissected from overlying 
connective tissue. Two 4-0 suture threads were placed beneath the left common carotid artery 
and lifted to expose a portion of the artery inferior to the common carotid artery bifurcation. 
Induction of anaesthesia and exposure of carotid arteries prior to microcoil placement was 
conducted within 20 min. A microcoil (Sawane Spring Company, Japan) with an internal 
diameter of either 0.16 mm or 0.18 depending on the specific experiment was then placed on 
the left carotid artery by wrapping the artery around the coil. Wrapping carotid arteries around 
microcoils was conducted within 5 min to minimise ischaemic damage. The wound site was 
then sutured and treated with 4 % lidocaine (LMX4) (w/ w) and mice were recovered in a 30 
oC chamber for 30 min. Mice were then re-anaesthetised and the same procedure was 
conducted on the right carotid artery. The wound site was then sutured and treated with 4 % 
lidocaine (LMX4) (w/ w) again.  
Mice were then given 20 μl/ g saline subcutaneously and recovered in a 30 oC incubator for 1 
h. For the first 72 h of recovery, mice were weighed twice daily and provided 20 μl/ g saline 
subcutaneously once daily to maintain hydration. Following this, mice were weighed twice a 
week and their welfare evaluated by assessing posture, motility/ exploratory behaviours in 
addition to ability to eat and drink. Mice demonstrating signs of overt focal brain damage 
immediately after surgery including circling or barrel rolling were euthanised. Mice 
demonstrating persistent laboured breathing and lack of movement after 72 h or weight loss 
greater than 30 % were also euthanised. 
 














 Laser speckle contrast imaging 
Laser speckle flowmetry was conducted to assess cerebral blood flow changes in blood 
vessels on the cortical surface of mice following BCAS or sham surgeries. When laser light 
illuminates a surface the backscattering of light creates an interference pattern known as 
speckle pattern. The speckle intensity will change depending on movement of the illuminated 
object such as red blood cells moving through a blood vessel therefore enabling quantification 
of blood flow. TREM2+/+ and TREM2-/- mice were anaesthetised in an induction chamber 
with 5 % isoflurane in O2 (500ml/ min). Mice were then transferred to a stereotaxic frame and 
ventilated with a nose cone at 150 breaths per min with 3 % isoflurane in O2 (500 ml/ min). 
Mice were secured in place with ear and nose bars and temperature monitored and maintained 
between 36.5 oC – 37.5 oC using a rectal probe and heat mat. A midline incision was first made 
across the scalp and skin deflected to reveal the skull. A thin film of ultra sound gel pre-warmed 
to 37 oC was applied to the skull to prevent drying. Cerebral blood flow was then recorded 
using a laser speckle contrast imager (Moor FLPI2 Speckle Contrast Imager, Moor 
Instruments, UK) for 2 min. The wound was then sutured and treated with 4 % lidocaine 
(LMX4) (w/ w) and mice were placed in a 30 oC recovery chamber for 1 h.  
Figure 2.3: BCAS as a model of chronic cerebral hypoperfusion. Chronic cerebral hypoperfusion 
was achieved by placing microcoils with internal diameters ranging from 0.16 – 0.22 mm around the 
common carotid arteries of mice resulting in vessel narrowing and cerebral hypoperfusion. 
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Speckle contrast images were then analysed using MoorFLPI-2 Review software (version 4.0). 
Regions of interest were placed across forebrain regions supplied by the middle cerebral artery 
on left and right hemispheres and mean flux was calculated over the period of a minute across 
each recording (fig. 2.4). Mean flux values recorded at 24 h and 28 d were then divided by 
baseline values obtained prior to conducting BCAS surgery and multiplied by 100 to determine 


















 Transcardiac perfusion  
Mice were terminally anaesthetised and saline perfused to minimise contamination of brain 
tissue with blood components. On the day of tissue harvest, mice were weighed and deeply 
anaesthetised with 5 % isoflurane in O2 (200 ml/ min) and NO2 (500 ml/ min) in an induction 





















Figure 2.4: Laser speckle contrast image analysis. Bright field and speckle contrast images were 
used to place regions of interest on the mouse skull prior to, and after BCAS to obtain flux data on 
cortical perfusion in response to BCAS. 
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in O2 (200 ml/ min) and N2O (500 ml/ min). A transverse incision was first made inferior to the 
sternum and connective tissue dissected to reveal the diaphragm. The diaphragm was then 
dissected and rib cage retracted to expose the thoracic cavity and heart. The right atrium was 
cut to allow outflow of blood. A 25G butterfly infusion needle was then carefully inserted into 
the apex of the left ventricle and animals were perfused transcardially with 20 ml saline 
containing 2 ml 3.8 % sodium citrate (w/ v) at a rate of 3 ml/ min. For microglial isolation 
experiments described in section 2.8, saline was additionally treated with 1 % diethyl 
pyrocarbonate (DEPC) (v/ v) (Sigma) to inhibit RNases. Once the perfusion was complete, 
brain tissue was extracted for downstream analyses. 
  Tissue processing for pathological assessment 
For brain tissue used in pathological analyses, tissue was first post-fixed for 24 h in 4 % 
paraformaldehyde (PFA) (w/ v) (see appendix III) at 4 oC. If whole brains were used, brains 
were placed in a coronal matrix and separated into 4 mm rostral and 3 mm caudal portions. A 
MB35 premier microtome blade (ThermoScientific) was first placed at the junction between 
the olfactory bulb and cerebral cortex 3.58 mm anterior to bregma. A second microtome blade 
was then placed 0.56 mm posterior to bregma creating a rostral tissue portion and a final 
microtome blade was placed 3.56 mm posterior to bregma creating a caudal tissue portion. 
Olfactory and cerebellum tissues were discarded and rostral and caudal samples were 
dehydrated in a series of solvents by staff within Easter Bush Pathology (Veterinary Teaching 
Building) or the histology department (Shared University Research Facilities, The Queen’s 
Medical Research Facility) over a 14 h period (table 2.3) and embedded in paraffin. A Leica 
RM2235 microtome was used to cut 6 µm thick coronal sections. Sections were then placed 
in a 40 oC water bath to remove tissue creases. Once removed, tissue sections were placed 
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 Immunohistochemistry and histology 
 Immunohistochemistry 
Sections were placed in xylene (Fisher Scientific) twice for 10 min each and submerged in 
decreasing concentrations of ethanol (99 %, 95 %, and 70 %) for 5 min each and rinsed in 
distilled H2O (dH2O) to rehydrate. Tissue sections requiring antigen retrieval were then placed 
in 0.01 M tri-sodium citrate antigen retrieval buffer (see appendix III) and heated in a Sharp 
1000W R-21 ATP microwave for 10 min and cooled. All tissue sections were then treated with 
0.3 % H2O2 (v/ v) (Sigma) in methanol (Fischer Scientific) for 10 min to block endogenous 
peroxidase activity. Sections were then rinsed with dH2O and washed with 0.01 M phosphate 
buffered saline (PBS) (Sigma). 10 % normal serum (Vector) (v/ v) derived from the species of 
the secondary antibody in 0.01 M PBS containing 5 % bovine serum albumin (BSA) (Sigma) 
(w/ v) was used to block sections for 1 h at room temperature (RT). Sections were then treated 
overnight with primary antibody and 2 % normal serum in 0.01 M PBS (v/ v)  or 2 % normal 
serum in 0.01 M PBS only to assess specificity of secondary antibodies at 4 oC (table 2.4) (fig. 
2.5 – 6). The following day, sections were washed with 0.01 M PBS and treated with a biotin-
conjugated IgG secondary antibody (Vector) for 1 h at RT (table 2.4). Sections were then 
washed with 0.01 M PBS and treated with avdidin-biotin peroxidase complex (Vector) for 30 
min at RT. Following this, sections were washed with 0.01 M PBS and treated with 0.015 % 
Treatment  Duration  
70% ethanol 1 h 
95% ethanol 1 h 
Absolute ethanol 4x1 h 
Xylene 3x1 h 
Wax 3x 1 h 20 mins 
Table 2.3: Processing schedule for paraffin embedded brain tissue. 
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H2O2 + 0.5 mg/ ml DAB (Sigma) in dH2O for 3 min. Once staining had developed, sections 
were washed with dH2O. Sections were then placed in increasing concentrations of ethanol 
(70 %, 95 % and 99 %) for 3 min each to dehydrate and then xylene twice for 5 min. Coverslips 
were then applied using Pertex mounting medium (CellPath) and slides were left to dry. 
Representative images demonstrating IBA1, GFAP and MAG staining and secondary antibody 
































































Table 2.4: Optimised conditions for immunostaining (IBA1, MAG & GFAP) in paraffin embedded 
brain tissue via immunoperoxidase-based detection. 
 
 






























Figure 2.5 Representative low magnification images of MAG, IBA1 and GFAP immunostaining 
in paraffin embedded brain tissue via immunoperoxidase-based detection. 
 



























Figure 2.6: Representative low magnification images showing specificity of secondary 
antibodies to MAG, IBA1 and GFAP antibodies in paraffin embedded brain tissue via 
immunoperoxidase-based detection.  
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 Myelin associated glycoprotein immunostaining 
quantification  
Myelin associated glycoprotein (MAG) immunostaining was conducted to assess white matter 
integrity in response to BCAS. MAG is a glycoprotein expressed on distal portions of 
oligodendrocyte processes at the axon-glial interface. MAG is preferentially lost in response 
to ischaemic or inflammatory damage compared to other myelin components such as myelin 
basic protein (MBP) enabling detection of subtle white matter changes (Aboul-Enein, 2003). 
MAG immunostaining was analysed using a Nikon Brightfield light microscope or Zeiss Axio 
Imager 2 at 200 X magnification in regions of interest in one tissue section. Regions of interest 
were chosen and are described in respective results chapters. A semi-quantitative grading 
scale was implemented to quantify the extent of myelin damage in each white matter tract 
consisting of 0 (no white matter debris, vacuolation or disorganisation of white matter fibres), 
1 (mild white matter debris, vacuolation and disorganisation of white matter fibres), 2 
(moderate white matter debris, vacuolation and disorganisation of white matter fibres) and 3 
(extensive white matter debris, vacuolation and disorganisation of white matter fibres) (fig. 
2.7). If both hemispheres were analysed, severity scores of white matter regions from each 
hemisphere were summated providing a total possible score of 6. Scores from each white 


























Figure 2.7: Assessment of myelin integrity using MAG immunostaining. In areas of white matter 
damage, myelin debris can be observed as darkened globular structures (black arrows) enabling 
quantification of the extent of myelin damage. A scoring method was utilised consisting of 0 (no white 
matter debris or disorganisation of white matter fibres), 1 (mild white matter debris and 
disorganisation of white matter fibres), 2 (moderate white matter debris, vacuolation and 
disorganisation of white matter fibres) and 3 (extensive white matter debris, vacuolation and 
disorganisation of white matter fibres). 
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 Ionised calcium binding adaptor protein 1 and glial fibrillary 
acidic protein immunostaining quantification  
Ionised calcium binding adaptor protein-1 (IBA1) is expressed by macrophages and microglia 
in the CNS and is upregulated following cell activation enabling investigation of microglial 
responses to CNS injury. On the other hand, GFAP is an intermediate filament protein almost 
exclusively expressed by astrocytes. Although astrocytes are widely distributed throughout the 
CNS, immunostaining primarily labels fibrous astrocytes of the white matter in the healthy 
brain. However, GFAP is upregulated in response to cell activation enabling assessment of 
reactive gliosis in response to CNS injury.   
To investigate glial responses to BCAS, images of IBA1 and GFAP immunostaining were 
obtained from one brain section per animal on a Zeiss Axio Imager 2 or Axioscan slide scanner 
at 200 X magnification. IBA1+ cell bodies were quantified in each white matter region by 
placing 4 regions of interest measuring 0.1 – 0.2 mm2  across each white tract per hemisphere 
using ImageJ software. If only one hemisphere was analysed IBA1+ cell bodies would be 
manually counted in four regions of interest per white matter region whilst if two hemispheres 
were analysed IBA1+ cell bodies would be manually counted in 8 regions of interest. Values 
from each region of interest were then averaged to provide the number of IBA1+ cells per 0.1 
– 0.2 mm2 in each white matter region. To quantify total IBA1+ cell number in whole brain 
sections, images of brain sections were first converted to 8-bit and thresholded to distinguish 
IBA1+ cell bodies from background on imageJ. The analyse particles plugin was then used to 
detect cell bodies and particle number was calculated to provide total IBA1+ cell counts in 
whole brain sections.  
GFAP immunostaining was quantified in white matter regions by converting images to 8-bit 
and applying thresholding to distinguish GFAP from background staining and determining 
percentage area of staining in areas of interest. If two hemispheres were analysed, values 
obtained from white matter regions in left and right hemispheres were averaged. The same 
method of thresholding and quantification was also utilised to quantify total GFAP 
immunostaining in whole brain sections.  
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 Histology  
Adjacent tissue sections were stained with haematoxylin and eosin (H&E) to detect neuronal 
pathology. Tissue sections were first rehydrated as described in section 2.6.1 and placed in 
Harris’ haematoxylin (TCS Biosciences Ltd) for 30 s. Tissue sections were then washed in 
dH20 and submerged in Scott’s tap water (Leica Biosystems) for 30 s and washed in dH20 for 
30 s. Sections were then placed in eosin (Leica Biosystems) for 3 min and rinsed in dH20 
before placing in 70 % ethanol for 5 min, 95 % ethanol for 5 min, 99 % ethanol for 5 min and 
xylene twice for 5 min. Coverslips were applied using Pertex mounting medium and dried. 
Grey matter regions analysed included the hippocampus, cortex, thalamus, striatum and 
hypothalamus. Neuronal pathology was identified by condensation of nuclei, vacuolation and 
pallor within the parenchyma.  
  Flow cytometry  
 Preparation of a brain cell suspension 
Flow cytometry was utilised to quantify changes in the immune cell composition of the brain 
following BCAS. Flow cytometry is a laser-based technique enabling multi-parameter analysis 
of cells. When cell suspensions are acquired by the cytometer they are aligned in sheath fluid 
so that cells pass laser light one cell at a time. Once the laser light contacts cells the forward 
and side scattering of light are detected providing information on both the size and granularity 
of cells, respectively. Furthermore, cell antigens can be labelled with fluorescent-conjugated 
antibodies which upon excitation with laser light at a particular wavelength, emit light. 
Fluorescence emission is then filtered and detected by sensors at a specific wavelength and 
converted into a digital value providing information on antigen expression. 
Following transcardiac perfusion, brains were extracted and placed in a coronal matrix. The 
cerebellum and olfactory bulb were dissected and removed, and a portion of forebrain 
dissected and placed in 5 ml ice cold 1X Hank’s buffered saline solution (HBSS) (without Ca2+ 
and Mg2+) (Gibco, Life Technologies). Tissue was then diced finely using a scalpel and 
centrifuged at 400 g for 5 min at 4 oC. Supernatant was discarded and samples were  incubated 
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in 10 ml enzyme cocktail (50 U/ ml collagenase type IV (Gibco, Life Technologies), 0.5 U/ ml 
dispase II (Gibco, Life Technologies), 200 U/ ml DNase I (Roche), 10µM tosyl-L-lysine 
chloromethyl ketone hydrochloride (TLCK) (Sigma) in 1X HBSS (containing Ca2+ and Mg2+) 
(Gibco, Life Technologies) on a roller/ shaker for 1 h at 37 oC. 1 ml foetal bovine serum (FBS) 
(Gibco, Life Technologies) was then added to deactivate enzyme activity and digested brain 
tissue was transferred to a 15 ml Dounce tissue homogeniser on ice and manually 
homogenised using 20 passes of a loose fitting pestle. Homogenate was then transferred to a 
new 15 ml falcon and centrifuged at 400 g for 5 min at 4 oC with no brake. Supernatant was 
aspirated to waste and homogenate resuspended in 8 ml 35 % percoll (GE healthcare) in 
1XHBSS (v/ v). To create this, 100 % isotonic Percoll was first made by diluting 10XHBSS 
(without Ca2+ & Mg2+) (Gibco, Life Technologies) in percoll 10 fold. 100 % isotonic percoll was 
then diluted to 35 % with 1XHBSS (without Ca2+ & Mg2+). Homogenate resuspended in 35 % 
percoll was then carefully overlaid with 5 ml 1XHBSS (without Ca2+ or Mg2+) and samples were 
centrifuged at 800 g for 45 min at 4 oC with no brake for density separation of cells from myelin.  
Following centrifugation, supernatant was aspirated to waste and samples were resuspended 
in 5 ml 1XHBSS (without Ca2+ or Mg2+) and transferred to a new 15 ml falcon. Samples were 
then centrifuged at 400 g for 5 min and supernatant was aspirated to waste. Samples were 
then resuspended in 1 ml FACS buffer (see appendix III). 20 μl of cell suspension was 
combined with 20 μl trypan blue (0.4 %) (Gibco, Life Technologies) to differentiate live and 
dead cells and a cell count was calculated using a haemocytometer. Briefly, the number of live 
cells in 16 squares was counted and multiplied by two as cells were diluted 1:1 in trypan blue. 
Values obtained were then multiplied by 10,000 to give the total number of viable cells per ml.  
 Labelling of cell surface antigens  
10 µl anti-CD16/ 32 (Clone: 93, Biolegend) was added to samples (0.5 mg / ml) to block non-
specific Fc receptor binding and samples were incubated for 30 min at 4 oC on a shaker. Cells 
were then resuspended at a density providing 1 x 106 cells/ ml in FACS buffer and seeded at 
a volume of 100 µl/ well in a 96-well plate (Nunc) and an additional 200 µl of FACS buffer was 
added to each well. Plates were centrifuged at 400 g for 3 min at 4 oC. Supernatant was 
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discarded thereafter and 50 µl fluorochrome-conjugated antibody was added to appropriate 
wells (table 2.5). Unstained and single stained samples were included as controls. Samples 
used to assess CNS cell composition were treated with two separate antibody cocktails to 
label and identify myeloid and lymphoid populations. Plates were then covered in foil and 
incubated for 30 min at 4 oC on a shaker. Afterwards, 200 µl FACS buffer was added to each 
well to wash and the centrifugation process repeated. Supernatant was discarded and cells 
were resuspended in 200 µl FACS buffer for acquisition. All data were acquired using a BD 


















Antigen Fluorochrome Clone Concentration 
CD11b APC Cy7 M1/ 70 1 µg/ ml 
CD45 PE Cy7 30/ F11 1 µg/ ml 
F4/ 80 Alexa flour 488 BM8 1 µg/ ml 
Ly6C Pacific blue HK1.4 1 µg/ ml 
Ly6G APC 1A8 1 µg/ ml 
CCR2 PE 475301 1 µg/ ml 
CD3 PE 17A2 1 µg/ ml 
B220 PE Cy7 RA3.6B2 1 µg/ ml 
BrdU FITC - 1 µg/ ml 
Table 2.5: Fluorochrome-conjugated antibodies used to investigate cell composition changes in 
response to chronic cerebral hypoperfusion. 
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 Labelling of intracellular BrdU  
Bromodeoxyuridine (BrdU) was used to investigate changes in cell proliferation in response to 
chronic cerebral hypoperfusion. Briefly, BrdU is a synthetic analogue of thymidine. During S 
phase of the cell cycle when DNA is replicating BrdU is incorporated into newly synthesised 
DNA substituting thymidine. Conjugated antibodies can then be used to label BrdU enabling 
identification of proliferating cells. The BD FITC conjugated BrdU flow kit was utilised to fix and 
permeabilise cells, and label BrdU following manufacturer’s instructions.  
Following preparation of a brain cell suspension, cells were seeded onto a separate plate at 1 
x 105 cells per well and labelled with conjugated antibodies to cell surface antigens as 
described in section 2.7.2. Following this, cells were fixed and permeabilised with 100 µl BD 
cytofix/ cytoperm buffer and incubated at 4 oC on a shaker for 30 min. Cells were then washed 
by adding 200 μl 1X BD wash/ perm buffer and centrifuged at 400 g for 3 min at 4 oC. 
Supernatant was removed and cells were permeabilised by resuspending in 100 µl BD 
cytoperm permeabilisation buffer for 10 min at 4 oC on a shaker. The wash step was repeated 
again and cells were re-fixed by resuspending in 100 µl BD cytofix/ cytoperm buffer for 5 min 
at 4 oC on a shaker. The wash step was repeated and cells were treated with DNase (300 µg 
/ ml) in PBS (with Ca2+ and Mg2+) (Gibco, life technologies) for 1 h at 37 oC. The wash step 
was repeated and cells were treated with FITC-conjugated BrdU antibody in 1X BD Wash/ 
Perm Buffer ( 1 µg/ ml) for 30 min at 4 oC on a shaker. The wash step was repeated and cells 
were resuspended in 200 µl FACS buffer prior to acquisition on a BD LSR Fortessa X20 
(Becton Dickinson, Oxford, UK) 
 Data acquisition and analysis  
Upon acquisition, an unstained sample was recorded and viable cells identified based on 
forward and side scatter properties. 2000 – 5000 cell events were recorded for unstained and 
single stained controls whilst 10,000 events were recorded for samples used to investigate 
cell composition. Once all samples had been recorded, data were saved as FCS3 files and 
exported for analysis. For flow cytometric quantification, data were analysed using FlowJo 
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version 10. Viable cells were first identified based on their forward and side scatter profile and 
doublets excluded (fig. 2.8). Compensation was applied to correct fluorochrome bleed through 
and cell populations identified based on positive and negative gating strategies using a 
combination of markers (table 2.6). Absolute cell counts were then calculated by the following 
equation:  
 
(# 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡)
(# 𝑣𝑖𝑎𝑏𝑙𝑒  𝑐𝑒𝑙𝑙𝑠)












B cells CD11b-B220+ 
T cells CD11b-CD3+ 
Viable cells         >        Single cells          >      Cells of interest 
 


























Table 2.6: Cell surface antigen labelling profile utilised to identify cell populations in brain 
cell suspensions. 
 
Figure 2.8: Representative dot plots showing gating strategy for identifying cells of interest. 
Viable cells were identified based on forward and side scatter properties. Doublets were then excluded 
and cell populations identified based on a combination of markers.  
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 Fluorescence activated cell sorting of microglia  
 Tissue dissection  
Following transcardiac perfusion described in section 2.4.3, brains were extracted and placed 
in a sagittal brain matrix and four 2 mm sagittal slices were cut and placed in ice cold 1XHBSS 
(without Ca2+ and Mg2+). Each tissue slice was then placed on an ice-cold surface under a 
dissection microscope. Olfactory bulb and cerebellum were first removed and placed in 50 ml 
falcon containing ice cold 5 ml 1XHBSS to be used for downstream unstained and single-
stained controls. Grey matter and white matter portions were then separated from the 
remaining tissue. For grey matter, a portion of cortex, hippocampus and striatum was isolated 
from each tissue slice and combined in a 50 ml falcon containing 5 ml ice cold 1XHBSS. For 
white matter, corpus callosum and portions of internal capsule were dissected and placed in 
















Figure 2.9: White matter and grey matter regions dissected for FACS isolation of microglia. The 
cerebellum (Cb) and olfactory bulb (OB) were dissected and used for unstained and single stained 
controls. The corpus callosum (CC) and internal capsule (IC) were dissected to isolate white matter 
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 Preparation of brain cell suspension  
Once tissue had been collected, samples were centrifuged at 400 g for 5 min at 4oC and 
supernatant aspirated to waste. White matter samples were reconstituted in 2 ml ice cold 
1XHBSS containing 12.5 mM HEPES whilst grey matter samples and samples used for 
unstained and single stained controls were reconstituted in 10 ml ice cold 1XHBSS, 12.5 mM 
HEPES. Grey matter samples and spare samples used for single and unstained controls were 
transferred to a 15 ml Dounce homogeniser whilst white matter samples were transferred to a 
2 ml Dounce homogeniser and homogenised with 40 passes.  
After tissue homogenisation, sample was transferred to a 15 ml falcon and centrifuged at 400 
g for 5 min at 4oC and supernatant was aspirated to waste. Samples were reconstituted in 8 
ml 35 % percoll, 12.5 mM HEPES and this was then carefully overlaid with 5 ml 1XHBSS, 12.5 
mM HEPES. Samples were then centrifuged at 800 g for 20 mins at 4oC with no brake for 
density separation of myelin and from cells. Cell pellets were then resuspended in 1 ml 
1XHBSS, 12.5 mM HEPES and transferred to a 5 ml polystyrene round bottomed FACS tube 
(Corning) and centrifuged at 400 g for 5 mins at 4 oC. Supernatant was then aspirated to waste 
and cells were reconstituted in 250 μl FACS buffer. 5 μl sample was then transferred to a 
microtube to conduct a cell count using a haemocytometer as described in section 2.7.1.  
 Labelling of cell surface antigens  
Once cell counts were completed 2.5 µl anti-CD16/ 32 was added (0.5mg/ ml) to block Fc 
receptors for 30 min on ice. Following this, spare cells obtained from dissected cerebellum 
and olfactory bulb for single and unstained controls were transferred to a 96 well plate. All 









Following incubation, samples were centrifuged at 400 g for 5 min at 4 oC and supernatant 
was aspirated to waste. Samples were then reconstituted in 250 μl FACS buffer and placed 
through a 40 µm filter to remove aggregated cells and large debris prior to acquisition. All 
samples were acquired and sorted using a BD FACSAria II (Becton Dickinson, Oxford, UK) by 
staff members at the Queen’s Medical Research Institute Flow Cytometry and Cell Sorting 
Facility.  Cells of interest were first identified based on forward and side scatter properties and 
doublets excluded. Dead cells were also excluded by gating on DAPI negative cells. 10,000 
events were recorded from this population for cell composition analysis. Microglia were 
identified as Ly6C-CD11b+CD45lo cells and sorted directly into 500 µl RLT cell lysis buffer 
(Qiagen) containing 1 % β-mercaptoethanol using a 100 µm diameter nozzle.  
  Microglial RNA extraction 
Following cell sorting, samples were vortexed for 10 s and centrifuged for 10 min at full speed 
at RT to promote efficient lysis. RNA extraction was then performed using a RNeasy Plus 
microkit following manufacturer’s instructions. First, amples were transferred to Qiashredder 
columns (Qiagen) and centrifuged at full speed for 2 min to homogenise. Samples were then 
transferred to genomic DNA (gDNA) column to remove contaminating genomic DNA and 
centrifuged at 8000 g for 2 min at RT. Sample was then transferred to a 15 ml falcon and 1 
Antigen Conjugate Clone Concentration 
CD11b PE M1/ 70 1 µg/ ml 
CD45 PE Cy7 30-F11 1 µg/ ml 
Ly6C APC HK1.4 1 µg/ ml 
Ly6G Pacific blue 1A8 1 µg/ ml 




Table 2.7: Fluorochrome-conjugated antibodies utilised to identify cell populations in brain 
cell suspensions for FACS-based isolation of microglia. 
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volume of 70 % ethanol added. Samples were inverted to mix and transferred to RNeasy 
MinElute spin column and centrifuged for 15 s at 8000 g at RT. Elute was removed to waste 
and 700 μl RW1 was added to columns. Columns were then centrifuged for 15 s at 8000 g at 
RT and elute was removed to waste. 500 μl RPE buffer was then added to columns before 
centrifugation at 8000 g for 15 s at RT. Elute was discarded and 500 μl 80 % ethanol was 
added to columns before centrifuging for 2 mins at 8000 g at RT. Both the collection tube and 
elute were discarded and the column was placed in fresh collection tube. Samples were then 
centrifuged at full speed for 5 min with lids left open to dry the silica membrane within the 
RNeasy MinElute spin column. Collection tubes and elute were discarded and again columns 
were placed in fresh collection tubes. Isolated RNA was then eluted by placing 14 μl nuclease-
free water directly onto the silica membrane and centrifuging for 5 min at full speed at RT. This 
process was then repeated to increase total yield of RNA extracted.  Once RNA was eluted, 
total yield was determined using a Nanodrop spectrophotometer and samples were stored at 
-80oC.  
 Assessment of RNA quality 
2.9.1.1 Spectrophotometer  
The DS-11-FX Nanodrop spectrophotometer (DeNovix) was used to determine RNA 
concentration and purity of extracted RNA. RNA concentration is determined by the extent of 
light absorption at 260 nm. Light absorption at 230 nm and 280 nm indicates contamination of 
sample with protein or organic compounds from the extraction process such as guanidine or 
phenol, respectively. RNA purity was assessed based on 260/ 280 ratios which typically range 
between 2.0 -2.2.  
2.9.1.2 Electrophoretic analysis 
The LabChip GX24 (Perkin Elmer) was used to assess quality of extracted microglial RNA 
with a RNA Pico sensitivity assay following manufacture instructions (assay conducted by 
Pamela Brown, Biomolecular Core, Queen’s Medical Research Institute). The LabChip GX24 
conducts automated analysis of RNA concentration and quality using electrophoresis and 
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fluorescence. A RNA quality score is generated to determine the extent of degradation 
between 0 – 10 with 10 being intact RNA based on the calculation of several factors including 
18S and 28S peak height and area, total RNA area and fast region area (region between the 































Figure 2.10: Electropherogram analysis used to determine RNA quality. (A) Representative 
electropherogram with parameters labelled to quantify RNA quality score. (B) Representative 
electropherograms showing differences between intact RNA (RQS: 9.6) and degraded RNA (RQS: 3.5). 
Clear 18S and 28S peaks can be observed in intact RNA samples and baseline is close to 0. However, 
in the degraded sample 28S peak height is reduced and smaller RNA fragments can be observed in 
the fast region characteristic of degraded RNA. Images obtained from PerkinElmer. 
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 cDNA synthesis  
To investigate gene expression from RNA via real time quantitative polymerase chain reaction 
(RT-QPCR) complementary DNA (cDNA) must first be generated by reverse transcription. 
Extracted RNA was first combined with 2 μl 10 mM deoxynucleotide triphosphate (dNTP) 
(Invitrogen) and 2 μl 0.5 μg/ μl oligo(dT)15 (Promega) and total reaction volume was made to 
14 μl with nuclease free dH20. A T100 thermal cycler was then used to heat the mixture to 65 
oC for 5 min and samples were incubated on ice for 1 min. Following this samples were briefly 
centrifuged and combined with 0.1 M dithiothreitol (DTT) (Promega) 5x, first strand buffer, 40 
U/ μl RNasinR Plus Inhibitor (Promega) and 200 U/ μl SuperscriptTM III reverse transcriptase 
(Invitrogen). In control samples, nuclease free water was added instead of Superscript III to 
test for DNA contamination. Samples were then vortexed and placed in a T100 thermal cycle 
and heated to 50 oC for 55 min to promote reverse transcription and then 70oC for 15 min to 
induce enzyme inactivation. Samples were then stored at -20 oC prior to conducting RT-qPCR.   
 Real time quantitative polymerase chain reaction (RT-qPCR) 
RT-QPCR was utilised to investigate gene expression in microglia compared to whole brain 
tissue. SYBR green was used as a DNA binding dye to intercalate newly formed double 
stranded DNA and quantify relative gene expression compared to control samples. A 
mastermix was first made by combining 10 ng cDNA, 1 μl ROX reference dye (diluted 1:10 
from stock) (Invitrogen), 12.5 μl Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen), 
1.25 μl forward primer, 1.25 μl reverse primer (table 2.8) and dH20 to a total volume of 25 μl. 
























Primers Sequence 5’ – 3’ 
Product 
length (bp) 
Gapdh forward strand CCTTGTGTCCTTGAACCAGC  
Gapdh reverse strand AAGGGAGGCTGGTAGAGAGA 140 
Aif1 forward strand GCAGCCTCTGTTCCACATACACTTCA  
Aif1 reverse strand ATCTCAGACTGCATTCTCCCACTCC 119 
Tmem119 forward strand CAGAGCTGGTTCCATAGCTCAA  
Tmem119 reverse strand CCGGGAGTGACACAGAGTAG 102 
Aldh1l1 forward strand TGCAGAAAGTGGTGGAGGAA  
Aldh1l1 reverse strand CACCACGTTGGCATACTCC 126 
Rbfox3 forward strand ATGGAGCGGTCGTGTATCAG  
Rbfox3 reverse strand AAGGATCAGCAGCGGCATAG 144 
Table 2.8: Oligonucleotide sequences of primers used to investigate relative gene 
expression in microglia compared to whole brain tissue. 
 
 






















The level of gene expression was determined by the cycle threshold (Ct) value at which point 
fluorescence emitted from DNA-bound SYBR green increases over baseline fluorescence. 
Baseline fluorescence was automatically determined by stratagene Mx3005P software. 
Relative gene expression by isolated microglia was compared with whole brain tissue using 
∆∆Ct.  Briefly, the Ct value of the used housekeeping gene, Gapdh, was first subtracted from 
Ct values of genes of interest providing the delta Ct value. The delta Ct value of control 
samples, in this case whole brain, were then subtracted from the delta Ct value from of genes 
of interest providing relative expression of genes of interest.  
Step Temperature (oC) Time Cycle 

















Table 2.9: Thermal profile used to amplify cDNA for RT-qPCR analysis. 
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 Statistics 
Data were analysed and statistics performed on Graphpad Prism version 7.4. Distribution of 
data were first determined by conducting a Shapiro-Wilk test. The Mann-Whitney U test was 
used to investigate differences between two groups whilst the Kruskal Wallis test was used to 
investigate differences between three or more groups when data were not normally distributed. 
If data were normally distributed, differences between two groups were investigated using 
Student’s or Welch’s t test depending on data variance whilst one way analysis of variance 
(ANOVA with Bonferroni post hoc was used to investigate differences between 3 groups. Two 
way ANOVA with Bonferroni adjustment was used to assess changes in cerebral blood flow 
following BCAS and sham surgeries in WT and TREM2-/- mice. Additional details of statistical 
analyses performed can be found in results chapter methods. All data analysis was conducted 
with blinding to treatment and genotype. Unless stated otherwise, data are presented as mean 
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Chapter 3: 
Validation of BCAS as a suitable model to 
investigate neuroinflammatory responses to 
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 Introduction 
Chronic cerebral hypoperfusion is suggested to be a key contributor to white matter damage, 
age related cognitive impairment and dementia. Various animal models in which cerebral 
blood flow is manipulated have therefore been developed to investigate the pathological 
mechanisms by which cerebral hypoperfusion mediates white matter damage and cognitive 
decline. The BCAS model, in which microcoils are fitted on the common carotid arteries of 
mice to induce cerebral hypoperfusion, recapitulates various pathological features of VCI 
(Shibata et, al., 2004). 28 d following microcoil placement, C57BL/6J mice demonstrate diffuse 
white matter pathology without overt neuronal perikarya damage associated with spatial 
working memory impairment (Shibata et al., 2004). Furthermore, areas of white matter 
damage are associated with robust neuroinflammation characterised by reactive gliosis 
(Shibata et al., 2004, Coltman et al., 2011, McQueen et al., 2014). This model therefore 
provides a powerful tool to investigate the mechanisms by which neuroinflammation 
contributes to loss of white matter integrity and cognitive impairment.  
Prior to characterising the neuroinflammatory response resulting from BCAS it was essential 
to validate that BCAS precipitated comparable pathology to previous studies in WT 
C57BL/6Ntac mice from the TREM2 colony. As it has previously been reported that use of 
0.18 mm internal diameter microcoils induces reproducible myelin damage after 28 d in 
C57BL6/J mice, it was hypothesised that BCAS would cause loss of myelin integrity in WT 
C57BL/6Ntac mice. To investigate this, key markers of neuronal damage, myelin integrity and 
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 Aims 
1. Investigate animal recovery associated with inducing BCAS for 28 d using 0.18 mm 
microcoils in WT C57BL/ 6Ntac mice.  
2. Determine frequency and severity of white matter and grey matter pathology, as well 
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 Methods 
 Animal procedures 
WT C57BL/6Ntac mice aged 2 - 3 m were utilised to investigate pathological changes resulting 
from BCAS. A total of 16 mice were used and randomly assigned to receive sham (n = 6) or 
BCAS (n = 10) surgeries. N numbers were chosen based on power analysis of data from 
previous BCAS studies. To achieve a significance level of p < 0.05, a group size of 8 was 
required to reach a power of 0.8. For BCAS surgeries, microcoils with 0.18 mm internal 
diameters were used bilaterally and sham surgeries were conducted as reported in section 
2.4.1. Following surgery, mouse recovery was assessed twice daily for the first 72 h and then 
twice weekly thereafter. 
 Tissue harvest 
28 d after surgery, mice were saline perfused and brains post-fixed in 4 % paraformaldehyde 
(w/ v) as described in section 2.4.3. Tissues were processed, paraffin embedded and 
sectioned as described in section 2.5. 6 μm tissue sections were obtained at the level of the 
striatum (~0.74 mm anterior to bregma) and hippocampus (~1.70 mm posterior to bregma) 
and histology and IHC were utilised to investigate white and grey matter pathology resulting 
from BCAS. 
 Histology 
Neuronal pathology was assessed by H & E staining as described in section 2.6.4. Neuronal 
pathology was identified by condensation of nuclei, vacuolation and pallor within the 
parenchyma (see fig. 3.2). All staining and subsequent analysis was conducted by the author 
with blinding to sham and BCAS groups. 
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 Immunohistochemistry 
MAG and IBA1 immunostaining were conducted by the author to assess myelin integrity and 
microglial reactivity following BCAS, respectively, as described in sections 2.6.1 - 2.6.2. A 
semi-quantitative method described in section 2.6.2 was used to quantify white matter integrity 
in white matter tracts. As both brain hemispheres were assessed, white matter damage scores 
for individual white matter tracts were summated from each hemisphere providing a total 
possible score of 6. A ‘total myelin damage’ score was also calculated by summating all myelin 
damage scores from each animal providing a total possible score of 36.  
For IBA1+ cell quantification, four regions of interest measuring 0.1 mm2 were randomly placed 
across each white matter tract analysed per hemisphere (see section 3.3.5 below) using 
ImageJ software. IBA1+ cell bodies were then manually counted within each region of interest 
and values from left and right hemispheres (total of 8 regions of interest) were averaged to 
provide the number of IBA1+ cells per 0.1 mm2 in each white matter tract. All immunostaining 
and subsequent analysis was conducted by the author with blinding to sham and BCAS 
groups. 
 Regions of interest 
For the purpose of this study, both brain hemispheres were analysed to characterise pathology 
resulting from BCAS. White matter regions analysed include the corpus callosum, 
hippocampal fimbria, internal capsule, external capsule, optic tract and striatal bundles. Grey 
matter regions analysed include the cerebral cortex, hippocampus, thalamus and striatum (fig. 
3.1). For IBA1 quantification, white matter regions analysed include the corpus callosum, optic 

























Figure 3.1: White and grey matter regions used for pathological assessment. Outlined regions 
demonstrate grey matter regions analysed (hippocampus, striatum, thalamus and cerebral cortex). 
Coloured regions demonstrate white matter tracts analysed (green: corpus callosum, orange: external 
capsule, red: hippocampal fimbria, purple: internal capsule, black: optic tract, yellow: striatal bundles). 
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 Statistics 
Fisher’s exact test was used to determine if BCAS increased the probability of myelin damage 
occurring. Mann Whitney U test was conducted to test for differences in myelin integrity and 
IBA1 cell number between BCAS and sham animals. All statistical analyses were performed 
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 Results 
 Animal recovery 
Following surgery, 5 of 6 sham and 6 of 8 BCAS animals were motile and responsive within 1 
h of surgery and exhibited eating and drinking with normal exploratory behaviour after 24 – 48 
h. Sham and BCAS mice demonstrated a maximal 5.9 % and 5.3 % loss in weight 3 d following 
surgery, respectively (see appendix section 8.1.1). These mice demonstrated no adverse 
neurological symptoms such as circling, seizures or barrel rolling and remained healthy until 
tissue harvest. 1 of 6 sham (16.6 % mortality) and 2 of 10 BCAS (20 % mortality) animals were 
culled within the first 48 h after surgery due to circling, persistent unresponsiveness and 
laboured breathing suggestive of overt neuronal damage or vagus nerve damage. The final 










Treatment group Final cohort size (n) 
Sham 5/ 6 
BCAS 8/ 10 
Table 3.1: Final ohort sizes 28 d after sham and BCAS surgeries. 
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 Pathological assessment 
3.4.2.1 H & E assessment of CNS pathology 
H & E staining was conducted to assess tissue integrity and identify potential neuronal 
perikarya damage 28 d following BCAS or sham surgeries. No neuronal pathology was 
observed in any brain region examined in sham animals. 7 of 8 BCAS animals also 
demonstrated no evidence of neuronal pathology in any region examined. 1 of 8 BCAS 
animals demonstrated extensive neuronal pathology in grey matter regions including the 
striatum, cortex, hippocampus and thalamus characterised by the presence of shrunken, 










Treatment Animals displaying neuronal pathology 
Sham 0/ 5 (0 %) 
BCAS 1/ 8 (12.5 %) 
Table 3.2: Mice displaying neuronal pathology detected by H & E staining 28 d after sham or 
BCAS surgeries. One tissue section analysed per animal. 
 
 










































Figure 3.2: Assessment of neuronal pathology by H & E staining in sham and BCAS mice 28 
d post surgery. Representative images demonstrating H & E staining of the CA1 region of the 
hippocampus (A, E, I), cortex (B, F, J), thalamus (C, G, K) and striatum (D, H, L) of sham animals 
(A-D) , BCAS mice (E-H) and a BCAS mouse demonstrating widespread neuronal pathology (I-L). 
Black arrows demonstrate examples of darkened, condensed nuclei. White arrows demonstrate 
examples of vacuolation.  Scale bar: 50 μm 
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3.4.2.2 Assessment of myelin integrity 
Myelin integrity was assessed across several white matter regions via MAG immunostaining 
in sham and BCAS animals 28 d post surgery and extent of myelin damage was quanitified. 
Loss of myelin integrity was not observed in any sham animals. In response to BCAS, 6 of 8 
animals demonstrated myelin damage (fig. 3.3). Fisher’s exact test demonstrated BCAS 
significantly increased the probability of myelin damage occurring compared to sham animals 
(p ≤ 0.05) (fig. 3.3A). However, the severity and extent of myelin damage was generally subtle 
and anatomically confined to one or two regions rather than being diffuse as reported in 
previous studies (Shibata, et al. 2004., Coltman, et al., 2011).  
One animal demonstrating extensive neuronal damage also demonstrated severe white 
matter damage with extensive myelin debris and loss of white matter fibre organisation in 
several white tracts analysed (data points shown in red) (fig. 3.4B). Statistical analysis of 
myelin damage scores in individual white matter tracts revealed no significant difference in 
damage between sham and BCAS animals (p ≥ 0.05) (fig. 3.4B). However, a significant 
increase in total white matter damage was observed in response to BCAS compared to sham 



























 Mice displaying 
myelin damage 
CC EC HF IC SB 





0/ 5   
(0%) 
0/ 5  
(0%) 
0/ 5  
(0%) 
BCAS 6/ 8 (75 %) 




2/ 8      
(25 %) 
3/ 8   
(37.5 %) 
2/ 8     
(25 %) 
 
























































































































Figure 3.3: Frequency of sham and BCAS mice demonstrating myelin damage detected by MAG 
immunostaining 28 d post surgery. (A) Overall frequency of mice demonstrating myelin damage 
detected via MAG immunostaining in sham and BCAS mice. BCAS significantly increased the 
probability of myelin damage occurring compared to sham animals. (B) Frequency of white matter 
tracts demonstrating damage in response to BCAS. *P ≤ 0.05. Fisher’s exact test.. One tissue section 
analysed per animal. N = 5 – 8 independent animals per group. CC: corpus callosum, EC: external 
capsule, HF: hippocampal fimbria, IC: internal capsule, SB: striatal bundles. 
 
 























































































































































Sham  BCAS  BCAS  
Figure 3.4: Extent of myelin damage detected by MAG 
immunostaining in sham and BCAS mice 28 d post 
surgery. (A) Representative images of MAG immunostaining 
of the optic tract of sham animals, BCAS animals with typical 
severity and distribution of white matter pathology and the 
BCAS animal demonstrating overt neuronal perikarya damage 
and widespread white matter pathology. Black arrows 
demonstrate examples of myelin debris. Scale bar: 50 μm. (B) 
Myelin damage in each white matter tract was quantified using 
a semi quantitive scoring method ranging from 0 (no damage) 
to 3 (extensive damage) via MAG immunostaining and scores 
from each hemisphere were summated providing a total 
possible score of 6 per white matter region. BCAS did not 
cause a significant increase in the extent of white matter 
damage compared to sham animals. (C) Myelin damage 
scores were summated from all analysed white matter tracts 
providing a ‘total myelin damage’ score per animal. BCAS 
significantly increased total myelin damage compared to sham 
animals. *P ≤ 0.05, Mann Whitney U test. Each data point 
represents an individual animal. One tissue section analysed 
per animal. Red data points represent the animal 
demonstrating extensive grey and white matter pathology. Bar 
shows median. N = 5 – 8 independent animals per group. 
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3.4.2.3 Assessment of microgliosis 
Previous studies investigating pathological outcomes to BCAS frequently demonstrate 
microgliosis in regions of myelin damage. Microglial morphology was assessed by IBA1 
immunostaining and number of microglia in white matter tracts were quantified in sham and 
BCAS animals 28 d post-surgery. No overt differences in microglial morphology were observed 
in grey or white matter regions in sham animals. Microglia retained a ramified morphology with 
small cell bodies in all regions analysed indicative of a ‘non-activated’ phenotype. The majority 
of BCAS mice similarly demonstrated no overt differences in microglial morphology  (fig. 3.5A). 
However, 1 of 8 BCAS mice demonstrating severe white matter pathology also demonstrated 
extensive microgliosis in most white matter tracts analysed (data points highlighted in red) (fig. 
3.5B). Quantification of IBA1 cell number revealed no significant difference in microglial 
number in response to BCAS in any white matter tract analysed compared to sham animals 





















































































































































Figure 3.5: Quantification of IBA1+ cell number in sham and BCAS mice 28 d post surgery. 
(A) Representative images showing IBA1 immunostaining of the optic tract of sham animals, BCAS 
animals and the BCAS animal demonstrating extensive white and grey matter pathology. Black 
arrows show examples of ‘reactive’ microglia.  Scale bar: 50 μm (B) Quantification of IBA1+ cells in 
individual white matter tracts demonstrated BCAS did not increase the number of IBA1+ cells in 
white matter tracts compared to sham animals. Each data point represents an averaged value 
calculated from 8 0.1mm2 regions of interest placed across white matter tracts of an individual 
animal. One tissue section analysed per animal. Red data points represent the animal demonstrating 
extensive grey and white matter pathology. Mann Whitney U test. Bars show median. N = 5 – 8 
independent animals per group. 
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 Discussion 
Previous studies utilising the BCAS model to investigate mechanisms by which chronic 
cerebral hypoperfusion contributes to loss of white matter integrity and cognitive decline report 
reproducible diffuse white matter damage and reactive gliosis associated with spatial working 
memory impairment after 28 d (Coltman et al., 2011). Subsequent studies investigating the 
longer-term impact of BCAS report additional ischaemic and haemorrhagic lesions and 
hippocampal atrophy associated with reference memory impairment (Holland et al., 2015). As 
various pathological, radiological and behavioural features have been characterised over the 
temporal course of BCAS, the model provides a useful platform to investigate how 
neuroinflammation evolves in parallel to white matter damage and cognitive impairment. The 
current study was therefore conducted to determine if WT C57BL/6Ntac mice demonstrate 
comparable neuropathology to previous studies by investigating key markers of grey and white 
matter integrity and glial reactivity via histology and IHC.  
Overall, the results of the current study demonstrate BCAS induces subtle white matter 
damage in the absence of overt neuroinflammatory changes and neuronal perikarya damage  
28 d post surgery in WT C57BL/6NTac mice. Neurological symptoms characteristic of overt 
neuronal damage were absent from the majority of mice following surgery. Of the mice which 
were culled prior to tissue harvest, 2 of 10 BCAS mice demonstrated circling, reduced 
movement and persistent laboured breathing. Post-mortem analysis revealed large blood clots 
covering the carotid artery surface suggesting damage to the carotid arteries. It could be 
postulated misplacement of microcoils during the surgical procedure caused damage to the 
carotid artery and induced severe reductions in cerebral blood flow leading to ischaemic 
damage. One sham animal also demonstrated persistent laboured breathing suggestive of 
vagus nerve damage. As this was the first cohort of surgeries in which animals were recovered, 
increased mortality associated with surgical complications was expected.  
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In animals which recovered until tissue harvest, analysis of H & E staining revealed that BCAS 
did not cause extensive neuronal damage comparable to previous studies (Shibata et al., 
2004). However, BCAS induced only subtle alterations in white matter integrity as assessed 
by MAG immunostaining. It is unlikely that the methods utilised in this study were not of 
adequate sensitivity to detect alterations in white matter integrity induced by BCAS. One 
animal with widespread neuronal damage also demonstrated extensive myelin debris across 
several white matter tracts indicating that MAG immunostaining was able to detect areas of 
myelin damage. Previous studies have shown preferential loss of MAG compared to other 
myelin components in response to inflammatory or hypoxic stimuli due to its localisation on 
the most distal portions of oligodendrocyte processes (Aboul-Enein et al., 2003). Protein 
redistribution of MAG is observed from as early as 3 d after BCAS enabling its use to 
investigate subtle alterations in white matter integrity which may not be detected by assessing 
other myelin components or by using histological approaches such as luxol fast blue (Reimer 
et al., 2011).  Furthermore, analysis of IBA1 immunostaining revealed that microglia 
demonstrated a ‘resting’ phenotype in the majority of BCAS mice across all white matter 
regions. In response to CNS injury including myelin damage, microglia rapidly react in an 
attempt to repair damage and maintain CNS homeostasis. BCAS did not cause overt changes 
to microglial morphology except in one animal which also demonstrated severe neuronal 
perikarya and white matter damage. Therefore, the absence of microgliosis further suggests 
that BCAS did not induce white matter injury. The infrequent and subtle white matter pathology 
observed in response to BCAS differs to that described in previous studies. However, potential 
reasons for this will be discussed in detail in chapter 4.  
In the 1 BCAS animal which demonstrated extensive grey and white matter pathology, it is 
possible cerebral blood flow was severely reduced leading to ischaemic damage as a result 
of improper microcoil placement. However, a major limitation of the current study is that 
cerebral blood flow changes associated with placement of microcoils were not recorded. 
Previous studies report a 36 % reduction in cerebral blood flow 3 d after BCAS surgery using 
0.18 mm internal diameter microcoils which gradually resolves to 22 % after 28 d mimicking 
the subtle reductions in cerebral blood flow observed in elderly individuals (McQueen et al., 
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2014).  We could not determine if induction of BCAS resulted in a similar degree of 
hypoperfusion as equipment to do so was not available. It could therefore be postulated that 
BCAS did not induce hypoperfusion or at least a sufficient amount to precipitate white matter 
damage.  
An advantage of the BCAS model is that microcoils with varying internal diameters can be 
applied to moderate the extent of cerebral hypoperfusion and resultant white matter pathology. 
Previous studies have shown use of 0.18 mm internal diameter microcoils together with 0.16 
mm internal diameter microcoils induces severe hypoperfusion associated with extensive 
white matter pathology, neuroinflammation and impaired white matter function (Miki et al., 
2009, Fowler et al., 2018).  
Although 0.16 mm internal diameter microcoils could be utilised to precipitate more frequent 
and severe white matter damage a key aim of this thesis is to investigate the impact of TREM2 
deficiency on white matter integrity and glial responses to BCAS. Previous studies 
investigating the impact of TREM2 deficiency in models of CNS injury generally describe 
TREM2 exerts protective effects. Previous work in the McColl lab has demonstrated TREM2-
/- mice exhibit greater infarct volumes associated with poorer functional recovery in response 
to MCAO (unpublished data). Kawabori et al. (2015) similarly demonstrated reduced tissue 
resorption and poorer functional recovery in TREM2-/- mice following MCAO (Kawabori et al., 
2015). Therefore, although using smaller microcoils may precipitate more frequent and 
extensive white matter damage in WT mice, this may be further exacerbated in TREM2-/- mice 
resulting in severe pathology and increased mortality.  
 As white matter damage has shown to evolve with longer durations of BCAS it was considered 
that 28 d may be insufficient to precipitate robust white matter pathology in C57BL/ 6Ntac mice 
(Holland et al., 2015). Therefore, although subtle and infrequent myelin pathology was 
observed in response to BCAS after 28 d, it was concluded use of 0.18 mm internal diameter 
microcoils was worth pursuing as it was hypothesised that longer durations of recovery after 
BCAS induction would result in progressively more extensive white matter pathology extending 
to grey matter regions associated with reactive gliosis.  
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 Chapter 4: Investigating the temporal 
evolution of the neuroinflammatory response 
to BCAS  
 
Chapter 4: 
Investigation of the temporal 
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 Introduction 
Robust neuroinflammation characterised by reactive gliosis is consistently observed in areas 
of white matter damage in the elderly human brain and preclinical animal models of VCI 
(Miyanohara et al., 2018, McQueen et al., 2014, Coltman et al., 2011, Fernando et al., 2006; 
Simpson et al., 2007). Structural and functional white matter impairment closely correlate to 
microglial number and use of immunomodulatory drugs including dimethyl fumarate, cilostazol 
and minocycline have shown to ameliorate such changes (Manso et al., 2017, Fowler et al., 
2018, Kitamura et al., 2017, Miyanohara et al., 2018).  
While this suggests neuroinflammation may play a key role in influencing white matter injury 
and cognitive impairment there are various aspects of the neuroinflammatory response to 
chronic cerebral hypoperfusion which remain unclear. The precise role of microglia and 
whether they contribute to or protect from damage remains unclear. Furthermore, the temporal 
evolution of the neuroinflammatory response over longer durations has yet to be 
characterised. It also remains unclear if microglia exclusively contribute to the 
neuroinflammatory response or if peripherally-derived myeloid and lymphoid cells also 
infiltrate the CNS over longer durations of cerebral hypoperfusion.  
Considering neuroinflammation is suggested to play a key role in mediating white matter injury 
and cognitive impairment it is important to develop an understanding of how the cellular and 
molecular neuroinflammatory response to cerebral hypoperfusion develops in parallel to white 
and grey matter pathology. Such information would provide insight into components of the 
neuroinflammatory profile which could be modulated to ameliorate white matter damage and 
cognitive deficits caused by cerebrovascular dysfunction. 
In the previous study, characterisation of CNS pathology using IHC and histology 
demonstrated mild white matter pathology 28 d after BCAS. As previous studies have 
demonstrated white matter damage progresses with longer durations of BCAS it was 
hypothesised increasing the duration of BCAS from 28 d to 3 m would provoke more frequent 
and extensive myelin pathology in C57BL6/Ntac mice (Holland, et al., 2015).  
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We therefore set out to assess development of CNS pathology over extended durations of 
BCAS and characterise how neuroinflammation evolves in parallel. In addition to using IHC 
and histological approaches, flow cytometry was implemented as a sensitive measure to 
investigate subtle alterations in cell composition and phenotype to BCAS.  
 Aims 
1. Define white and grey matter pathology, and microglial responses to increasing 
durations of BCAS in WT C57BL6Ntac mice. 
2. Profile myeloid and lymphoid populations in the CNS in response to increasing 
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 Methods  
 Animal procedures 
Three cohorts of WT C57BL/6Ntac animals aged 8-10 w were used in this study. Animals were 
randomly assigned to receive sham or BCAS surgeries described in section 2.4.1 and left to 
recover for 1 w (cohort 1), 1 m (cohort 2) or 3 m (cohort 3).  Prior to tissue harvest, all animals 
were injected with BrdU intraperitoneally (50 mg/ kg) for three consecutive days to label 
dividing cells and investigate cell proliferation resulting from increased durations of BCAS via 
flow cytometry. Initial numbers of sham and BCAS animals in each cohort are shown in table 
4.1. N numbers were chosen based on power analysis of data from previous BCAS studies. 




 Tissue harvest 
Transcardiac perfusion of mice was performed as described in section 2.4.3.  Pathological 
assessments and flow cytometric analysis were conducted on opposing hemispheres from the 
same animal to characterise pathology and alterations in CNS cell composition resulting from 
increasing durations of BCAS. Brains were first placed in a coronal brain matrix and olfactory 
bulb and cerebellum removed. A microtome blade was then placed 0.80 mm posterior to 
bregma separating the brain into rostral and caudal portions. The right hemisphere of the 
caudal portion was used for flow cytometry while the left hemisphere was used for pathological 
Cohort 
Duration of BCAS) 
Sham (n) BCAS (n) 
1 (1 week) 10 12 
2 (1 month) 8 10 
3 (3 months) 9 8 
Table 4.1 Cohort sizes prior to conducting sham and BCAS surgeries.  
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assessment. The remaining tissue from the rostral portion was separated into left and right 
hemispheres and right hemisphere was used for flow cytometric analysis whilst tissue from 
left hemisphere was taken for gene expression analysis (fig. 4.1). Tissue for gene expression 
analysis was snap frozen in isopentane at -65 oC and stored in Eppendorfs at -80 oC. However, 
this tissue was not used. Tissue used for pathological assessment was processed, embedded 
and sections were prepared for staining as described in section 2.5. Hind limbs were also 
amputated and bone marrow extracted from select animals to use as a positive control for 












Figure 4.1: Method of tissue harvest to investigate neuroinflammatory responses to BCAS. A 
microtome blade was placed 0.80 mm posterior to bregma separating the brain into rostral and 
caudal portions. The right hemisphere of the caudal portion was used for flow cytometry while the 
left hemisphere was used for pathology. The remaining tissue from the rostral portion was separated 
into left and right hemispheres and right hemisphere was used for flow cytometric analysis whilst 
tissue from left hemisphere was taken for gene expression analysis C: caudal, FC: flow cytometry, 
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 Histology  
H & E staining was conducted to identify potential areas of neuronal pathology caused by 
increasing durations of BCAS as described in section 2.6.4. All staining and subsequent 
analysis was conducted by the author with blinding to sham and BCAS groups. 
 Immunohistochemistry  
Myelin damage was detected by MAG immunostaining while glial reactivity was detected by 
IBA1 immunostaining in hemi brains on adjacent sections by the author as described in 
sections 2.6.1 and 2.6.2. Quantification of myelin integrity was conducted in each region of 
interest using a semi quantitative scoring described in section 2.6.2. A ‘total myelin damage’ 
score was also calculated by summating scores from each region of interest per animal.  
For IBA1+ cell quantification, four regions of interest measuring 0.2 mm2 were randomly placed 
across each white matter tract analysed (see section 4.3.5 below) using ImageJ software. 
IBA1+ cell bodies were then manually counted within each region of interest and averaged to 
provide the number of IBA1+ cells per 0.2 mm2 in each white matter tract. All staining and 
subsequent analyses were conducted by the author with blinding to sham and BCAS groups.  
 Regions of interest 
Grey matter regions analysed to assess neuronal pathology included the cerebral cortex, 
thalamus, hippocampus and striatum. White matter regions analysed to investigate the effect 
of increasing durations of BCAS on myelin integrity include the corpus callosum, hippocampal 
fimbria, internal capsule and optic tract (fig. 4.2). White matter regions analysed to quantify 
IBA1+ cells following BCAS include the corpus callosum, hippocampal fimbria, internal 
capsule and optic tract.  
 
 









 Flow cytometry  
Flow cytometry was utilised to investigate the impact of BCAS on CNS cellular composition 
and cell phenotype. After harvesting brain tissue, homogenisation and preparation of a brain 
cell suspension was conducted by the author as described in section 2.7. Bone marrow was 
also isolated and prepared from select animals as a positive control for BrdU staining. Cell 
populations analysed to investigate the impact of BCAS on CNS immune cell composition 
include microglia, macrophages, neutrophils, B cells and T cells. Marker profiles used to 
distinguish cell populations are described in table 4.2. Whilst labelling of cell surface antigens 
and data acquisition was conducted by the author, preparation of cells for intracellular BrdU 




Figure 4.2: White and grey matter 
regions chosen for pathological 
assessment. Outlined regions 
demonstrate grey matter regions analysed 
(hippocampus, striatum, thalamus and 
cerebral cortex). Coloured regions mark 
white matter tracts analysed. (Red: corpus 
callosum, green: hippocampal fimbria, 
purple: internal capsule, black: optic tract).  
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 All data was acquired using a BD LSR Fortessa X20 (Becton Dickinson, Oxford, UK). Absolute 
cell counts of identified myeloid and lymphoid populations were calculated as described in 
section 2.7.4. CD45 mean fluorescence intensity (MFI) was also calculated from identified 
microglia (Ly6G-Ly6C-Cd11b+CD45lo) to investigate the impact of BCAS on microglial 
phenotype. The proportion of viable BrdU+ cells was calculated per sample to investigate the 
impact of BCAS on cell proliferation. Analysis and quantification of data was conducted using 
FlowJo version 10 by the author with blinding to sham and BCAS groups as described in 








Fisher’s exact test was used to determine if BCAS increased the probability of myelin damage 
occurring. Mann Whitney U test was conducted to test for differences in myelin integrity 
between BCAS and sham treatment groups at 1 w, 1 m and 3 m. Student’s unpaired t test was 
used to test for differences in IBA1+ cell number, CD45 MFI and cell proliferation between 
BCAS and sham treatment groups at 1 w, 1 m and 3m. Two way ANOVA with Bonferroni 
correction for post hoc was used to investigate the impact of BCAS on cell composition in WT 
and BCAS mice with time and surgery as between subject factors. All statistical analyses were 
performed with Graphpad Prism software version 7.4 with statistical significance considered p 
≤ 0.05. 




B cells CD11b-B220+ 
T cells CD11b-CD3+ 
Table 4.2: Marker profiles used to identify cell populations for flow cytometric analysis. 
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 Results  
 Animal recovery 
Following surgery, no sham or BCAS mice demonstrated adverse neurological symptoms 
such as circling, seizures or barrel rolling indicative of overt neuronal damage. Mice were 
motile and responsive within 1 h of surgery. Within 24 – 48 h mice were also observed eating 
and drinking with normal exploratory behaviour. All animals remained healthy until tissue 
harvest. In cohort 1 (1 week), sham and BCAS mice demonstrated a maximal 3.1 % and 5.6 
% loss in weight 3 d following surgery, respectively. In cohort 2 (1 month) sham and BCAS 
mice demonstrated a maximal 2.8 % and 6.4 % loss in weight 3 d following surgery, 
respectively. In cohort 3 ( 3 months), sham and BCAS mice demonstrated a maximal 5  % and 
10.2 % loss in weight 3 d following surgery, respectively (see appendix sections 8.2.1 – 8.2.3). 










(Duration of BCAS) 
Sham (n) BCAS (n) 
1 (1 week)  10/ 10 12/ 12 
2 (1 month)  8/ 8 10/ 10 
3 (3 months)  9/ 9  8/ 8 
Table 4.3: Final cohort sizes following sham and BCAS surgeries (1 w, 1 m & 3 m).  
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 Pathological Assessment  
4.4.2.1 H & E assessment of CNS pathology 
 H & E staining was utilised to investigate if BCAS over various durations provoked neuronal 
pathology. No sham animals displayed evidence of neuronal pathology at any time point 
analysed. Furthermore, there was no evidence of neuronal pathology in any grey matter region 








Treatment 1 week 1 month 3 months 
Sham 0/ 10 (0 %) 0/ 8 (0 %) 0/ 9 (0 %) 
BCAS 0/ 12 (0 %) 0/ 10 (0 %) 0/ 8 (0 %) 
Figure 4.3: Representative images of H & E staining in the CA1 region of the hippocampus 
1 w, 1 m and 3 m following sham and BCAS surgeries. Scale bar: 100 μm 
 
Table 4.4: Mice displaying neuronal pathology identified via H & E staining following sham 
and BCAS surgeries (1 w, 1 m and 3 m). No animals demonstrated evidence of neuronal 
pathology 1 w, 1 m or 3 m following BCAS surgeries. Regions analysed include the thalamus, 












1 week  1 month  3 months  
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4.4.2.2 Assessment of myelin integrity 
MAG immunostaining was conducted to investigate the impact of increasing durations of 
BCAS on myelin integrity. Sham animals displayed minimal myelin damage at any time point 
analysed (1 w: 0 of 10, 1 m: 1 of 8, 3 m: 0 of 9). Induction of BCAS resulted in infrequent myelin 
damage at all time points analysed (1 w: 3 of 12, 1 m: 4 of 10, 3 m: 4 of 8) (table 4.5). Damage 
was subtle and anatomically confined to one or two white matter regions per animal. 1 w after 
BCAS, myelin damage was most frequently observed in the corpus callosum (3 of 12) followed 
by the optic tract (1 of 12) and internal capsule (1 of 12). No damage was observed in the 
hippocampal fimbria. After 1 m, damage was observed in the corpus callosum (1 of 10), optic 
tract (1 of 10), internal capsule (1 of 10) and hippocampal fimbria (1 of 10). After 3 m, damage 
was most frequently observed in the corpus callosum (3 of 8) and optic tract (2 of 8) but was 
absent in the internal capsule or hippocampal fimbria (fig. 4.4). Increasing BCAS duration did 
not increase the probability of overall myelin damage occurring (p ≥ 0.05). No significant 
difference in myelin integrity was observed compared to sham animals in individual white 
matter tracts at any time point analysed (p ≥ 0.05) (fig. 4.5B). Furthermore, no difference in 
total myelin damage was observed following BCAS compared to sham animals at any time 




























Treatment 1 week 1 month 3 months 
Sham 0/ 10 (0 %) 1/ 8 (12.5 %) 0/ 9 (0 %) 
BCAS 3/ 12 (25 %) 4/ 10 (40 %) 4/ 8 (50 %) 
Figure 4.4: Frequency of myelin damage detected by MAG immunostaining 1 w, 1 m and 3 
m following BCAS. One tissue section analysed per animal. CC: corpus callosum, HF: 
hippocampal fimbria, IC: internal capsule, OT: optic tract. 
 
Table 4.5: Mice displaying myelin damage detected by MAG immunostaining following sham 
and BCAS surgeries (1 w, 1 m & 3 m). BCAS caused infrequent myelin damage at all time points 
analysed. Increasing duration of BCAS did not increase the probability of myelin damage occurring. 
Fisher’s exact test. One tissue section analysed per animal. 
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Figure 4.5: Quantification of myelin integrity detected by MAG immunostaining 1 w, 1 m and 3 
m following BCAS. (A) Representative images showing MAG immunostaining of the optic tract 1 w, 1 
m and 3 m after BCAS and sham surgeries. Scale bar: 50 µm (B) Myelin damage in each white matter 
tract was quantified by MAG immunostaining using a semi quantitive scoring method ranging from 0 
(no damage) to 3 (extensive damage) providing a total possible score of 3 per white matter region. 
BCAS did not cause a significant increase in the extent of white matter damage compared to sham 
animals at any time point analysed. (C) Myelin damage scores were summated from all analysed white 
matter tracts providing a ‘total myelin damage’ score per animal. No difference in total myelin damage 
was observed following BCAS surgeries at any time point analysed. Mann Whitney U test. One tissue 
section analysed per animal. Each data point represents an independent animal. Bars show median. N 
= 6 – 12 independent animals per group.  
C) 
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4.4.2.3  Assessment of microgliosis 
Microglial morphology was assessed by IBA1 immunostaining and microglial number 
quantified to investigate how microglial react to increasing durations of BCAS.  No overt 
differences in microglial morphology were observed in grey or white matter regions in response 
to BCAS at any time points analysed. Microglia largely retained a ramified morphology with 
small cell bodies in all regions analysed. Only one mouse displaying moderate white matter 
damage in the optic tract (severity score 2) demonstrated detectable microgliosis (fig. 4.6). 
Quantification of IBA1+ cells in white matter tracts revealed increasing durations of BCAS had 














Figure 4.6: Representative images of MAG and IBA1 immunostaining showing microgliosis 
in areas of white matter damage. Black arrows show areas of white matter debris. White arrows 































































Figure 4.7: Quantification of IBA1+ cell number 1 w, 1 m and 3 m following BCAS. (A) 
Representative images of IBA1 immunostaining of the internal capsule 1 w, 1 m and 3 m following 
sham and BCAS surgeries. Scale bar: 50 μm (B) Quantification of IBA1+ cells in individual white 
matter tracts demonstrated IBA1+ cell number was unchanged in all white matter tract analysed 
following BCAS at all time point analysed. Each data point represents a value calculated and 
averaged from 4 regions of interest measuring 0.2 mm2 placed across each white matter tract from 
an independent animal. One tissue section analysed per animal. Student’s unpaired test. Bars show 
mean ± SEM. N = 6 - 12 independent animals per group.  
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 Flow cytometric analysis  
Although pathological assessment revealed BCAS did not induce detectable white or grey 
matter pathology at the level of the hippocampus it could be possible that pathology may have 
developed elsewhere in the brain outside of the regions of interest selected. Flow cytometry 
was conducted on opposing hemispheres to determine if increasing durations of BCAS 
provoked alterations in microglial phenotype or inflammatory cell composition.  
Analysis of myeloid and lymphoid cell populations revealed microglia were the primary cell 
type constituting 75-85 % of the total cell population while all other identified myeloid and 
lymphoid cell populations formed < 1 % of the total cell population (fig. 4.8). BCAS animals 
demonstrated similar numbers of each cell type compared to sham animals at all time points 
analysed. Interestingly, both sham and BCAS animals showed increased numbers of T cells 
and microglia 3 months post surgery. Two way ANOVA demonstrated significant effects of 
time on microglial F(2, 51)=25.1, p<0.0001) and T cell F(2, 51)=17.44 p<0.0001) number. Post 
hoc analysis demonstrated microglia and T cells were significantly increased in sham and 
BCAS mice 3 months post-surgery compared to mice 1 week and 1 month following sham and 
BCAS surgeries (p<0.0001). However, no surgery or interaction effect was detected at any 
time point analysed (p ≥ 0.05) (fig. 4.8). Furthemore, no significant time, surgery or interaction 
effects on cell number were detected for any other cell type at any time point analysed (p ≥ 
0.05).   
As increased CD45 expression is typically associated with microglial activation, CD45 MFI 
was also measured. In response to BCAS, no significant difference in CD45 MFI was observed 
compared to sham animals at any time point analysed (p ≥ 0.05) (fig. 4.9). Analysis of BrdU 
labelling demonstrated increased expression on bone marrow-derived cells suggesting that 
cell proliferation could be detected (fig. 4.10).  However, no significant difference in the 
proportion of BrdU positive cells was observed with increasing durations of BCAS compared 
to sham animals (p ≥ 0.05) (fig. 4.10). 
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Interaction p ≥ 0.05 
Time p ≥ 0.05 
Surgery p ≥ 0.05 
Interaction p ≥ 0.05 
Time p < 0.0001 
Surgery p ≥ 0.05 
Interaction p ≥ 0.05 
Time p ≥ 0.05 
Surgery p ≥ 0.05 
Interaction p ≥ 0.05 
Time p ≥ 0.05 
Surgery p ≥ 0.05 
Interaction p ≥ 0.05 
Time p < 0.0001 
Surgery p ≥ 0.05 
Figure 4.8: Quantification of CNS myeloid and lymphoid populations 1 w, 1 m and 3 m 
following BCAS. Microglia and T cells were significantly increased in mice 3 m post-BCAS and 
sham surgeries compared to mice 1 w and 1 m post-BCAS and sham surgeries. No effects of 
BCAS surgery or interaction effects were observed in any cell population at any time point 
analysed.Two way ANOVA with Bonferroni correction for post hoc. Each data point represents an 
independent animal. Data show mean ± SEM. N = 8 – 12 independent animals per group.     
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Figure 4.9: Quantification of CD45 MFI 1 w, 1 m and 3 m following BCAS. (A) Representative 
histogram plots of CD45 fluorescence in sham and BCAS animals at 1 w, 1 m and 3 m. (B) 
Quantification of MFI in 1 w, 1 m and 3 m following sham or BCAS surgeries by flow cytometry. 
CD45 MFI was unchanged after 1 w, 1 m or 3 m BCAS compared to sham animals. Student’s 
unpaired t-test. Each data point represents an independent animal. Data show mean ± SEM. N = 
8 – 12 independent animals per group.  
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Figure 4.10: Quantification of cell proliferation 1 w, 1 m and 3 m following BCAS. (A) 
Representative dot plots of total BrdU positive cells 1 w, 1 m and 3 m following sham and BCAS 
surgeries. Bone marrow-derived cells were used as a positive control from selected animals. (B) 
Quantification of BrdU+ cells 1 w, 1 m and 3 m following sham and BCAS surgeries. The proportion of 
viable BrdU+ cells was unchanged1 w, 1 m or 3 m after BCAS compared to sham animals. Student’s 
unpaired t-test. Each data point represents an individual animal. Data show mean ± SEM. N = 8 – 12 
independent animals per group. 
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 Discussion 
From this study it can be concluded that induction of BCAS using 0.18 mm internal diameter 
microcoils for extended periods does not provoke grey matter pathology and only infrequent 
and mild alterations in myelin integrity in WT C57BL6/Ntac mice. Furthermore, no overt 
changes in microglial reactivity or alteration in other myeloid or lymphoid cell populations were 
observed.  
Although a robust neuroinflammatory response is commonly observed in areas of white matter 
damage in preclinical models of VCI and the elderly, the precise contribution to white matter 
injury and cognitive impairment remains unclear. It is unknown how the neuroinflammatory 
response to hypoperfusion develops over time or how CNS inflammatory cell composition 
evolves with this. Previous studies have demonstrated microglial number closely correlates to 
loss of white matter structural and functional integrity (Fowle et al., 2018, Manso et al., 2018) 
and pharmacological or genetic modulation of the neuroinflammatory response has shown to 
ameliorate white matter structure and function in various models of chronic cerebral 
hypoperfusion (Manso et al., 2018). Although such findings suggest inhibition of microglial 
activation may be beneficial in the context of chronic cerebral hypoperfusion it is difficult to 
make firm conclusions about the precise role of microglia. Firstly, pharmacological 
interventions used to dampen neuroinflammation in models of VCI such as minocycline affect 
additional cell types including astrocytes, oligodendrocytes and neurons have also been 
reported (Moller et al., 2016). Studies specifically ablating microglial function in models of VCI 
are limited and the impact of chronic cerebral hypoperfusion on the microglial transcriptome is 
unknown. Therefore, the precise function of microglia in this context remains unclear. 
Inflammatory mediators secreted upon microglial activation including cytokines, ROS and 
proteases are likely to contribute to cerebrovascular pathology and white matter damage. IL-
1β and TNF-α downregulate tight junction proteins on endothelial cells increasing BBB 
permeability (Wu, et al., 2010, Yamagata, et al., 2004, Mark, et al., 1999, Wong, et al., 2007).  
Excess IL-1β may also be detrimental to myelin integrity as treatment with an IL-1R antagonist 
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ameliorates hypomyelination following intracerebral LPS injection in neonatal mice (PangCai 
and Rhodes, 2003).  
Furthermore, TNF-α-treated oligodendrocytes demonstrate increased apoptosis in vitro and 
overexpression promotes a chronic demyelinating disease with early mortality in rodents 
(Buntinx et al., 2004, Probert et al., 1995). Microglia are also a source of MMPs including 
MMP2 which has shown to contribute to white matter damage and BBB disruption in response 
to BCAS (ihara et al., 2001, Nakaji et al., 2006). However, release of such inflammatory 
mediators may also serve beneficial functions. Mice lacking TNF-α or IL-1β demonstrate 
delayed remyelination and impaired OPC maturation in the cuprizone model of demyelination 
(Arnett et al., 2001, Mason et al., 2001). Furthermore, microglial phagocytosis of myelin debris 
is also essential for remyelination and microglia are a source of various trophic mediators 
including BDNF, IGF-1 and LIF (Lampron et al., 2015, Goldstein et al., 2016).  
Although microglia are predominant mediators of neuroinflammation being the primary innate 
immune cells of the CNS, various other cell types also contribute to the neuroinflammatory 
response.  Inhibition of astrocyte-derived NFκB ameliorated white matter damage, gliosis and 
memory deficits resulting from BCAS suggesting astrocytes also contribute to inflammatory-
mediated damage (Saggu et al., 2016). This is further supported by a recent study in which 
astrocyte-specific overexpression of the transcription factor Nrf2 reduced inflammation and 
improved white matter integrity and memory performance after BCAS (Sigfridsson et al., 
2018).  
Pericytes, endothelial cells, perivascular macrophages and meningeal macrophages have 
also been reported to release inflammatory mediators. However, their contribution to 
hypoperfusion-mediated inflammation and subsequent white matter injury remains unclear. 
Considering neuroinflammation is suggested to play a key role in mediating white matter injury 
and cognitive impairment it is crucial to gain a detailed understanding of the cellular and 
molecular neuroinflammatory profile and how inflammatory cells function in this context. This 
study therefore sought to provide insight into the key cellular players in the neuroinflammatory 
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response to chronic cerebral hypoperfusion and determine if microglia exclusively contribute 
to the neuroinflammatory response or if peripherally derived leucocytes also play a role.  
In the previous study, subtle alterations in myelin integrity were observed 28 d following 
induction of BCAS. Separate studies demonstrate rapid loss of axon-glial integrity 3 d after 
BCAS and diffuse white matter damage extending over various white matter tracts after 28 d 
(Coltman et al., 2011, Reimer et al., 2011). Extending the duration of BCAS to 6 m further 
exacerbates pathology with multiple ischaemic and haemorrhagic lesions observed 
throughout the brain in grey and white matter regions (Holland et al., 2015). As only mild 
alterations in white matter integrity were observed after 28 d it was initially thought the duration 
of BCAS was insufficient to provoke significant white matter pathology and reactive gliosis. It 
was therefore hypothesised that increasing the duration of hypoperfusion further would elicit 
more extensive pathology. 
In the current study, histological assessment of CNS tissue revealed increasing durations of 
BCAS did not cause overt neuronal pathology at any time point analysed comparable with 
previous studies (Shibata et al., 2004, Coltman et al., 2011). Although BCAS has shown to 
induce robust white matter changes after 28 d this study found only infrequent and negligible 
alterations in myelin integrity at both 28 d and 3 m with no progression of damage.  
As discussed in the previous chapter, it is unlikely that the methods utilised in this study were 
not of adequate sensitivity to detect subtle alterations in white matter integrity induced by 
BCAS. Previous studies have also demonstrated rapid disruption of paranodal proteins 
detected via loss of Caspr and Neurofascin colocalisation and increased voltage-gated sodium 
channel length in response to cerebral hypoperfusion (Reimer et al., 2011, Koizumi et al., 
2018). This was not conducted in this study but would have proved useful to further investigate 
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As loss of axon glial and nodal/ paranodal integrity develop prior to other pathological 
hallmarks including endothelial dysfunction, pericyte loss and BBB breakdown it is also 
unlikely other pathologies would be detected in the absence of reduced white matter integrity. 
The absence of white matter pathology is further supported by lack of microgliosis in analysed 
white matter tracts. Previous studies have demonstrated microglial activation in adjacent 
sections corresponding to areas of white matter damage (Coltman et al., 2011, Liu et al., 2015, 
Manso, et al., 2018). As microglial morphology and number remained largely unchanged in 
analysed white matter regions at all time points it is likely that BCAS failed to induce white 
matter injury.   
Although alterations in white matter structure and glial reactivity were investigated, white 
matter function was not assessed. However, it is unlikely that behavioural or functional 
abnormalities would be detected as previous studies typically describe impaired spatial 
working memory and reduced white matter conduction velocity in the presence of white matter 
pathology (Coltman et al., 2011, Fowler et al., 2018, Manso et al., 2018). Interestingly, a recent 
study using a modified version of BCAS described defects in network connectivity and spatial 
learning in the absence of detectable white matter pathology or reactive gliosis (Boehm-Sturm 
et al., 2017). Although luxol-fast blue was used to examine gross myelin changes which may 
not reveal more subtle alterations in myelin integrity it is surprising glial reactivity was not 
observed. It could therefore be postulated that white matter connectivity may still have been 
impaired in the absence of structural abnormalities detected by IHC. However, this was 
beyond the scope of this study. 
As pathological assessment was only conducted on a single hemisphere at the level of the 
hippocampus it could be suggested that pathology developed elsewhere in the brain. 
However, this is unlikely as flow cytometry on bulk tissue from opposing hemispheres failed to 
detect any BCAS-related differences in cell composition or phenotype. As flow cytometric 
analysis presents information on cell characteristics on a cell-by-cell basis it is unlikely the 
technique was not of adequate sensitivity to detect BCAS-related alterations in cell 
composition and phenotype.  
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Although bone marrow derived cells were utilised as a positive control to ensure cell 
proliferation could be detected via BrdU labelling, a positive control was not implemented to 
determine if changes in cell composition or phenotype could be detected via flow cytometry. 
Extracted brain tissue was treated with proteolytic enzymes prior to tissue homogenisation. 
Subsequent optimisation experiments for FACS-based microglial isolation described in 
chapter 6 demonstrated enzyme treatment alters microglial phenotype increasing microglial 
granularity and CD45 MFI suggestive of microglial activation. Although previous studies in the 
McColl lab have demonstrated detectable neuroinflammatory changes using this method in 
models of stroke and sterile inflammation it could be argued that more subtle alterations in cell 
composition or phenotype may have been masked by phenotypic alterations caused by 
enzyme digestion prior to data acquisition. 
BCAS did not alter CNS cell composition compared to sham animals at any time point 
analysed. However, both sham and BCAS mice demonstrated increased numbers of microglia 
and T cells in the CNS 3 m post-surgery. Age-dependant changes in CNS immune 
composition have been reported in aged mice including T cell infiltration and increased 
microglial density (Poliani et al., 2015, Dulken et al., 2019). However, many of the changes 
have been reported in mice aged between 12- 24 months whilst mice used in this study were 
just 5-6 m of age at tissue harvest. Whilst increased numbers of microglia were detected via 
flow cytometry 3 months post sham and BCAS surgery, no such changes were observed in 
white matter regions analysed by IHC. It could be postulated changes in microglial density 
occurred in brains regions outside those analysed by IHC. In addition to this, changes in T cell 
composition were not validated via IHC in opposing brain hemispheres.  It therefore, remains 
unclear precisely why increased numbers of microglia and T cells were observed 3 months 
following sham and BCAS surgeries.  
Although studies investigating changes in CNS cell composition following cerebral 
hypoperfusion are limited, a recent study demonstrated lymphocyte infiltration does not occur 
1 m after BCAS (Fuechtemeier et al., 2015). A separate study using IHC also demonstrated 
lack of neutrophil infiltration in response to BCAS (Miyanohara et al., 2018). Furthermore, 
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studies utilising microglial-specific markers such a TMEM119 or adoptive transfer suggest 
macrophage infiltration does not occur in response to BCAS implying that microglia are the 
predominant contributors to the neuroinflammatory response following chronic cerebral 
hypoperfusion (Manso et al., 2018, Miyanohara et al., 2018). On the other hand, post mortem 
studies have identified leucocyte infiltration in the vascular wall and perivascular spaces of 
cSVD patients (Wardlaw, Smith and Dichgans, 2013).  As preclinical studies were conducted 
only 1-3 m following BCAS surgery it could be postulated that infiltration of peripheral myeloid 
or lymphoid cells occur at later time points when more profound vascular pathology is 
observed including BBB breakdown.  
White matter tissue was also dissected from animals and stored to conduct gene expression 
analysis to characterise the temporal molecular neuroinflammatory profile resulting from 
BCAS. However, this was not completed as it is unlikely that any gene expression changes 
would be detected given the lack of pathology or glial reactivity. This is supported from gene 
expression analysis demonstrating no detectable changes in key inflammatory genes in 
isolated white matter with significant pathology and reactive gliosis following BCAS (Manso et 
al., 2018). Alterations in the molecular neuroinflammatory profile would likely be determined 
via transcriptomic analysis of isolated microglia, however, this was beyond the scope of this 
study.  
Overall, the data from the current study demonstrates use of 0.18 mm internal diameter 
microcoils is insufficient to induce overt white matter pathology and neuroinflammation in WT 
C57BL/6Ntac mice. As previous studies have utilised similar methods and detected white 
matter damage and neuroinflammatory changes it is unlikely that lack of sensitivity is a primary 
reason. It remains unclear why use of 0.18 mm internal diameter microcoils failed to induce 
detectable white matter changes comparable to previous studies. As stated previously, a 
limitation of the current study is that changes in cerebral blood flow could not be measured as 
equipment to do so was unavailable. Use of a hypoxia probe similar to that used by Koizumi 
et al. (2018) following BCAS may have proved useful to validate if induction of BCAS caused 
tissue hypoxia (Koizumi, et al., 2018). Therefore, whilst previous studies have reported use of 
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0.18 mm internal diameter microcoils reproducibly reduces cerebral blood flow it cannot be 
assumed in this case. It may be that the internal diameter of microcoils were too large resulting 
in insufficient carotid artery stenosis. It could also be postulated that cerebral blood flow was 








Previous studies using 0.18 mm internal diameter microcoils consistently demonstrate an 
acute reduction in cerebral blood flow after microcoil placement (Shibata et al. 2004, McQueen 
et al. 2014). Although partial recovery of cerebral blood flow occurs over time, hypoperfusion 
is typically maintained over extended durations. However, Füchtemieier et al. (2015) 
demonstrated near-complete recovery of cerebral blood flow after 28 d and negligible 
pathology attributed to loss of microcoil integrity (Füchtemieier, et al., 2015). Microcoils 
dissected from selected animals used in this study were covered in brown fibrous material and 
appeared rusted. Furthermore, microcoils disintegrated when attempting to remove encased 
carotid arteries (fig. 4.11). It could therefore be postulated that compromised microcoil integrity 
may have prevented sufficient stenosis and cerebral hypoperfusion to precipitate white matter 
damage. However, as stated before, cerebral blood flow measurements were not taken in this 
study so this can only be suggested. 
 
Figure 4.11: Microcoil integrity 28 d following implantation. Microcoils extracted 28 d following 
surgery appeared rusted and disinitergrated upon dissection. Therefore, compromised microcoil 
integrity may have prevented sufficient stenosis and cerebral hypoperfusion to precipitate white matter 
damage in the current study. 
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It is unlikely that surgical error and misplacement of microcoils is a cause for lack of pathology 
as improper placement typically causes profound reductions in cerebral blood flow and overt 
cerebral ischaemia. Animals were anaesthetised with inhalational isoflurane which has 
previously demonstrated to elicit neuroprotection in various preclinical stroke models (Jiang et 
al., 2017a). Longer anaesthetic preconditioning is associated with reduced ischaemic injury 
and neurological deficit in response to MCAO (Gaidhani et al., 2017). As this model was novel 
within the lab group it took longer to dissect and isolate carotid arteries from surrounding 
tissue. It could therefore be postulated that longer durations of anaesthesia prior to microcoil 
placement may have elicited protection to BCAS. 
Animals were additionally anesthetised with 70 % nN2O. N2O is an N-methyl-D-aspartate 
(NMDA) receptor antagonist suggested to exert neuroprotection. However, studies 
investigating the protective role of N2O have yielded inconsistent results. For example, addition 
of 50 % N2O 2 h after transient MCAO reduced infarct volume in rats (Haelewyn et al., 2008). 
In other studies, addition of 70 % N2O to anesthetic had no effect on ischaemic pathology 
(Yokoo et al., 2004). The specific impact of N2O on CNS pathology in response to BCAS has 
never been investigated. Previous studies have however implemented N2O and identified 
white matter pathology 28 d after BCAS suggesting N2O does not exert profound protection to 
BCAS (Miyanohara et al., 2018, Kakae et al., 2019).  
Additional factors including temperature, handling, environmental enrichment, diet and 
microbiota can all impact outcome from cerebrovascular-mediated injury (Hase et al., 2017, 
Benakis et al., 2016). As procedures and recovery were carried out in a separate unit to 
previous studies in which animal housing, diet and maintenance differ, it could be suggested 
that a combination of factors impacted the extent of pathology caused by BCAS. Age has also 
demonstrated to contribute to the severity of CNS pathology resulting from BCAS. 21 m old 
mice demonstrate greater white matter pathology associated with exacerbated 
neuroinflammation and cognitive deficits compared to 3 m old mice following BCAS (Wolf et 
al., 2017). Mice used in this study were 8-10 w of age and may have had increased resilience 
to white matter injury resulting from BCAS. However, previous studies have utilised mice of a 
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similar age and detected robust white matter injury in response to BCAS making age an 
unlikely contributor to discrepancies observed (Khan et al., 2015). 
Susceptibility to ischaemic injury is also highly dependent on mouse strain due to variation in 
cerebrovascular anatomy (Barone et al., 1993). C57BL/6J mice are preferentially used in 
preclinical models of VCI due to underdevelopment of the posterior communicating arteries 
within the circle of Willis (Kitagawa et al., 1998). The posterior communicating arteries enable 
communication between the basilar artery of the vertebral circulation and the posterior cerebral 
arteries which arise from the carotid circulation. Therefore, if underdeveloped, compensatory 
blood flow from the vertebral circulation is impaired if carotid circulation is compromised and 
vice versa reducing the threshold for ischaemic injury. 
As WT and TREM2-/- mice were bred on a C57BL6/Ntac background it could be postulated 
that genetic differences could explain discrepancies in BCAS-induced pathology. Various 
studies have demonstrated genetic and phenotypic differences between C57BL/6 substrains 
in behavior, immune and metabolic responses (Fontaine and Davis, 2016, Simon et al., 2013, 
Bryant et al., 2008). Indeed, a recent study utilising FVB/C57BL/6JF1 demonstrated BCAS 
caused loss of white matter integrity limited to the optic tract which was more extensive 
compared to mice on a pure C57BL/6J background (Sigfridsson, et al., 2018). No overt 
differences in circle of Willis anatomy have been observed between C57BL/6N or C57BL/6J 
animals. Furthermore, laser speckle contrast imaging has demonstrated no difference in 
cortical blood flow between C57BL/6N and C57BL/6J substrains (ZhaoMulligan and Nowak, 
2019). Whether substrain differences exist in cerebrovascular architecture supplying deeper 
subcortical regions remains to be established.  
A prominent genetic difference identified between C57BL/6 substrains includes a deletion 
spanning exons 7 to 11 of the gene encoding nicotinamide nucleotide transhydrogenase (Nnt) 
in C57BL/6J mice resulting in complete loss of function (Mekada et al., 2009). Nnt is an 
enzyme found in the inner mitochondrial membrane and plays a key role in reducing NADP+ 
to NADPH enabling subsequent elimination of ROS generated during ATP generation. Liver 
mitochondria isolated from C57BL/6J mice demonstrate increased ROS release (Ronchi et 
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al., 2013). Furthermore, Lopert and Patel demonstrated Nnt deletion in brain mitochondria 
increased ROS production, oxidative stress and cell death (Lopert and Patel, 2014). It could 
therefore be suggested that mitochondrial dysfunction resulting from BCAS is further 
exacerbated in C57BL6/J mice compared to C57BL6/Ntac due to the absence of Nnt resulting 
in greater ROS generation and oxidative stress-induced damage. 
Indeed, oxidative stress is a key mechanism contributing to matter injury resulting from chronic 
cerebral hypoperfusion. Surprisingly, studies investigating effect of substrain on ischaemic 
injury have demonstrated the opposite. Despite having similar defects in posterior 
communicating artery development, C57BL/6N animals have increased infarct volume in 
response to MCAO (Zhao et al., 2019). Furthermore, neuronal cell death and 
neuroinflammation is exacerbated in C57BL/6N mice following postnatal hypoxia compared to 
C57BL/6J mice (Wolf, et al., 2016). The reasons as to why C57BL/6N mice demonstrate more 
severe ischaemic pathology compared to C57BL/6J mice remain unclear. One possible 
explanation is reversal of Nnt function first described by Nickel and colleages in response to 
excessive metabolic demand (Nickel et al., 2015). Using a model of heart failure, it was 
demonstrated that Nnt function reverses from being anti-oxidative to pro-oxidative 
exacerbating oxidative stress and cell death. Such findings suggest C57BL/6Ntac mice would 
develop more extensive pathology compared to C57BL/6J mice in response to BCAS. It 
cannot be concluded if substrain was a key contributor to lack of pathology observed in this 
study as this has never been investigated in the BCAS model. It is likely that a combination of 
genetic and environmental factors contributed to increased resilience to BCAS-related 
damage. Although increasing the duration of hypoperfusion to 6 m may increase the extent of 
damage this was not considered feasible to investigate due to time constraints. 
 As stated previously, an advantage of the BCAS model is that microcoils with varying internal 
diameters can be applied to the carotid arteries to modify the extent of hypoperfusion. Initial 
studies revealed application of 0.16 mm internal diameter microcoils bilaterally increased 
mortality to 75 % and induced severe white and grey matter damage (Shibata et al., 2004). 
More recent studies have implemented a 0.16 mm internal diameter microcoil in combination 
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with a 0.18 mm internal diameter microcoil to increase perfusion deficits. These studies have 
demonstrated robust white matter damage and neuroinflammation just 6 days after surgery 
associated with reduced mortality (18 %) (Miki et al., 2008, Fowler, et al., 2018). The 30 min 
recovery period between placement of microcoils is suggested to allow for restoration of 
haemodynamics thus placement of microcoils at the same time is suggested to increase the 
extent of hypoperfusion and white matter damage. This was implemented however no change 
in extent of white matter damage or neuroinflammation was observed in a small cohort of WT 
or TREM2-/- mice (see appendix I). 
Prior to investigating the impact of TREM2 deficiency it was crucial to optimise the BCAS 
model to precipitate white matter pathology and overt neuroinflammatory changes. 0.16 mm 
internal diameter microcoils were used together with 0.18 mm internal diameter microcoils and 
0.16 mm internal diameter microcoils were also tested bilaterally. Mortality, cerebral blood flow 
dynamics and resultant pathology were investigated in WT and TREM2-/- mice to determine 
a suitable model to investigate downstream pathology and neuroinflammatory changes 
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 Chapter 5: Investigating the impact of 
TREM2 deficiency on CNS pathology and glial 
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 Introduction 
TREM2 is an immunoreceptor expressed by CNS resident microglia with key roles in microglial 
survival, proliferation, phagocytosis, metabolic adaptation and immomodulation (Jay, et al., 
2017). Genetic studies demonstrating TREM2 mutations predispose to neurodegenerative 
conditions and dementia highlight the importance of microglial dysfunction and innate 
immunity in dementia pathogenesis (Guerreiro et al., 2013a, Guerreiro et al., 2013b, Jonsson 
et al., 2013). Since this discovery, numerous studies have been conducted to determine how 
TREM2 regulates microglial processes across neurodegenerative disease settings including 
AD, MS, stroke and prion disease (Kober and Brett, 2017).  
Studies repeatedly demonstrate TREM2 deficiency dampens microglial responses to CNS 
injury. Although this is generally associated with exacerbated CNS pathology the impact on 
end stage disease can vary. Given the significance of neuroinflammation in VCI and dementia 
pathogenesis, it is crucial to understand how TREM2 functions in the context of chronic 
cerebrovascular dysfunction associated with ageing and dementia. If TREM2 exerts protective 
effects, investigation of mechanisms warrants further study as this may lead to the 
identification of novel therapeutic strategies. 
In the previous study, BCAS failed to provoke detectable CNS pathology or neuroinflammatory 
changes in WT C57BL6/Ntac mice. Cerebral blood flow was not measured meaning it could 
not be concluded if cerebral hypoperfusion was achieved following BCAS surgery. It was 
therefore important to optimise the BCAS procedure, validate cerebral blood flow was reduced 
following microcoil placement, and ensure BCAS provoked sufficient CNS pathology to 
investigate the role of TREM2. In addition to modifying the BCAS surgery to induce more 
substantial hypoperfusion, laser speckle flowmetry was utilised to assess cerebral blood flow 
in WT and TREM2-/- mice following BCAS. In this study, it was hypothesised that use of 
microcoils with smaller internal diameters would evoke myelin pathology and that this would 
be exacerbated in TREM2-/- mice.  
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  Aims 
1. Optimise the BCAS procedure and validate induction of chronic cerebral 
hypoperfusion in WT and TREM2-/- mice.  
2. Characterise CNS pathology and glial responses resulting from 28 d BCAS in WT and 
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 Methods  
 Animal procedures  
WT and TREM2-/- male mice aged 7 - 9 m were assigned to receive sham or BCAS surgeries.  
In cohort 1, the BCAS procedure described in 2.4.1 was modified so that a smaller 0.16 mm 
internal diameter microcoil was fitted on the right carotid artery whilst a 0.18 mm internal 
diameter microcoil was placed on the left carotid artery (WT: n = 10, TREM2-/-: n = 6). In 
cohort 2, animals were fitted with 0.16 mm internal diameter microcoils bilaterally to induce 
greater perfusion deficits (WT: n = 13, TREM2-/-: n = 12). Sham surgeries were conducted as 
described in 2.4.1. Due to lack of breeding and limited animal numbers, a single group of WT 
and TREM2-/- mice were used as shams for both cohort 1 and cohort 2 (WT: n = 7, TREM2-
/-: n = 6). N numbers were chosen based on power analysis of data from previous BCAS 
studies. With a  significance level of p < 0.05, a group size of 8 was required to reach a power 
of 0.8. All BCAS and sham surgeries were conducted by the author. 
Laser speckle contrast flowmetry was utilised to investigate changes in cerebral blood flow 
caused by placement of microcoils in WT and TREM2-/- mice. Measurements were taken as 
described in section 2.4.2 to obtain a baseline value prior to BCAS or sham surgeries and then 
again 24 h and 28 d after surgeries. Values obtained at 24 h and 28 d were divided by baseline 
values and multiplied by 100 to determine the percentage change in cerebral blood flow 
caused by BCAS or sham surgeries. All laser speckle contrast imaging and subsequent 
analysis was conducted by the author with blinding to treatment and genotype. After surgeries, 
animals were monitored twice daily for 72 h and then twice weekly. Initial cohort sizes are 
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 Tissue harvest 
Animals were culled 28 d after BCAS or sham surgeries and saline perfused transcardially by 
the author as described in section 2.4.3. Whole brains were extracted and submerged in 4 % 
PFA (w/ v) for 24 h.  Brains were placed in a coronal brain matrix and olfactory and cerebellum 
were removed. A microtome blade was then placed 0.22 mm posterior to bregma separating 
brain tissue into rostral and caudal portions. Subsequent tissue processing and paraffin 
embedding was conducted by QMRI Histology Services and 6 μm tissue sections were 
prepared for staining by the author as described in section 2.5.  
 Histology  
H & E staining was conducted as described in section 2.6.4 to assess neuronal pathology and 
white matter lesions resulting from BCAS. The extent of grey matter damage was quantified 
by summating the total number of areas displaying neuronal pathology in each animal. White 
matter lesions were defined as areas of white matter demonstrating extensive vacuolation. All 
staining and assessment was conducted by the author with blinding to treatment and 
genotype.  
 
 Microcoils WT (n) TREM2-/- (n) 
Cohort 1 
(Mixed coil) 
Right CA: 0.16 mm  






( 2x 0.16 mm coil) 
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 Immunohistochemistry 
Loss of myelin integrity was detected by MAG immunostaining while glial reactivity was 
detected by IBA1 and GFAP immunostaining on adjacent sections as described in sections 
2.6.2 – 2.6.3. Myelin damage was quantified using a semi quantitative scoring method 
described in section 2.6.2. As both hemispheres were used, myelin damage scores from 
individual white matter tracts were summated from left and right hemispheres providing a 
possible total score of 6. Total myelin damage scores were calculated per animal by 
summating scores from all white matter tracts providing a possible total score of 24.  
 For IBA1 quantification, four regions of interest measuring 0.2 mm2 were randomly placed 
across white matter tracts in each hemisphere (see section 5.3.5 below) using ImageJ 
software. IBA1+ cell bodies were then manually counted within each region of interest (8 
regions of interest in total) and averaged to provide the number of IBA1+ cells per 0.2 mm2 in 
each white matter region. Total IBA1+ cell number was also quantified in whole brain sections 
using the analyse particles plugin on ImageJ as described in section 2.6.3. For quantification 
of GFAP, images were thresholded to detect GFAP positive staining and the % area of staining 
was measured in each white matter region using image J software. Total GFAP coverage 
across brain sections was also quantified using this method. As WT and TREM2-/- mice 
demonstrated differences in myelin damage, IBA1+ cell counts and GFAP % area values were 
divided by myelin damage scores to correct for between group differences in pathology 
severity.  
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 Regions of interest 
Both brain hemispheres were used for pathological characterisation. Grey matter regions 
analysed to investigate neuronal pathology caused by BCAS include the cerebral cortex, 
thalamus, striatum and the CA1, CA2, CA3 and dentate gyrus of the hippocampus. White 
matter regions analysed to determine the impact of BCAS on myelin integrity using histology 
and IHC include the corpus callosum, internal capsule, hippocampal fimbria and optic tract 
(fig. 5.1). Glial reactivity was assessed and quantified in whole brain sections and individual 







Figure 5.1: White and grey matter regions used for pathological assessment. Outlined regions 
demonstrate grey matter regions analysed (hippocampus, striatum, thalamus and cerebral cortex). 
Coloured regions demonstrate white matter tracts analysed (green: corpus callosum, red: 
hippocampal fimbria, purple: internal capsule, black: optic tract).  
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 Statistics 
Two way ANOVA with Bonferroni correction for post hoc was used to investigate the impact 
of BCAS on cerebral blood flow in WT and TREM2-/- mice with genotype and surgery as 
between subject factors. For pathological characterisation and investigation of glial responses, 
sham groups were excluded from analysis and key comparisons focused on differences 
between WT and TREM2-/- mice following BCAS only.  Fisher’s exact test was used to 
determine if TREM2 deficiency increased the probability of grey matter or white matter damage 
occurring in response to BCAS compared to WT mice. Mann Whitney U test was used to 
investigate the impact of TREM2 deficiency on white and grey matter pathology following 
BCAS. Welch’s unpaired t-test was used to investigate the impact of TREM2 deficiency on 
IBA1+ cell number and GFAP coverage in response to BCAS. Spearman’s rank correlation 
was used to investigate the relationship between total myelin damage and IBA1+ cell number 
in addition to GFAP coverage in WT and TREM2-/- mice following BCAS. SPSS version 22 
(IBM Corp.) was used to conduct two way ANOVA. All other statistical analysis, were 
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 Results 
 Animal recovery 
All animals receiving sham surgeries survived until tissue harvest and demonstrated no 
adverse neurological symptoms such as circling, seizures or barrel rolling indicative of overt 
focal brain damage. In cohort 1 (mixed coil), 0 of 10 TREM2-/- animals were culled, whilst 3 of 
10 WT animals were culled within the first 48 h after BCAS surgery due to poor recovery 
observed by persistent circling or barrel rolling which is usually indicative of severe 
haemorrhage (16 % mortality). Remaining animals were motile and responsive within 1 h of 
surgery and were observed eating and drinking with normal exploratory behaviour within 24 -
48 h. BCAS caused a maximal 9.9 % and 8.9 % loss in weight in WT and TREM2-/- mice 3 d 
following surgery, respectively (see appendix section 8.2.4). 
In cohort 2 (2x 0.16 mm coil), 5 of 13 WT animals and 3 of 12 TREM2-/- animals were culled 
within the first 48 h after BCAS surgery due to poor recovery (32 % mortality). Remaining 
animals were responsive within 1 – 2 h post-surgery and normal exploratory behaviour and 
eating and drinking were observed after 48 - 72 h. BCAS caused a maximal 9.9 % and 12.4 
% loss in weight 5 d following surgery in WT and TREM2-/- mice, respectively (see appendix 




 Microcoils WT (n) TREM2-/- (n) 
Cohort 1          
(Mixed coil) 
Right CA: 0.16 mm ID 
Left CA: 0.18 mm ID 
Sham: 7 / 7 
BCAS: 7/ 10 
Sham: 6/ 6                
BCAS: 6 / 6 
 
Cohort 2 
(2x 0.16 mm coil) 
 
0.16 mm ID bilaterally 
Sham: 7/ 7 
BCAS: 8/ 13 
Sham: 6 / 6 
BCAS: 9 / 12 
Table 5.2: Final cohort sizes following 28 d sham and BCAS surgeries in WT and TREM2-/- 
mice. CA: carotid artery, ID: internal diameter.  
Table X: Final cohort sizes following BCAS and sham surgeries. 
 
 
Table 5.3: Final cohort sizes following BCAS and sham surgeries. 
Table X: Final cohort sizes following BCAS and sham surgeries. 
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 Laser speckle flowmetry  
Laser speckle contrast flowmetry was performed prior to surgery and 24 h and 28 d after 
surgery to validate BCAS induced cerebral hypoperfusion and assess whether TREM2 
defiency affected cerebral blood flow. Blood flow data was calculated as percentage change 
from baseline flow values. In cohort 1, analysis of percentage change in blood flow from 
baseline revealed significant effects of time F(2, 32)=18.485, p < 0.0001) and surgery (F(1, 
16)=15.769, p < 0.0001), but no effect of genotype (p < 0.05). No significant interaction 
between surgery and genotype was detected (p < 0.05). However, a significant interaction 
between time and surgery was detected F(2, 32)=9.561, p < 0.001). Post-hoc analysis 
demonstrated that blood flow was significantly reduced 24 h after surgery in WT mice (p < 
0.01) and TREM2-/- mice (p < 0.05). However, 28 d following surgery WT and TREM2-/- mice 
demonstrated no significant difference in blood flow compared to shams (p < 0.05). (fig. 5.2).   
In cohort 2, analysis of percentage change in blood flow from baseline also revealed significant 
effects of time F(2, 52)=78.009, p < 0.0001) and surgery (F(1, 26)=93.136, p < 0.0001). 
Similarly, there was no effect of genotype (p > 0.05) and no significant interaction between 
surgery and genotype (p > 0.05). However, a significant interaction between time and surgery 
was detected (F(2, 52)=39.969, p < 0.0001) and post-hoc analysis demonstrated that blood 
flow was significantly reduced in both WT and TREM2-/- mice compared to shams 24 h 
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Figure 5.2: Quantification of cerebral blood flow in WT and TREM2-/- mice 28 d post sham and 
BCAS surgeries in cohort 1 (mixed coil). (A) Representative laser speckle images showing cortical 
cerebral blood flow in sham and BCAS WT and TREM2-/- mice at baseline, 24 h and 28 d after 
surgery. (B) Quantification of cerebral blood flow in sham and BCAS WT and TREM2-/- mice at 
baseline, 24 h and 28 d after surgery. 24 h following BCAS surgery, WT and TREM2-/- mice 
demonstrated a 35 %  and 36 % reduction in cerebral blood flow compared to sham animals, 
respectively. After 28 d, WT and TREM2-/- mice demonstrated an 11.2 % and 15.7 % reduction in 
cerebral blood flow compared to sham animals. TREM2 deficiency had no impact on cerebral blood 
flow.  **P ≤ 0.01 WT BCAS vs WT sham, # P ≤ 0.05 TREM2-/- BCAS vs TREM2-/- sham. Two way 
ANOVA with Bonferroni correction for post hoc. Data show mean ± SEM.  N = 3 - 7 independent 
animals per group. 
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Figure 5.3: Quantification of cerebral blood flow in WT and TREM2-/- mice 28 d post sham 
and BCAS surgeries in cohort 2 (2x0.16 mm coils). (A) Representative laser speckle images 
showing cortical cerebral blood flow in sham and BCAS WT and TREM2-/- mice at baseline, 24 h 
and 28 d after surgery. (B) Quantification of cerebral blood flow in sham and BCAS WT and 
TREM2-/- mice at baseline, 24 h and 28 d after surgery. 24 h following BCAS surgery, WT and 
TREM2-/- mice demonstrated a 50.74 % and 49.92 % reduction in cerebral blood flow compared 
to sham animals, respectively. After 28 d cerebral blood flow remained reduced and WT and 
TREM2-/- mice demonstrated a 32.53 % and 36.75 % reduction in cerebral blood flow compared 
to sham animals. TREM2 deficiency had no impact on cerebral blood flow.  ****P ≤ 0.0001 WT 
BCAS vs WT sham, ####P ≤ 0.0001 TREM2-/- BCAS vs TREM2-/- sham. Two way ANOVA with 





Days post BCAS 
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 Pathological assessment 
5.4.3.1 H & E assessment of CNS pathology  
H & E staining was conducted on brain sections to investigate tissue integrity and characterise 
neuronal damage resulting from BCAS in WT and TREM2-/- mice. No sham animals displayed 
evidence of neuronal damage. In cohort 1 (mixed coil), neuronal pathology was confined to 
hippocampal regions and observed in 2 of 7 WT mice and 2 of 6 TREM2-/- mice in response 
to BCAS (fig. 5.4A & B). Fisher’s exact test demonstrated TREM2 deficiency did not increase 
the probability of neuronal pathology occurring in response to BCAS (p ≥ 0.05) (fig. 5.4A). 
Furthermore, TREM2 deficiency had no impact on the extent of neuronal pathology (p ≥ 0.05) 
(fig. 5.5).  
In cohort 2 (2x 0.16 mm coil), BCAS resulted in neuronal damage across multiple grey matter 
regions in 4 of 8 WT mice and 5 of 9 TREM2-/- mice (fig. 5.6A & B). Fisher’s exact test 
demonstrated TREM2 deficiency did not increase the probability of neuronal pathology 
occurring in response to BCAS (p ≥ 0.05) (fig. 5.6A). Although TREM2-/- mice demonstrated 
more extensive grey matter damage than WT mice this did not reach statistical significance (p 
= 0.817) (fig. 5.7).  
In cohort 1 (mixed coil), assessment of H & E staining demonstrated no evidence of overt 
white matter lesions in response to BCAS in WT and TREM2-/- mice. In cohort 2 (2x 0.16 mm 
coil) however, focal necrotic lesions were observed in the internal capsule characterised by 
extensive vacuolisation in 5 of 9 TREM2-/- mice while no such lesions were observed in WT 
mice in response to BCAS (fig. 5.9A & B). Fisher’s exact test demonstrated TREM2 deficiency 
significantly increased the probability of white matter lesions occurring in response to BCAS 


























































































































































































































































































Figure 5.4: Frequency of WT and TREM2-/- mice demonstrating neuronal pathology detected 
by H & E staining 28 d post BCAS in cohort 1 (mixed coil). (A) Overall frequency of mice 
demonstrating grey matter damage detected via H & E staining in WT and TREM2-/- mice following 
sham and BCAS surgeries. TREM2 deficiency did not increase the probability of grey matter damage 
occurring 28 d following BCAS surgery. (B) Frequency of grey matter regions demonstrating damage 
in WT and TREM2-/- mice following BCAS. Fisher’s exact test. One tissue section analysed per animal. 
N = 6 – 7 independent animals per group. 
 
Figure 5.5: Total number of areas demonstrating 
neuronal pathology in WT and TREM2-/- mice 28 d 
post BCAS in cohort 1 (mixed coil). The total 
number of grey matter regions displaying damage 
detected by H & E were summated in WT and 
TREM2-/- mice.  The total number of grey matter 
regions displaying damage were unchanged in 
TREM2-/- mice compared to WT mice 28 d following 
BCAS.  Mann Whitney U test. Bars shows median. 
One tissue section analysed per animal. N = 6 – 7 
independent animals per group. 
 
 







































































































































Figure 5.7: Total number of areas demonstrating 
neuronal pathology detected by H & E staining in WT 
and TREM2-/- mice 28 d post BCAS surgeries in cohort 
2 (2x 0.16 mm coil). The total number of grey matter 
regions displaying damage were summated in WT and 
TREM2-/- mice.  Although statistically non-significant, the 
total number of areas demonstrating grey matter damage 
was increased in TREM2-/- mice compared to WT mice 28 
d following BCAS.  Mann Whitney U test. Each data point 
represents an independent animal. Bars shows median. 
One tissue section analysed per animal. N = 6 – 9 





















































































































































Figure 5.6: Frequency of WT and TREM2-/- demonstrating neuronal pathology detetcted by 
H & E staining 28 d post BCAS surgeries in cohort 2 (2x 0.16 mm coil). (A) Overall frequency 
of mice demonstrating grey matter damage detected by H & E staining in WT and TREM2-/- mice 
following sham and BCAS surgeries. TREM2 deficiency did not increase the probability of grey 
matter damage occurring 28 d following BCAS surgery. (B) Frequency of grey matter regions 
demonstrating damage in WT and TREM2-/- mice following BCAS. Fisher’s exact test. One tissue 
section analysed per animal. N = 6 – 9 independent animals per group. 
 
 




















Figure 5.8: Representative images of H & E staining in grey matter regions 28 d post sham 
and BCAS surgeries in cohorts 1 and 2. In cohort 1 (mixed coil), neuronal pathology was limited 
to the hippocampus of WT and TREM2-/- mice following 28 d BCAS. In cohort 2 (2x 0.16 mm coil) 
however, neuronal pathology was more severe and observed across multiple grey matter 
regions.Black arrows demonstrate small condensed nuclei of apoptotic neurons. White arrows 
demonstrate vacuolation. Scale bar: 50 µm. 
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Figure 5.9: Frequency of white matter lesionsdetected by H & E staining in WT and TREM2-/- mice 
28 d post BCAS surgeries. (A) Frequency of WT and TREM2-/- BCAS mice demonstrating white matter 
lesions in cohorts 1 and 2. The probability of developing white matter lesions was significantly increased 
in TREM2-/- mice compared to WT mice following BCAS. (B) Representative images of H & E staining 
of the internal capsule in WT and TREM2-/- BCAS animals demonstrating differences in tissue integrity 
in cohort 2 (2x 0.16 mm coil) Scale bar: 50 μm. *P ≤ 0.05.  Fisher’s exact test.  One tissue section 
analysed per animal. N = 6 – 9 independent animals per group. 
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5.4.3.2 Assessment of myelin integrity 
MAG immunostaining was conducted to investigate the impact of TREM2 deficiency on myelin 
integrity in response to BCAS. Animals receiving sham surgeries demonstrated no alterations 
in myelin integrity. In cohort 1 (mixed coil) BCAS precipitated small foci of myelin debris across 
white matter tracts in 5 of 7 WT and 5 of 6 TREM2-/- mice (fig. 5.10, fig. 5.13). Areas most 
frequently demonstrating damage included the optic tract (WT: 4 of 7, TREM2-/-: 3 of 6) and 
corpus callosum (WT: 3 of 7, TREM2-/-: 4 of 6) (fig. 5.10B). Fisher’s exact test demonstrated 
TREM2 deficiency did not increase the probability of myelin damage occurring following BCAS 
(p ≥ 0.05) (fig. 5.10A). The extent of myelin damage was mild in all white matter regions 
analysed and TREM2 deficiency had no impact on the severity of myelin damage (p ≥ 0.05) 
(fig. 5.11A). Furthermore, TREM2 deficiency had no impact on the extent of total myelin 
damage (p ≥ 0.05) (fig. 5.11B).  
In cohort 2 (2x 0.16 mm coil), use of microcoils with smaller internal diameters increased the 
frequency and severity of myelin damage. Myelin damage was observed in all WT and 
TREM2-/- BCAS mice. However, severity and spatial distribution varied considerably (fig. 5.13 
& fig. 5.14). Fisher’s exact test demonstrated TREM2 deficiency did not increase the 
probability of myelin damage occurring following BCAS (p ≥ 0.05) (fig. 5.13A). TREM2-/- 
animals demonstrated exacerbated myelin damage in the internal capsule (p ≤ 0.05) whilst 
non-significant trends for greater damage were observed in other white matter tracts (optic 
tract: p = 0.421, hippocampal fimbria: p = 0.3114, corpus callosum: p = 0.2947)  (fig. 5.15 & 
fig. 5.14A). Assessment of total myelin damage also revealed TREM2-/- mice had greater 
damage in response to BCAS however this did not reach statistical significance (p = 0.1078) 
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Assessment of myelin integrity: Cohort 1 (mixed coil) 
 








































































































T R E M 2  -/-
A) B) 
Figure 5.10: Frequency of WT and TREM2-/- mice demonstrating myelin damage detected by 
MAG immunostaining 28 d post sham and BCAS surgeries in cohort 1 (mixed coil). (A) Overall 
frequency of WT and TREM2-/- mice demonstrating myelin damage detected via MAG 
immunostaining 28 d following sham and BCAS surgeries. TREM2 deficiency did not increase the 
probability of myelin damage occurring 28 d following BCAS surgery. (B) Frequency of white matter 
regions demonstrating damage in WT and TREM2-/- mice following BCAS. Fisher’s exact test. One 
tissue section analysed per animal. N = 6 – 7 independent animals per group. CC: corpus callosum 
HF: hippocampal fimbria, IC: internal capsule, OT: optic tract. 
 
 



































































































































































































































































































































Figure 5.11: Quantification of myelin damage detected by MAG immunostaining in white 
matter tracts of WT and TREM2-/- mice in cohort 1 (mixed coil)  28 d post BCAS surgeries. (A) 
Myelin damage in each white matter tract was quantified using a semi quantitive scoring method 
ranging from 0 (no damage) to 3 (extensive damage) via MAG immunostaining and scores from each 
hemisphere were summated providing a total possible score of 6 per white matter region. TREM2 
deficiency had no impact on the extent of myelin damage compared to WT mice in any white matter 
region analysed 28 d following BCAS. (B) Myelin damage scores were summated from all analysed 
white matter tracts providing a ‘total myelin damage’ score per animal. TREM2 deficiency had no 
impact on the extent of total myelin damage compared to WT animals 28 d following BCAS surgeries. 
Mann Whitney U test. Each data point represents an independent animal. Bars show median. One 
tissue section analysed per animal. N = 6 – 7 independent animals per group. 
 
 






















































Sham BCAS (WT) BCAS (TREM2-/-) 
Figure 5.12: Representative images of MAG immunostaining in white matter regions of WT and 
TREM2-/- mice in cohort 1 (mixed coil) 28 d post sham and BCAS surgeries. White matter regions 
including the corpus callosum, internal capsule and hippocampal fimbria (not shown) demonstrated 
negligible alterations in myelin integrity in response to BCAS in WT and TREM2-/- BCAS mice. Although 
the optic tract showed greatest damage (black arrows show areas of myelin debris) in response to 
BCAS the extent of damage was mild and no difference in pathology severity was observed between 
WT and TREM2-/- mice. Scale bar: 50 µm. 
 
 

















Cohort 2 Animals displaying 
myelin damage 

























Assessment of myelin integrity: Cohort 2 (2x 0.16 mm coil) 
 














































































































Figure 5.13: Frequency of WT and TREM2-/- mice demonstrating myelin damage detected 
by MAG immunostaining 28 d post sham and BCAS surgeries in cohort 2 (2x 0.16 mm coil). 
(A) Overall frequency of WT and TREM2-/- mice demonstrating myelin damage detected via MAG 
immunostaining 28 d following sham and BCAS surgeries. TREM2 deficiency did not increase the 
probability of myelin damage occurring 28 d following BCAS surgery. (B) Frequency of white 
matter regions demonstrating damage in WT and TREM2-/- mice following BCAS. Fisher’s exact 
test. One tissue section analysed per animal. N = 6 – 9 independent animals per group. CC: corpus 
callosum HF: hippocampal fimbria, IC: internal capsule, OT: optic tract. 
 
 





























































































































































































































































































































Figure 5.14: Quantification of myelin damage detected by MAG immunostaining in white matter 
tracts of WT and TREM2-/- mice 28 d post BCAS in cohort 2 (2x 0.16 mm coil). (A) Myelin damage 
in each white matter tract was quantified using a semi quantitive scoring method ranging from 0 (no 
damage) to 3 (extensive damage) via MAG immunostaining and scores from each hemisphere were 
summated providing a total possible score of 6 per white matter region. TREM2 deficiency had no 
impact on myelin damage in the CC, OT and HF compared to WT mice 28 d following BCAS. However, 
a significant increase in myelin damage was observed in the IC of TREM2-/- mice compared to WT 
mice 28 d following BCAS surgery. (B) Myelin damage scores were summated from all analysed white 
matter tracts providing a ‘total myelin damage’ score per animal. TREM2-/- mice demonstrated a non-
significant increase in myelin damage compared to WT mice following 28 d BCAS. *P ≤ 0.05. Mann 
Whitney U test. Each data point represents an independent animal. Bars show median. One tissue 
section analysed per animal. N = 6 – 9 independent animals per group. CC: corpus callosum HF: 
hippocampal fimbria, IC: internal capsule, OT: optic tract. 
 
 
























































Sham BCAS (WT) BCAS (TREM2-/-) 
Figure 5.15: Representative images of MAG immunostaining in white matter tracts of WT and 
TREM2-/- mice 28 d post BCAS and sham surgeries in cohort 2 (2x 0.16 mm coil). White matter 
regions including the corpus callosum, internal capsule and optic tract demonstrated diffuse myelin 
damage in WT mice following BCAS whilst this was further exacerbated in the internal capsule in 
TREM2-/- mice. Black arrows demonstrate examples of myelin debris. White arrows demonstrate 
examples of vacuolation. CC: corpus callosum, HF: hippocampal fimbria, IC: internal capsule, OT: optic 
tract. Scale bar: 50 µm. 
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5.4.3.3 Assessment of microgliosis 
Investigation of glial responses was restricted to cohort 2 (2x 0.16 mm coil) only as animals 
demonstrated robust white matter pathology following BCAS. IBA1 immunostaining was 
assessed and IBA1+ cell bodies quantified in white matter tracts and whole brain sections to 
characterise the impact of TREM2 deficiency on IBA1 cell responses to BCAS. Assessment 
of IBA1 immunostaining demonstrated accumulation of cells with an amoeboid morphology 
and shortened thickened processes in regions of robust pathology characteristic of cell 
activation. Morphologically, TREM2-/- IBA1+ cells appeared less hypertrophied compared to 
WT microglia in areas of pathology and were reduced in density (fig. 5.18).  
In response to BCAS, TREM2-/- mice demonstrated significantly less IBA1+ cells in the optic 
tract compared to WT animals (p ≤ 0.05) whilst no differences were observed in other analysed 
white matter tracts (p ≥ 0.05) (fig. 5.16). Furthermore, TREM2-/- mice demonstrated no 
difference in total IBA1+ cell number across whole brain sections compared to WT mice 
following BCAS (fig. 5.17).  As the extent of myelin damage varied between WT and TREM2-
/- mice, IBA1+ cell counts calculated from whole brain sections were plotted against myelin 
damage scores to assess how TREM2 impacted microglial number for a given severity of 
white matter damage. Plotting total IBA1+ cell numbers calculated from whole brain sections 
against total myelin damage scores revealed IBA1+ cell number positively correlated with 
white matter damage in WT mice (p ≤ 0.001, R2 :0.89) whilst this relationship was tempered in 
TREM2-/- animals (p ≤ 0.05, R2:0.46) (fig. 5.19). 
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Figure 5.16: Quantification of IBA1+ cell number in white matter tracts of WT and TREM2-/- 
mice 28 d post BCAS. TREM2-/- mice had significantly less IBA1+ cells in the OT compared to WT 
mice 28 d following BCAS whilst IBA1+ cell number was unchanged in other white matter regions.  *P 
≤ 0.05. Welch’s unpaired t test. Each data points represents a value averaged from 8 regions of 
interest measuring 0.2mm2 placed across each white matter tract in left and right brain hemispheres. 
One tissue section was analysed per animal. Data show mean ± SEM. N = 6 – 9 independent animals 
per group. 
 
Figure 5.17: Quantification of total IBA1+ 
cell number in whole brain sections of WT 
and TREM2-/- mice 28 d post BCAS. IBA1 
cell number was unchanged in TREM2-/- mice 
compared to WT mice in whole brain sections 
following 28 d BCAS. Welch’s unpaired t test. 
Each data point represents values obtained 
from one tissue section per animal. Data show 



























Figure 5.18: Representative images of IBA1 immunostaining in the optic tract of WT and TREM2-
/- mice 28 d post BCAS. 28 d following BCAS surgeries, WT mice demonstrated accumulation of 
IBA1+ cells with an amoeboid morphology and shortened thickened processes in regions of robust 
pathology characteristic of cell activation (black arrows). However, TREM2-/- IBA1+ cells appeared less 
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Figure 5.19: The relationship between total IBA1+ cell number and overall myelin damage 28 d 
post BCAS in WT and TREM2-/- mice. Plotting total IBA1+ cell numbers calculated from whole brain 
sections against total myelin damage scores demonstrated IBA1+ cell number positively correlated with 
myelin damage in WT mice 28 d following BCAS whilst this relationship was tempered in TREM2-/- 
animals. *P ≤ 0.05, ***P ≤ 0.001. Spearman’s rank correlation. Each data point represents values 
obtained from one tissue section per animal. N = 8 – 9 independent animals per group. 
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5.4.3.4 Assessment of astrocyte reactivity  
GFAP immunostaining was also conducted to investigate whether TREM2 deficiency 
impacted astrocyte reactivity following BCAS. Assessment of GFAP immunostaining 
demonstrated hypertrophied astrocytes in areas of myelin damage characteristic of reactive 
gliosis (fig. 5.22). TREM2 deficiency did not affect GFAP coverage in white matter tracts (p ≥ 
0.05) (fig. 5.20) or whole brain sections (p ≥ 0.05) (fig. 5.21) following BCAS. Plotting total 
GFAP coverage across whole brain sections against total white matter damage scores 
revealed GFAP coverage positively correlated to total white matter damage (p ≤ 0.05, R2: 0.85) 



































































































































































































































































































































Figure 5.20: Quantification of GFAP in white matter tracts of WT and TREM2-/- mice 28 d post 
BCAS. GFAP % area was unchanged in TREM2-/- mice compared to WT mice in all white matter 
regions analysed 28 d following BCAS.  *P ≤ 0.05. Welch’s unpaired t test. Each data points represents 
a value averaged from left and right brain hemispheres from one tissue section per animal. Data show 
mean ± SEM. N = 6 – 9 independent animals per group.   
 
Figure 5.21: Quantification of GFAP in whole 
brain sections of WT and TREM2-/- mice 28 
d post BCAS. GFAP % area was unchanged in 
TREM2-/- mice compared to WT mice in whole 
brain sections  28 d following BCAS. Welch’s 
unpaired t test. Each data point represents a 
value obtained from one tissue section per 
animal. Data show mean ± SEM. N = 6 – 9 
independent animals per group. 
 
 






























Figure 5.22: Representative images of GFAP immunostaining in the optic tract of WT and 
TREM2-/- mice. 28 d following BCAS surgeries, WT animals demonstrated hypertrophied 
astrocytes in areas of myelin damage characteristic of reactive gliosis. TREM2-/- mice 
demonstrated similar changes in response to BCAS. Dotted lines mark optic tract border. Scale 
bar: 50 µm 
 
 




























 P R2 
BCAS (WT) * (0.0114) 0.85 
BCAS (TREM2-/-) * (0.0380) 0.71 
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Figure 5.23: The relationship between total GFAP coverage and overall myelin damage in WT 
and TREM2-/- mice 28 d post BCAS. Plotting GFAP % area calculated from whole brain sections 
against total myelin damage scores demonstrated GFAP % area positively correlated with myelin 
damage in WT mice whilst this relationship was party tempered in TREM2-/- mice.  *P ≤ 0.05. 
Spearman’s rank correlation. Each data point represents values obtained from one tissue section per 
animal. N = 8 – 9 independent animals per group. 
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 Discussion 
In the previous study, induction of BCAS using 0.18 mm internal diameter microcoils failed to 
induce white matter pathology or neuroinflammatory changes in C57BL/6Ntac mice. Although 
the precise reasons for this remain unclear, it is likely a combination of genetic factors due to 
mouse substrain and environmental factors (e.g. housing facility, temperature, pathogen 
status) contributed to the phenotype observed. Cerebral blood flow was not measured 
therefore it cannot be concluded if application of microcoils induced chronic cerebral 
hypoperfusion.  It was therefore crucial to optimise the BCAS model using microcoils with 
smaller internal diameters to precipitate robust white matter pathology in WT and TREM2-/- 
mice while using laser speckle flowmetry to validate perfusion status. Although cohort 1 (mixed 
coil) demonstrated mild and infrequent myelin pathology, cohort 2 (2x 0.16 mm coil) 
demonstrated diffuse myelin damage. In the absence of TREM2 expression, IBA1+ cell 
number was reduced in areas of myelin damage. Furthermore, several TREM2-/- mice 
exhibited infarcts in the internal capsule which were absent in WT mice suggesting TREM2 
exerts protective effects following BCAS.  
Previous reports have demonstrated both BCAS techniques induce robust white matter 
pathology (Shibata, et al., 2004, Miki, et al., 2009, Fowler, et al., 2018). In the current study, 
use of the mixed coil approach had a mortality rate of 16 % comparable with previous studies 
(Miki, et al., 2009, Fowler, et al., 2018). Although this was increased to 32 % in cohort 2 (2x 
0.16 mm coil), this was substantially less than that reported by Shibata et al. (2004) (75 %) 
(Shibata, et al., 2004). It is likely a combination of genetic factors due to mouse substrain and 
environmental factors including housing facility, temperature and pathogen status contributed 
to reduced mortality. Boehm-Sturm et al. (2017) also reported reduced mortality using 0.16 
mm internal diameter microcoils (Boehm-Sturm, et al., 2017). However, this is likely due to the 
fact this group extended the period between microcoil placement from 30 min to 24 h during 
which compensatory mechanisms such as autoregulation and adaptive hypoxic responses 
may have conferred protection to chronic cerebral hypoperfusion.  
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Assessment of cerebral blood flow by laser speckle flowmetry confirmed both BCAS 
techniques induced acute reductions in cerebral blood flow in WT and TREM2-/- mice. In 
cohort 1 (mixed coil), induction of BCAS caused an initial ~35 % reduction in cerebral blood 
flow in both WT and TREM2-/- animals compared to shams. Although previous studies report 
clear hemispheric differences in cerebral blood flow following microcoil placement this was not 
observed in the current study. Furthermore, previous reports demonstrate more substantial 
reductions in cerebral blood flow following microcoil placement (Miki, et al., 2009, Fowler, et 
al., 2018). Strain difference is an unlikely contributor as C57BL/6J and C57BL/6N mice do not 
demonstrate overt differences in circle of Willis anatomy (Zhao, et al., 2019). The BCAS 
procedure was conducted in a similar manner and factors known to influence cerebrovascular 
responses such as temperature as well as depth and duration of anaesthesia were controlled 
to minimise impact on cerebral blood flow. It therefore remains unclear why animals did not 
demonstrate clear hemispheric differences in cerebral blood flow. 
Furthermore, the data suggests recovery of cerebral blood flow 28 d after BCAS in cohort 1 
(mixed coil) close to sham levels and may explain why WT and TREM2-/- mice demonstrated 
mild and infrequent white matter pathology. However, it must be noted that a large number of 
WT of TREM2-/- mice had to be excluded from the 28 d BCAS group as the laser speckle 
equipment was serviced mid-study. Following servicing, all recorded blood flow flux values 
demonstrated an upward shift (fig. 5.24). Therefore, all BCAS animals with 24 h data recorded 
prior to servicing with 28 d data acquired afterwards were excluded as these data could not 
be used. WT and TREM2-/- 28 d BCAS groups therefore have low n numbers within this cohort 
(n = 3) which may not accurately represent cerebral blood flow dynamics in WT and TREM2-
/- mice following BCAS.  
 







Using 0.16 mm internal diameter microcoils bilaterally induced a greater degree of 
hypoperfusion with both WT and TREM2-/- animals demonstrating a 50-60 % reduction in 
cerebral blood flow 24 h following BCAS comparable with previous studies (Shibata, et al., 
2004, Boehm-Sturm, et al., 2017). Furthermore, cerebral blood flow remained reduced after 
28 d with no differences observed between WT and TREM2-/- mice. As WT and TREM2-/- 
mice demonstrated similar cerebral blood flow profiles it is unlikely TREM2 deficiency affects 
cerebrovascular architecture or cerebral blood flow regulation. Kawabori, et al. similarly 
demonstrated TREM2 deficiency did not impact on cerebral blood flow in response to MCAO 
(Kawabori, at al., 2015). Furthermore, carbon black perfusion of the non-diseased brain 
demonstrated no overt differences in cerebrovascular architecture between WT and TREM2-
/- mice (Kawabori, at al., 2015). 
As laser speckle flowmetry only enables quantification of cortical blood flow, it is unclear how 
blood flow may differ in deeper subcortical regions. Use of arterial spin labelling has 
demonstrated cerebral blood flow is further reduced in subcortical regions following BCAS 
(Hattori et al., 2016b, Morimoto et al., 2018). How TREM2 deficiency impacts cerebrovascular 
integrity in deeper subcortical regions remains unclear. Microglia and macrophages have been 
suggested to play key roles in angiogenesis and arteriogenesis during development and in 
response to injury (Fantin et al., 2010, Liu et al., 2016). However, the role of TREM2 in this 
context remains unclear. Reduced microvessel density has been demonstrated at the infarct 
border in TREM2-/- mice following MCAO suggestive of impaired angiogenesis (Kawabori, et 
B e fo r e  s e r v ic e Af te r  s e r v ic e
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e Figure 5.24: Baseline laser speckle 
flowmetry flux values prior to, and after 
servicing. Following servicing, all recorded 
blood flow flux values demonstrated an 
upward shift. ****P ≤ 0.0001. Student’s 
unpaired t test. Each data point represents an 
individual animal. Data show mean ± SEM. N 
= 11 independent animals per group.  
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al., 2015). Furthermore, recent whole genome sequencing of CNS tissue identified region and 
time-dependant changes in endothelial gene networks in the absence of TREM2 expression 
suggesting cerebrovascular function may be altered in TREM2-/- mice (Carbajosa et al., 
2018). Neuroimaging studies have demonstrated Nasu Hakola disease patients exhibit 
reduced cerebral perfusion and glucose metabolism (Ueki et al., 2000, Montalbetti et al., 
2005). Similar findings have also been observed in TREM2 p.T66M knock in mice suggesting 
TREM2 may play key roles in regulation of cerebrovascular integrity and brain glucose 
metabolism (Kleinberger et al., 2017).  
Perivascular macrophages (PVM) also express TREM2 (Chertoff et al., 2013). In addition to 
clearance of waste products from the brain parenchyma, PVMs are also suggested to regulate 
peripheral cell recruitment, cerebrovasculature remodelling and regulation of cerebral blood 
flow (Faraco et al., 2017). Given the multifaceted roles of TREM2 in microglial and 
macrophage responses, it could be argued TREM2-/- PVMs may also impact cerebrovascular 
integrity and neuroinflammation. In future studies it will be interesting to decipher how TREM2 
regulates perivascular macrophage function. Given that microglia and macrophages interact 
with endothelial cells with key roles in cerebrovascular maintenance it will also be important to 
characterise the impact of TREM2 deficiency on endothelial function and microvessel 
architecture in response to BCAS as this may have contributed to exacerbated damage. 
Investigation of white and grey matter pathology in cohort 1 (mixed coil) revealed BCAS 
induced much milder and infrequent pathology compared to previous studies (Miki, et al., 
2009, Fowler, et al., 2017). Observed discrepancies are likely due to a variety of genetic 
differences between mouse substrains as well as environmental features impacting on BCAS-
induced white matter damage as discussed in chapter 4. This version of the BCAS model was 
therefore unfavourable due to the infrequent and mild nature of observed pathology. In cohort 
2 (2x 0.16 mm coil), 0.16 mm internal diameter microcoils induced more frequent and 
extensive neuropathology. However, a limitation of this model is the variability of observed 
pathology. While ~50 % of WT and TREM2-/- BCAS animals demonstrated damage limited to 
white matter regions with no grey matter involvement, the remaining 50 % demonstrated 
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additional grey matter pathology of varying severities. Furthermore, although 0.16 mm internal 
diameter microcoils were used bilaterally, clear hemispheric differences in the degree of 
damage were observed between animals.  
The spectrum of pathology observed is likely due to variation in cerebrovascular anatomy. 
Absence of both posterior communicating arteries is observed in 30 % of C57BL6/J mice whilst 
at least one posterior communicating artery is present in 60 % (McColl et al., 2004). Similar 
variation has also been observed in C57BL/6N mice (Zhao et al., 2019). Therefore, the extent 
of compensatory blood flow via the vertebral circulation will vary from mouse to mouse 
resulting in varying degrees of hypoperfusion and inconsistent pathology in regions dependent 
on posterior supply. Furthermore, microcoil internal diameter can vary by 0.1 mm impacting 
the degree of hypoperfusion induced by BCAS. Assessment of cerebral blood flow 
demonstrated variation in the degree of hypoperfusion 24 h after BCAS with reductions in 
cortical blood flow varying from 30 % to 84 % in WT and TREM2-/- animals.  
4 of 5 animals displaying extensive grey matter damage demonstrated cerebral blood flow 
reductions of 65 - 85 % 24 h after BCAS surgery. It could therefore be postulated that observed 
pathology may be due to acute ischaemic insult rather than longer durations of cerebral 
hypoperfusion. To distinguish damage caused by acute or sustained reductions in cerebral 
blood flow it will be important to characterise the temporal evolution of CNS pathology. If acute 
hypoperfusion following microcoil placement is a key cause of observed pathology the GCAS 
or ACAS models could be implemented to circumvent this. However, as substantial 
hypoperfusion was required to precipitate myelin damage it is unclear if either of these models 
would be suitable.  
Due to the extent of variation it may be necessary to apply criteria in future studies to exclude 
animals demonstrating extremely mild or severe hypoperfusion to ensure observed pathology 
is more consistent. As this was a characterisation study, exclusion criteria were not applied 
and all animals were included in analyses of cerebral blood flow and CNS pathology. Given 
the variation observed, an additional limitation of the current study is the low sample size . 
Larger sample sizes of 12-14 mice per group were intended to improve statistical, however, 
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this was not possible due to breeding issues and may explain why many of the data 
demonstrate non-significant trends.  
Although an increase in total grey matter damage was observed in TREM2-/- animals in cohort 
2 (2x 0.16mm) this did not reach statistical significance. The impact of TREM2 deficiency on 
neuronal  pathology remains unclear as the approach used for quantification lacked sensitivity. 
Although multiple regions may demonstrate neuronal pathology, the method of quantification 
does not reveal the degree by which they are affected. A more appropriate method would be 
to conduct NeuN immunostaining and quantify the degree of neuronal loss to provide an 
accurate measure of neuronal pathology. However, this was not completed due to time 
constraints and will be conducted in future.  
Assessment of MAG immunostaining demonstrated the optic tract was susceptible to 
hypoperfusion-mediated damage in WT and TREM2-/- mice. Similar findings were also 
reported by Sigfridsson et al. (2018) in FVB/C57Bl/6J F1 animals 28 d after BCAS 
(Sigfridsson, et al., 2018). Previous studies in rats have also reported susceptibility of the 
optic tract in response to chronic cerebral hypoperfusion (Wakita et al., 2002). This is likely 
due to the fact that the optic tract is supplied by the ophthalmic artery which branches from 
the internal carotid via the pterygopalatine and palatine artery. Therefore, application of 
microcoils may evoke greater hypoperfusion in regions such as the optic tract compared to 
other white matter regions. Given that the optic tract showed greatest susceptibility to 
hypoperfusion-mediated damage it will be important to assess visual function in future as 
behavioural studies utilise visualise cues.  
TREM2 deficiency exacerbated white matter damage in the internal capsule and trends for 
increased damage where observed in other white matter tracts. Compiling scores similarly 
demonstrated a trend towards increased total white matter damage in TREM2-/- mice. As 
TREM2 deficiency predominantly exacerbated damage in the internal capsule it could be 
suggested that TREM2 function may be region dependant. It is well known microglia 
demonstrate regional heterogeneity in the adult CNS (Grabert et al., 2016). White matter 
microglia demonstrate more pronounced morphological changes and upregulation of genes 
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associated with phagocytosis and activation with aging compared to grey matter microglia 
(Hart et al., 2012, Raj et al., 2017). Furthermore, patients with microgliopathies demonstrate 
extensive demyelination suggesting white matter microglia may differ phenotypically from grey 
matter microglia. It could be postulated the internal capsule is more dependent on TREM2 
function for maintenance of homeostasis resulting in exacerbated damage in its absence. 
However, it remains unknown whether microglia exhibit distinct phenotypic profiles within white 
matter regions or how TREM2 regulates this.   
Investigation of IBA1+ immunostaining revealed increased IBA1+ cell number in the optic tract 
in response to BCAS. Despite other regions demonstrating white matter damage, only 
negligible changes in IBA1+ cell number were observed. Given that the extent and spatial 
distribution of damage varied in the corpus callosum, internal capsule and hippocampal fimbria 
this could explain why these areas were not associated with a robust microglial response. 
Interestingly, TREM2 deficiency blunted increases in IBA1+ cell number following BCAS 
suggesting microglial responses to BCAS are TREM2 dependant. TREM2 deficiency has been 
suggested to attenuate various microglial functions including survival, proliferation, migration 
and phagocytic capacity. Recent studies implementing single cell sequencing have 
demonstrated TREM2 plays a key role in reprogramming microglia to respond to CNS 
perturbation through upregulation of genes associated with phagocytic and lysosomal 
pathways as well as lipid metabolism (Keren Shaul, et al., 2017). Although the impact of 
TREM2 deficiency in the context of chronic cerebrovascular insufficiency has never been 
investigated, studies have investigated the role of TREM2 in preclinical models of stroke and 
demyelination.  
TREM2-/- animals demonstrate worsened ischaemic damage and functional recovery in 
response to MCAO associated with reduced microgliosis (Kawabori, et al., 2015). A separate 
study similarly demonstrated increased infarct volume and neuronal apoptosis in response to 
MCAO following TREM2 gene silencing using small interfering RNA (Wu, et al., 2017). In the 
cuprizone model of oligodendrocyte degeneration and demyelination, TREM2-/- animals 
demonstrate worsened axonal pathology and reduced clearance of degraded myelin. 
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Furthermore, investigation of IBA1 immunostaining revealed reduced microglial coverage in 
areas of white matter pathology. Poliani et al. (2015) also observed reduced microgliosis in 
TREM2-/- animals accompanied by reduced myelin debris clearance and progressive loss of 
oligodendrocytes in response to cuprizone treatment (Poliani, et al., 2015).  
The findings of the current study are in line with previous reports describing reduced 
microgliosis in response to CNS injury in TREM2-/- mice. TREM2-/- microglia demonstrate 
decreased viability and reduced proliferation via defective Wnt/ β catenin signalling (Zheng et 
al., 2017). It could therefore be postulated that microglia were more vulnerable to cell death or 
failed to proliferate in response to BCAS resulting in less IBA1+ cells in areas of myelin 
pathology. It remains unclear however if the dampened microglial response to BCAS was 
predominantly due to increased cell death or reduced proliferation.  
As white matter damage was exacerbated in TREM2-/- mice this suggests TREM2 expression 
may protect white matter integrity in response to BCAS. Due to time constraints the results 
presented in this study show gross features of CNS pathology and glial responses associated 
with BCAS in WT and TREM2-/- mice Therefore, the precise mechanisms by which TREM2 
deficiency exacerbates white matter damage resulting from BCAS remain unclear.  
TREM2 deficiency may have exacerbated white matter damage by impairing microglial-
mediated clearance of myelin debris in the local microenvironment. TREM2 binds to various 
myelin components including phosphatidylethanolamine, sphingomyelin and 
phosphatidylserine and regulates expression of phagocytic receptors important for myelin 
debris clearance (Poliani et al. 2015, Cannon et al. 2012, Cantoni et al., 2015, Wang et al., 
2015). Microglial and macrophage-mediated removal of myelin debris is critical for effective 
remyelination to occur. Myelin debris prevents OPC differentiation into mature 
oligodendrocytes (Kotter et al., 2006). Furthermore, myelin components including Nogo-A, 
Semaphorin 4D, oliogodendrocyte myelin protein and MAG inhibit axonal growth (Huebner 
and Strittmatter, 2009).  
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In the current study it could therefore be suggested that in the absence of TREM2, microglial 
detection of white matter injury and subsequent activation was impaired, reducing microglial 
phagocytic capability leading to increased myelin debris accumulation. Accumulating myelin 
debris may have impaired OPC maintenance and maturation preventing remyelination, 
exacerbating white matter injury in response to BCAS.  
It could also be suggested that microglial degradation of myelin was impaired. Safaiyan et al. 
(2016) recently demonstrated microglial mediated uptake of myelin results in the accumulation 
of intracellular undegradable deposits which contributes to microglial senescence and immune 
dysfunction in the aging brain (Safaiyan et al., 2016). In response to BCAS, efficient 
degradation of internalised myelin may require TREM2 function as recent studies 
demonstrated TREM2-mediated microglial activation is associated with upregulation of 
various lysosomal genes (Forabosco et al., 2013, Keren-Shaul et al., 2017). Therefore, in the 
absence of TREM2 expression, impaired clearance mechanisms may have caused an 
accumulation of internalised myelin leading to microglial dysfunction and exacerbated 
pathology.  
Factors secreted by microglia also regulate various cell types within the gliovascular unit.  In 
vitro studies have demonstrated treatment of OPCs with conditioned microglial media 
promotes survival and maturation into myelinating oligodendrocytes (Zhang et al., 2006, Miron 
et al., 2013). Analysis of conditioned media reveals expression of various factors important for 
OPC survival and differentiation including vascular endothelial growth factor (VEGF), IGF-1 
and platelet derived growth factor AA (PDGF-AA) (Pang et al., 2013). In the cuprizone model 
of demyelination, microglia isolated from regions of remyelinating white matter demonstrate 
upregulation of genes associated with OPC proliferation and differentiation including TNFα, 
IGF-1 and fibroblast growth factor 2 (FGF-2) (Voss et al., 2012).  Furthermore, microglial 
activation in response to focal demyelination enhances OPC generation from neural stem cells 
in the subventricular zone suggesting microglia play key roles in OPC maturation in response 
to injury (Naruse et al. 2018). In addition, microglia also play a key role in early postnatal and 
adult OPC maintenance in the non-disease brain (Hagemeyer et al., 2017).  
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Increased numbers of OPCs and mature oligodendrocytes have been reported 28 d after 
BCAS demonstrating the regenerative capacity of white matter in response to chronic cerebral 
hypoperfusion (McQueen et al., 2015, Yu et al., 2018). Although it remains unclear, this 
process may in part be regulated by TREM2. TREM2-/- microglia demonstrate reduced 
expression of mediators implicated in OPC differentiation including IGF-1 in the cuprizone 
model of demyelination (Poliani et al., 2015). Therefore, it could be suggested that reduced 
secretion of factors necessary for survival and differentiation of OPCs into myelin forming 
oligodendrocytes impaired the regenerative capacity of white matter resulting in exacerbated 
pathology following BCAS  
As stated earlier, alterations in endothelial gene networks have been reported in TREM2-/- 
mice suggesting TREM2 regulated microglial responses may be crucial for endothelial function 
and cerebrovascular integrity. Microglia secrete various factors known to impact endothelial 
function including MMPs, ROS and cytokines such as IL-1β and TNF-α. In response to BCAS, 
ICAM1 expression closely correlates to the degree of microgliosis suggesting microglia 
contribute to endothelial activation in the context of chronic cerebral hypoperfusion (Kitamura 
et al., 2017). It could therefore be postulated microglial responses to BCAS may impact 
endothelial function and BBB integrity in TREM2-/- animals. However, the impact of TREM2 
deficiency on endothelial cell function remains unknown.  
In addition to IBA1+ cell number, GFAP coverage was also assessed to determine if TREM2 
regulated astrocyte responses. In the current study, TREM2 deficiency did not impact white 
matter GFAP coverage.  Kawabori et al. (2015) similarly reported no difference in GFAP 
coverage in TREM2-/- animals in a preclinical model of stroke (Kawabori, et al., 2015). 
However, TREM2-/- APPPS1 mice demonstrate reduced GFAP expression and astrocyte 
coverage (Jay et al., 2015). Similar findings were also observed in a model of tauopathy (Leyns 
et al., 2017). It could be postulated that the impact of TREM2 on astrocyte responses may be 
disease dependent. While astrocyte responses to misfolded protein may depend on microglial 
TREM2 expression, TREM2-independent astrocyte responses may be initiated following 
hypoxic insult.  
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It could also be suggested the impact of TREM2 deficiency on astrocyte responses is region 
specific. Although TREM2 deficiency did not impact white matter GFAP coverage, a non-
significant decrease in GFAP coverage was observed across whole brain sections in TREM2-
/- mice suggesting TREM2 deficiency may have impacted GFAP coverage elsewhere in the 
brain. Previous work in the McColl lab has demonstrated reduced GFAP coverage in CA1 
regions of the hippocampus in the non-diseased brain and reduced hippocampal GFAP 
expression in response to MCAO in TREM2-/- mice. In future studies it will therefore be 
important to further characterise the impact of TREM2 deficiency on GFAP coverage in other 
brain regions outside the white matter. As release of microglial derived factors are suggested 
to regulate astrocyte function in neurodegenerative disease it will be interesting to decipher 
how TREM2 may affect this (Liddelow et al., 2017). 
Overall, the data in the current study suggests TREM2 is necessary for microglial responses 
to BCAS and promotes white matter integrity.  Due to time constraints, the current study 
characterised only basic features of pathology resulting from BCAS. In future studies it will be 
important to characterise additional features of white matter pathology including axonal health 
and investigate vascular pathologies such as endothelial dysfunction and BBB breakdown. 
Furthermore, the distribution of pathology throughout the brain and the impact of TREM2 
deficiency remains unclear as pathological assessment was only conducted at the level of the 
hippocampus. In addition, although 50 % of animals demonstrated additional grey matter 
pathology investigation of glial responses was limited to the white matter. Therefore, further 
characterisation of the BCAS model is necessary to gain understanding on the distribution of 
CNS pathology and the impact of TREM2 deficiency.  
Although TREM2 deficiency impaired microglial responses to BCAS and exacerbated white 
matter damage the precise mechanisms remain unclear. It is therefore crucial to gain a deeper 
understanding of how microglia respond to BCAS and the impact of TREM2 deficiency using 
whole genome expression profiling. Given that TREM2 deficiency exacerbated white matter 
damage investigation of the microglial transcriptome may identify novel TREM2 regulated 
pathways which could be manipulated to promote neuroprotection in response to BCAS.  
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 Chapter 6: Investigating the impact of 
TREM2 deficiency on microglial phenotype 
and CNS immune cell composition in 
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 Introduction  
In the previous study, induction of BCAS using 0.16 mm internal diameter microcoils caused 
an acute and sustained reduction in cerebral blood flow in WT and TREM2-/- mice. 
Pathological assessment after 28 d revealed diffuse myelin damage and 50 % of animals 
demonstrated additional neuronal pathology covering several grey matter regions. In the 
absence of TREM2 expression, the extent of microgliosis in areas of myelin damage was 
reduced suggesting TREM2 plays a key role in mediating microglial/ macrophage responses 
to BCAS. Furthermore, TREM2 deficiency exacerbated myelin damage suggesting TREM2 
mediates protective responses to BCAS.  
Precisely how TREM2 regulates microglial responses to BCAS remains unclear. 
Transcriptomic studies investigating microglial phenotype in neurodegenerative diseases have 
identified microglia with a conserved phenotype named disease associated microglia (DAM). 
Interestingly, recent single cell sequencing suggests TREM2 is required for microglia to adopt 
a DAM phenotype associated with attenuation of neurodegeneration (Keren-Shaul et al., 
2017). However, it remains unknown if microglia adopt a similar phenotype in the context of 
chronic cerebrovascular-mediated degeneration. As TREM2 may confer protection to BCAS, 
further understanding of TREM2 regulated processes may lead to the identification of novel 
pathways which could be modulated to promote resilience and reduce disease burden.  
In the current study we therefore sought to develop and optimise a method of fluorescence 
activated cell sorting (FACS) to extract WT and TREM2-/- microglia from discrete areas of 
brain tissue and investigate the impact of BCAS on the microglial transcriptome. Tissue was 
dissected from white and grey matter enriched regions and microglia were extracted. 
Additional markers of myeloid and lymphoid cell populations were incorporated and flow 
cytometric analysis was conducted in parallel to characterise the impact of TREM2 deficiency 
on microglial phenotype and CNS cell composition in response to BCAS. 
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 Aims 
1. Develop and optimise a FACS-based method of microglial extraction to investigate 
BCAS-induced alterations to the microglial transcriptome in WT and TREM2-/- mice.  
 
2. Investigate alterations in microglial phenotype as well as CNS myeloid and lymphoid 
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 Methods 
 Animal procedures 
Male C57BL/6J mice (2 - 3 m) were purchased from Charles River and used to validate a 
FACS-based method for isolation of microglia from whole brain. Male WT and TREM2-/- mice 
(8 - 9 m) were used to investigate the impact of TREM2 deficiency on microglial phenotype 
and CNS cell composition following BCAS. N numbers were chosen based on power analysis 
of data from previous BCAS studies. To achieve a significance level of p < 0.05, a group size 
of 8 was required to reach a power of 0.8. Animals were randomised to receive BCAS ( 0.16 
mm internal diameter microcoils bilaterally) or sham surgeries described in section 2.4.1. Due 
to lack of breeding and limited animal numbers a TREM2-/- sham group was not included.   
Laser speckle contrast imaging described in section 2.4.2 was conducted to validate BCAS 
induced chronic cerebral hypoperfusion in WT and TREM2-/- mice. Measurements were taken 
prior to conducting BCAS and sham surgeries to obtain a baseline value and then again 24 h 
and 28 d after surgeries. Laser speckle contrast imaging and subsequent analysis was 
conducted by the author with blinding to treatment and genotype. After surgeries, animals 
were monitored, and weight loss recorded twice daily for 72 h and then twice weekly. Initial 







 Sham (n) BCAS (n) 
WT 7 11 
TREM2-/- - 8 
Table 6.1: Cohort sizes prior to conducting BCAS and sham surgeries.  
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 Tissue harvest 
Animals were transcardially perfused with saline 28 d after BCAS or sham surgeries as 
described in section 2.4.3 by Clare Latta. Subsequent dissection of white and grey matter 
regions for FACS isolation of microglia described in section 2.8.1 was conducted by the author.  
 FACS isolation of microglia and flow cytometric analyses 
FACS isolation of microglia and flow cytometric analyses were utilised to investigate the impact 
of TREM2 deficiency on CNS cellular composition and microglial phenotype in response to 
BCAS. Preparation of a brain cell suspension and antigen labelling of antigens was conducted 
by the author as described in sections 2.8.2 and 2.8.3. 
Upon acquisition, DAPI- viable cells were first identified and doublets excluded.  Microglia 
were identified as Ly6C-CD11b+CD45lo cells and sorted directly into RLT lysis buffer. Myeloid 
and lymphoid populations analysed included microglia, macrophages, neutrophils and 
lymphocytes. Marker profiles in table 6.2 were utilised to distinguish different cell populations. 
Microglial CD45, CD11b and F4/ 80 MFI were also quantified to investigate the impact of 
TREM2 deficiency on microglial phenotype in response to BCAS. All analysis and 















 RNA extraction  
Extraction of microglial RNA was conducted by the author using a Qiagen RNeasy microplus 
kit following manufacturer’s instructions as described in section 2.9. RNA yield and purity was 
assessed using a nanodrop spectrophotometer. Samples were then stored at -80oC.  
 Statistics 
Student’s or Welch’s unpaired t test was used to test for differences between two groups in 
FACS optimisation experiments. Two way ANOVA with Bonferroni correction for post hoc was 
used to investigate the impact of BCAS on cerebral blood flow in WT and TREM2-/- mice with 
genotype and surgery as between subject factors. One way ANOVA  with Bonferroni correction 
for post hoc was used to investigate differences in microglial CD45, CD11b and F4/ 80 MFI 
and CNS cell composition following BCAS in WT and TREM2-/- mice. All statistical analyses 
were performed with Graphpad Prism software version 7.4 with statistical significance 
considered p ≤ 0.05. 





Table 6.2: Cell surface marker profiles used to distinguish cell populations for flow 
cytometric analysis. 
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 Results 
 Validation of microglial enrichment 
To determine the efficiency of the FACS extraction method, the proportion of viable microglia 
were compared prior to and after sorting. Prior to sorting, Ly6C-CD11B+CD45lo microglia were 
identified as ~30 % of the viable brain suspension. Post sort, microglia were enriched 
constituting almost all viable cells indicating specific and efficient extraction of microglia via 
FACS (fig. 6.1). To further validate purity of isolated microglia, RNA was extracted and 
expression of microglial, neuronal and astrocyte genes was compared with whole brain tissue. 
Microglial genes Iba1 and Tmem119 were highly enriched in isolated microglia compared to 
whole brain tissue whilst expression of neuronal (Rbfox3) and astrocyte (Aldh1l1) genes were 
negligable suggesting the FACS procedure results in a highly enriched population of microglia 













 Proportion of viable microglia 
Pre-sort 30% 







Figure 6.1: Proportion of viable Ly6C-CD11b+CD45lo microglia prior to, and after FACS sorting. 








 Iba1 Tmem119 Rbfox3 Aldh1l1 Gapdh 
Whole brain 28.70 ± 
0.35 
28.73 ±   
0.25 
23.24 ±     
0.29 
25.57 ±        
0.19 



















































































































Figure 6.2: Comparison of signature gene expression in sorted microglia compared to whole 
brain. (A) Ct values for microglial genes (Iba1, Tmem119) and astrocyte (Aldh1l1) and neuronal genes 
(Rbfox3) in FACS isolated microglia and  whole brain tissue. (B) Relative expression of microglial 
genes (Iba1, Tmem119) and astrocyte (Aldh1l1) and neuronal genes (Rbfox3) in FACS isolated 
microglia compared to whole brain tissue. Relative to whole brain tissue, microglial transcripts were 
highly enriched in FACS isolated microglia whilst expression of astrocyte and neuronal transcripts was 
negligible. Gapdh was used as a house keeper gene. Data show mean ± SEM. Each data point 
represents an independent microglial extraction from one brain hemisphere. N = 4 independent 
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 Optimisation of fluorescence activated cell sorting of 
microglia  
6.4.2.1 Optimising microglial yield 
The methodology used to obtain a homogenous brain cell suspension for flow cytometric 
acquisition was further optimised for FACS-based microglial isolation to reduce cell death and 
maximise yield. Firstly, Pasteur pipettes were used instead of Gilson pipettes to limit cell death 
caused by shear stress when pipetting. The buffering agent HEPES (25mM, Fisher) was also 
added to all buffers to help maintain physiological pH throughout the isolation procedure.   
Many microglial extraction procedures also include an enzyme digestion step to promote cell 
dissociation from surrounding extracellular matrix prior to tissue homogenisation. However, a 
limitation of this method is that enzyme treatment is suggested to alter the microglial 
transcriptome (Kang et al., 2018). To determine the impact of enzyme treatment on microglial 
phenotype, microglial cell properties were characterised by flow cytometric analysis in samples 
treated with or without enzymes prior to tissue homogenisation. Investigation of microglial 
forward and side scatter properties demonstrated enzyme treatment significantly increased 
microglial forward scatter (size) and side scatter (granularity) values (p ≤ 0.001) (fig. 6.3A & 
B). Furthermore, microglia demonstrated increased CD45 MFI (p ≤ 0.05) suggesting enzyme 
treatment alters microglial activation status (fig. 6.3C).  
Flow cytometric analysis revealed enzyme treatment also reduced cell viability (p ≤ 0.05) (fig 
6.4B) and although statistically non-significant, reduced the yield of isolated microglia (fig. 
6.4C) (p ≥ 0.05).  Enzyme treatment of brain tissue prior to tissue homogenisation was 
therefore removed from the isolation protocol to reduce microglia phenotypic alterations and 
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Figure 6.3: Flow cytometric analysis of microglial properties in brain samples treated with or 
without enzymes prior to tissue homogenisation. (A) (B) Forward and side scatter properties of 
microglia treated with or without enzyme digestion prior to tissue homogenisation. Enzyme treatment 
significantly increased microglial forward scatter and side scatter values.  (C) (D) Quantification and 
representative histogram plots of CD45 MFI in samples treated with and without enzyme digestion. 
CD45 MFI was significantly increased in samples treated with enzyme. **P ≤ 0.01, ***P ≤ 0.001; 
Student’s unpaired t test. Each data point represents an independent microglial isolation from one 
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Figure 6.4: Microglial yield following FACS isolation with or without enzyme treatment. (A) 
Representative flow cytometry dot plots of viable cells in brain cell suspensions treated with or without 
enzymes prior to FACS. (B) Flow cytometric analysis of viable (DAPI negative) cells within brain cell 
suspensions treated with or without enzymes. Enzyme treatment significantly reduced the proportion 
of viable cells retrieved from brain tissue for FACS-based isolation. (C) Comparison of microglial 
yield in brain cell suspensions treated with or without enzymes. Enzyme treatment significantly 
reduced the yield of microglia obtained via FACS. *P ≤ 0.05; (B) Student’s unpaired t test (C) Welch’s 
unpaired t test. Each data point represents an independent microglial isolation from one brain 
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Prior to separating cells from myelin using a Percoll gradient, homogenisation of tissue is 
required to provide an even brain cell suspension. Previous studies in the McColl lab have 
demonstrated liquid-based homogenisation via 20 passes with a Dounce homogeniser is 
sufficient to provide a homogenous suspension from brain tissue following enzyme digestion 
(Grabert and McColl, 2018). As enzyme digestion was omitted it was predicted increasing the 
number of Dounce passes may further increase microglial yield. Investigation of microglial 
yield after homogenising brain tissue with 20 or 40 Dounce passes demonstrated microglial 
yield was enhanced when the number of Dounce passes was increased to 40 (p ≤ 0.05) (fig. 
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Figure 6.5: Quantification of microglial yield following liquid-based homogenisation of brain 
tissue using 20 and 40 passes of a Dounce homogeniser. Microglial yield was significantly 
increased when the number of Dounce passes was increased to 40 from 20 when homogenising 
brain tissue.  *P ≤ 0.05; Student’s unpaired t test. Each data point represents an independent 
microglial isolation from one brain hemisphere.  Data show mean ± SEM. N = 3 independent 
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6.4.2.2 Optimisation of microglial RNA extraction 
 Prior to RNA extraction efficient cell lysis is required. Isolated cells can be sorted into media 
and lysed after centrifugation or sorted directly into cell lysis buffer. An advantage of the latter 
method is that potential gene expression changes from sorting into media are minimised. 
Furthermore, subsequent cell death from sorting and centrifugation are avoided therefore 
maximising yield. However, it must be noted that cells are sorted in 5 nl sheath fluid. Therefore, 
if sorting high numbers of cells, dilution of cell lysis buffer by sheath fluid may impact lysis 
efficiency and RNA yield.  
To determine an optimal method of cell lysis prior to RNA extraction, total yield and quality of 
microglial RNA was quantified from microglia isolated into microglial media (see appendix III) 
and compared with microglia isolated directly into Qiagen RLT lysis buffer containing 10 % β-
mercaptoethanol. Although statistically non-significant, RNA yield was increased when 
microglia were sorted directly into lysis buffer (fig. 6.6A).  Furthermore, both methods of cell 
lysis yielded high quality RNA (fig. 6.6B). Therefore, microglia were sorted directly in cell lysis 
buffer in subsequent experiments to minimise potential alterations in microglial phenotype 



















































Figure 6.6: RNA yield and quality using different cell lysis methods following FACS sorting. (A) 
Total RNA yield was increased if microglia were sorted directly in RLT lysis buffer compared to media 
prior to RNA extraction. (B) RNA quality was higher if microglia were sorted directly into RLT lysis buffer 
compared to media prior to RNA extraction. Each data point represents an independent microglial 
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 Investigating the impact of TREM2 deficiency on microglial 
phenotype and cell composition in response to BCAS 
6.4.3.1 Animal recovery 
No animals receiving sham surgeries demonstrated adverse effects from surgery and survived 
until tissue harvest. 4 out of 19 BCAS mice were culled (21 % mortality) due to poor recovery 
characterised by circling or barrel rolling within the first 48 hours after surgery. Of these all 
were WT animals. Furthermore, 1 TREM2-/- mouse was excluded from analysis due to 
experimental error during preparation of the brain cell suspension. BCAS caused an average 
maximal 12.4 % loss of weight 8 d following surgery whilst TREM2-/- mice demonstrated an 
average maximal 12.8 % loss of weight 22 d following surgery (see appendix section 8.3.1). 





6.4.3.2 Laser speckle flowmetry  
Laser speckle contrast flowmetry was performed prior to surgery and 24 h and 28 d after 
surgery to validate that BCAS induced cerebral hypoperfusion and determine whether TREM2 
deficiency affected cerebral blood flow. Blood flow data was calculated as % change from 
baseline flow values. Analysis of percentage change in blood flow from baseline revealed 
significant effects of time F(2, 36)=62.400, p < 0.0001) and surgery (F(1, 18)=73.638, p < 
0.0001). However, there was no effect of genotype (F(1, 18)=0.083, p > 0.05) (fig. 6.7). A 
significant interaction between time and surgery was detected (F(2, 36)=30.252, p < 0.0001) 
and post-hoc analysis demonstrated that blood flow was significantly reduced in WT mice 
compared to shams 24 h (p<0.0001) and 28 d (p<0.0001) following BCAS (fig. 6.7). 
 
 Sham (n) BCAS (n) 
WT 7 7/ 11 
TREM2-/- - 7/ 8 
Table 6.3: Final cohort sizes 28 d following BCAS and sham surgeries. 
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Figure 6.7: Quantification of cerebral blood flow in WT and TREM2-/- mice 28 d post sham and 
BCAS surgeries. (A) Representative laser speckle images showing cortical cerebral blood flow in 
sham and BCAS WT and TREM2-/- mice at baseline, 24 h and 28 d after surgery. (B) Quantification 
of cerebral blood flow in sham and BCAS WT and TREM2-/- mice at baseline, 24 h and 28 d after 
surgery. 24 h following BCAS surgery, WT and TREM2-/- mice demonstrated a 61.52 % and 70.11 
% reduction in cerebral blood flow compared to sham animals, respectively. After 28 d cerebral blood 
flow remained reduced and WT and TREM2-/- mice demonstrated a 62.69 % and 50.11 % reduction 
in cerebral blood flow compared to sham animals. TREM2 deficiency had no impact on cerebral blood 
flow. ****P ≤ 0.0001 WT BCAS vs WT sham; Two way ANOVA with Bonferroni correction for post 
hoc. Data show mean ± SEM. N = 7 independent animals per group.  
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6.4.3.3 The impact of TREM2 deficiency on microglial phenotype 
in response to BCAS 
Microglial CD45, CD11b and F4/ 80 MFIs were assessed to investigate the impact of TREM2 
deficiency on microglial phenotype in white and grey matter enriched tissue following BCAS. 
One way ANOVA demonstrated a significant effect of surgery on CD45 MFI (F(2, 18)=4.774, 
p ≤ 0.01) in grey matter enriched tissue. Post hoc analysis demonstrated BCAS caused a 
significant increase in CD45 MFI (p ≤ 0.05) in WT mice compared to sham mice. Furthermore, 
this response was significantly reduced in TREM2-/- mice compared to WT mice following 
BCAS (p ≤ 0.05). Although an overall effect of surgery on CD11b and F4/ 80 MFI was not 
detected (p ≥ 0.05), post hoc analysis demonstrated BCAS caused a significant increase in 
CD11b MFI (p ≤ 0.05) and a significant decrease in F4/ 80 MFI (p ≤ 0.05) in WT mice compared 
to sham animals. Although this response was partly attenuated in TREM2-/- mice this did not 
reach statistical significance (F4/ 80: p = 0.120, CD11b: p = 0.248) (fig. 6.8).     
Within white matter-enriched tissue, a significant effect of surgery on microglial CD11b (F(2, 
18)=4.196, p ≤ 0.05), CD45 (F(2, 18)=4.774, p ≤ 0.05) and F4/ 80 (F(2, 18)=5.6, p ≤ 0.05) MFI 
was detected. Post hoc analysis demonstrated that BCAS significantly increased CD11b (p ≤ 
0.05) and CD45 (p ≤ 0.05) MFI and decreased F4/ 80 MFI (p ≤ 0.01) in WT mice compared to 
sham mice. Although this response was blunted in TREM2-/- mice following BCAS this did not 
























Marker MFI Sham BCAS (WT) BCAS (TREM2-/-) 
CD45 WM 1779 2578 1956 
CD45 GM 1793 2272 1755 
CD11b WM 19961 24737 22069 
CD11b GM 19352 22187 20987 
F4/80 WM 891 612 781 
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Figure 6.8: Quantification of WT and TREM2-/- microglial CD45, CD11b and F4/ 80 MFI 
intensities 28 d post BCAS and sham surgeries. (A) Microglial CD45, CD11b and F480 MFI 
values in grey and white matter regions in WT and TREM2-/- mice following sham and BCAS 
surgeries. (B)  In grey matter enriched tissue, WT animals demonstrated a significant increase in 
CD45 MFI 28 d following BCAS whilst this response was significantly attenuated in TREM2-/- mice. 
WT animals also demonstrated a significant increase in CD11b MFI and a significant decrease in 
F4/ 80 MFI 28 d following BCAS. Although this response was attenuated in TREM2-/- mice, this did 
not reach statistical significance. Within white matter-enriched tissue, CD11b and CD45 MFI were 
significantly increased whilst F4/ 80 MFI was significantly decreased in WT mice 28 d post BCAS. 
Although this response was attenuated in TREM2-/- mice this did not reach statistical significance. 
*P ≤ 0.05, **P ≤ 0.01; One way ANOVA with Bonferroni post hoc. Data show mean ± SEM. N = 7 
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6.4.3.4 The impact of TREM2 deficiency on CNS cell composition 
in response to BCAS  
Myeloid and lymphoid cell surface markers were used to assess the impact of TREM2 
deficiency on CNS immune cell composition in grey and white matter-enriched tissue following 
BCAS. One way ANOVA demonstrated no significant effect of surgery on microglia, neutrophil 
or lymphocyte cell counts in grey matter enriched tissue (p ≥ 0.05). However, each cell type 
showed a non significant increase following BCAS in WT mice (microglia: p = 0.473, neutrophil: 
p = 0.386, lymphocyte: p = 0.087) compared to sham animals. Furthermore, although non-
significant this response was partly reduced in TREM2-/- mice  (microglia: p = 0.179, 
neutrophil: p = 124, lymphocyte: p = 0.119) following BCAS (fig. 6.9). On the other hand, 
significant effects of surgery on macrophage cell counts (F(2, 18)=5.796, p ≤ 0.05) were 
detected. Post hoc analysis demonstrated that, in comparison to sham mice, BCAS caused a 
significant increase in macrophages in WT mice. Furthermore, this response was significantly 
reduced in TREM2-/- mice following BCAS (p ≤ 0.05).  
In white matter enriched tissue, main surgery effects were not detected for microglial or 
neutrophil cell counts. However, WT animals demonstrated a non significant increase in each 
cell type following BCAS compared to sham animals (microglia: p = 0.080, neutrophils: p = 
0.252). However, significant effects of surgery on  macrophage (F(2, 18)=7.301, p ≤ 0.01) and 
lymphocyte cell counts (F(2, 18)=7.371, p ≤ 0.01) were detected. Post hoc analysis 
demonstrated that, in comparison to sham mice, BCAS caused a significant increase in 
macrophages (p ≤ 0.01) and lymphocytes (p ≤ 0.01) in WT mice. However, TREM2-/- mice 
demonstrated no significant difference in cell number compared to WT mice following BCAS 
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Figure 6.9: Quantification of CNS myeloid and lymphoid populations in WT and TREM2-/- mice 
28 d post BCAS and sham surgeries.  In grey matter enriched tissue, WT  mice demonstrated a 
significant increase in macrophages 28 d post BCAS and this response was significantly attenuated 
in TREM2-/- mice.  A non-significant increase in microglia, lymphocytes and neutrophils was also 
observed in WT mice. Although non-significant, this response was partly reduced in TREM2-/- mice. 
In white matter enriched tissue, macrophages and lymphocytes were significantly increased whilst a 
non-significant increase in microglia and neutrophils was observed 28 d post BCAS. TREM2-/- mice 
demonstrated no difference in cell number compared to WT mice 28 d post BCAS. *P ≤ 0.05, **P ≤ 
0.001. One way ANOVA with Bonferroni post hoc. Data show mean ± SEM. N = 7 independent 
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 Discussion  
In conclusion, the results presented in this study demonstrate a FACS-based method to extract 
microglia from whole brain was optimised enabling parallel flow cytometric analysis of cell 
phenotype and CNS cell composition. Investigation of microglial phenotype and CNS cell 
composition revealed TREM2 deficiency blunted microglial activation and peripheral leucocyte 
recruitment. Although microglia were isolated from grey and white matter regions and RNA 
extracted, whole genome expression profiling of WT and TREM2-/- microglia was not 
completed due to time constraints. However, information on microglial RNA yield and quality 
can be found in appendix II. Future studies will utilise RNA sequencing to investigate the 
impact of chronic cerebral hypoperfusion on the microglial transcriptome and role of TREM2 
in this context. Such studies will reveal important functions of microglia and distinguish if 
microglia and TREM2 function differs spatially between white and grey matter regions.  
The isolation procedure implemented in the current study was based on a method developed 
by Grabert et al. (2016) which utilised magnetic bead isolation to extract CD11b+ cells from 
whole brain (Grabert, et al., 2016). Although this was demonstrated as an efficient method to 
extract highly enriched populations of microglia, it cannot distinguish resident microglia from 
infiltrating CD11b expressing cells. Therefore, while this may be sufficient for isolation of 
microglia in the non-diseased brain, this method may not be suitable for isolation of microglia 
under inflammatory conditions. An advantage of FACS-based extraction is that additional 
antibodies and gating strategies defining cell populations based on combinatorial marker 
expression can be used for precise detection and isolation of cell populations and parallel flow 
cytometric analysis of cell phenotype and composition.   
In the current study, microglia were identified and distinguished from other macrophage 
populations based on CD45 expression. Steady state microglia were identified as Ly6G-Ly6C-
CD11b+CD45lo whilst macrophages were identified as Ly6G-Ly6C+CD11b+CD45hi. Under 
inflammatory conditions it becomes increasingly difficult to distinguish microglia from 
macrophages as microglia upregulate CD45 expression. Although microglia upregulated 
CD45 expression in response to BCAS, macrophages could still be discriminated as they 
 
  187 
demonstrated 10-fold higher CD45 expression compared to microglia. Ideally additional 
microglial specific markers would have been used to further validate sorted cells were indeed 
microglia. TMEM119 was recently described as a microglial-specific marker enabling 
discrimination between microglia and macrophages under steady state and inflammatory 
conditions (Bennett et al., 2016). An anti-TMEM119 antibody was implemented to attempt to 
identify microglia in initial optimisation experiments however this could not be detected via flow 
cytometry and its use was discontinued. 
Although FACS-based extraction enables more precise isolation of microglia, various steps of 
the procedure including tissue homogenisation and antibody binding may alter the microglial 
transcriptome. Indeed, comparison of cell isolation strategies has demonstrated FACS-based 
isolation of microglia introduces artefact gene expression changes (Haimon et al., 2018). In 
future studies, the recently developed ‘RiboTag approach’ could be utilised to isolate microglial 
translatomes via immunoprecipitation of epitope-tagged ribosomes to avoid potential artefact 
introduced by cell isolation (Haimon, et al., 2018). To reduce potential transcriptome changes 
in current study, all samples were kept at 4 oC throughout the isolation procedure. 
Furthermore, enzyme treatment of brain tissue prior to tissue homogenisation was omitted.  
Although changes in microglial gene expression were not assessed to determine whether 
enzyme treatment of brain tissue altered the microglial transcriptome, this is likely to have 
occurred as flow cytometric analysis revealed enzyme treatment increased microglia size, 
granularity and CD45 protein expression. It could be postulated enzyme treatment may have 
activated microglia via protease activating receptors. Furthermore, debris generated following 
enzyme digestion and tissue homogenisation may have contributed to microglial activation. 
While previous studies suggest enzyme treatment improves microglial yield due to improved 
dissociation from extracellular matrix the current study demonstrated the opposite (Grabert & 
McColl, 2018). Although the precise reasons for this remain unclear, the extent of debris in 
brain cell suspensions following enzyme treatment may have impacted on microglial viability.  
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Flow cytometric and RT-QPCR analysis of isolated cells demonstrated the FACS extraction 
protocol provided a highly enriched population of microglia with minimal contamination of other 
CNS cell types. Furthermore, investigation of RNA integrity revealed the RNA extraction 
protocol yielded high quality RNA sufficient for bulk RNA sequencing to investigate the impact 
of TREM2 deficiency on the microglial transcriptome in response to BCAS. However, as stated 
earlier, transcriptome profiling could not be completed due to time constraints. Therefore, the 
current study focused on flow cytometric analysis of microglial phenotype and CNS cell 
composition in WT and TREM2-/- mice following BCAS.  
An unavoidable limitation of the current study due to sample processing requirements is that 
pathological assessment was not conducted in parallel. Therefore, the extent and distribution 
of pathology in WT and TREM2-/- mice is unknown. This would have proved useful to assess 
whether observed pathology was comparable to the previous study and determine whether 
changes in microglial phenotype and CNS cell composition were dependant on pathology 
severity. Given the variability of the data it is likely the extent of pathology varied between 
animals comparable to the previous study. Furthermore, it is likely BCAS induced both grey 
and white matter pathology as changes in microglial phenotype and CNS composition were 
observed in both regions.  
In the previous study, it was demonstrated that use of 0.16 mm internal diameter microcoils 
induced acute and sustained reductions in cerebral blood flow in WT and TREM2-/- animals. 
While WT and TREM2-/- demonstrated a 50 - 60 % reduction in cerebral blood flow, this was 
enhanced to 60 – 70 % in the current study. It is unclear why animals demonstrated greater 
cerebrovascular insufficiency as methodology remained consistent between studies. 
Investigation of microglial phenotype by flow cytometric analysis revealed upregulation of 
microglial CD11b and CD45 expression and downregulation of F4/ 80 in white and grey matter 
regions in response to BCAS. Interestingly, such changes were more prominent in white 
matter enriched samples. Pathological assessment in the previous study demonstrated white 
matter regions were predominantly affected in response to BCAS. Although the extent of 
pathology is unknown in the current study, such changes could reflect increased microgliosis 
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in white matter regions. Although non-significant, alterations in CD11b, CD45 and F4/80 
expression were blunted in TREM2-/- mice suggesting microgliosis was impaired. Similar 
TREM2-dependant effects have also been demonstrated by flow cytometry in the 5XFAD 
model of AD (Wang, et al., 2015).  
Recent single cell sequencing studies suggest TREM2 signalling is required for microglia to 
adopt a DAM phenotype associated with attenuation of neurodegeneration. Microglia with a 
DAM phenotype demonstrate downregulation of homeostatic genes including p2ry12, Cx3cr1, 
Cd33 and Tmem119 and upregulation of genes associated with phagocytic and lysosomal 
processes as well as lipid metabolism such as Axl, Lpl and Cst7 (Keren-Shaul, et al., 2017). 
While initial DAM activation is initiated by a TREM2 independent mechanism, TREM2 
signalling is required for further activation and up regulation of genes associated with 
phagocytosis, lysosomal processes and lipid metabolism. Although these microglia were 
originally identified in models of AD, a similar phenotype has also been observed in models of 
MS, ALS and aging suggesting the DAM phenotype is conserved across various 
neurodegenerative conditions (Deczkowska et al., 2018).  
Whether microglia exhibit a similar phenotype in the context of cerebrovascular-mediated 
neurodegeneration remains unknown. As alterations in microglial cell surface markers were 
blunted in the absence of TREM2 expression it could be suggested microglia were unable to 
adopt a DAM phenotype and instead acquired an intermediate activation state. Given that 
microglial phenotype is strongly influenced by microenvironment it could be argued microglia 
exhibit a distinct phenotype to those previously reported in other models of neurodegenerative 
disease. Further understanding of the impact of TREM2 deficiency on the microglial 
transcriptome in the current model by RNA sequencing may identify phenotypic changes 
specific to BCAS in addition to those commonly observed across multiple neurodegenerative 
disease settings which play a key role in mediating CNS pathology.  
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In addition to investigating the impact of TREM2 on microglial phenotype additional markers 
of myeloid and lymphoid populations were implemented to characterise the impact of TREM2 
deficiency on CNS cell composition in response to BCAS. In addition to increased numbers of 
microglia, infiltration of leukocytes was also observed suggesting resident microglia and 
macrophages do not exclusively contribute to the neuroinflammatory response to BCAS. 
Given that peripheral cell infiltration was observed it will be important to further profile 
infiltrating myeloid and lymphoid subsets and characterise the temporal evolution to 
understand how this is influenced by increasing durations of BCAS. Tissue obtained in the 
previous study could be utilised to validate findings from the current study and investigate the 
spatial distribution of cell subsets. Such studies will be useful for determining how cell 
composition relates to pathology severity in response to BCAS.   
Although vascular pathology was not characterised in the current study, it could be suggested 
leukocyte infiltration occurred as a result of endothelial dysfunction and BBB breakdown. 
Increased expression of endothelial adhesion molecules is observed in response to chronic 
cerebral hypoperfusion promoting leukocyte attachment and migration across the BBB 
(Huang, et al., 2010, Kitamura, et al., 2017). Recent in vivo two photon imaging also 
demonstrated leukocyte attachment and rolling in response to BCAS (Yata et al., 2014). 
Interestingly, previous studies demonstrate no evidence of myeloid and lymphoid cell 
infiltration in response to BCAS (Manso, et al., 2018, Fuchtemeier, et al., 2015). Manso, et al. 
utilised TMEM119 to co-label IBA1 cells to distinguish microglia from infiltrating macrophages 
and demonstrated microglia exclusively contribute to the IBA1+ cell population (Manso, et al. 
2018). As immunohistochemistry was implemented to investigate cell composition in the 
corpus callosum it could be postulated that leukocyte infiltration occurred elsewhere in the 
brain. Furthermore, cell labelling was limited to IBA1 and TMEM119 therefore it is unclear if 
infiltration of other cell types occurred.  
While lymphocyte infiltration was observed in the current study, Fuchtemeier, et al. (2015) 
demonstrated absence of lymphocyte subsets in the CNS in response to BCAS. As 
Fuchtemeier et al. (2015) utilised 0.18 mm internal diameter microcoils to induce chronic 
 
  191 
cerebral hypoperfusion it could be postulated resultant pathology was much less severe. 
Although DTI demonstrated BCAS induced white matter degeneration after 6 w, IHC was not 
implemented to characterise CNS pathology. In the previous study, use of 0.16 mm internal 
diameter microcoils resulted in extensive white matter pathology with 50 % of animals 
demonstrated additional grey matter pathology after 28 d. Although pathological assessment 
was not conducted in the current study it could be postulated that the extent of hypoperfusion 
induced more severe pathology evoking leukocyte recruitment from the periphery. 
In the absence of TREM2 expression only negligible alterations in cell number were observed 
in white matter enriched samples in response to BCAS.  In the previous study, initial 
assessment of IBA1+ cell number via IHC demonstrated no difference in IBA1+ cell number 
in WT and TREM2-/- mice except in the optic tract where consistent white matter damage was 
observed.  As the extent of white matter damage differed between WT and TREM2-/- mice, 
subsequent correction for between group differences revealed reduced IBA1+ cell number 
across multiple white matter tracts in TREM2-/- mice. 
Differences in microglial phenotype or cell number could not be corrected to account for 
potential differences in CNS pathology between WT or TREM2-/- BCAS animals in this study. 
This may therefore therefore explain why only modest differences were observed in TREM2 
deficient animals in response to BCAS. As leukocyte recruitment was observed in response 
to BCAS it will be crucial to determine how these cells contribute to disease pathogenesis. As 
TREM2 deficiency was associated with exacerbated white matter damage and reduced 
leukocyte infiltration it could be hypothesised that infiltrating leukocytes play a beneficial role 
in response to BCAS.    
Reduced peripheral infiltration may occur as TREM2 deficient animals demonstrate blunted 
neuroinflammatory responses in the diseased brain (Sieber, et al., 2013, Poliani, et al., 2015, 
Jay, et al., 2015, Leyns, et al., 2017). Microglial activation and subsequent secretion of 
inflammatory mediators influences expression of endothelial adhesion molecules as well as 
endothelial permeability and BBB integrity, all of which promote leukocyte attachments and 
migration across the BBB.  Therefore, TREM2 deficiency may impact on endothelial function 
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reducing peripheral immune cell infiltration into the CNS. Furthermore, reduced chemokine 
expression may directly impact on leukocyte migration within the CNS. 
It could also be postulated TREM2 deficiency directly impacts myeloid cells in the periphery 
reducing infiltration into the CNS. It remains unclear if TREM2 differentially regulates myeloid 
cell subsets in the context of neurodegeneration. Given that CNS-resident microglia and blood-
derived macrophages are capable of immunomodulation and phagocytosis, distinguishing 
how TREM2 regulates different myeloid subsets will provide greater understanding of the role 
of TREM2 in neurodegenerative disease. In future studies, bone marrow chimerism 
experiments could be conducted in WT and TREM2-/- animals to elucidate whether TREM2-
mediated effects in the CNS are primarily due to resident microglia and macrophages or blood-
derived myeloid cells.  In the context of stroke, TREM2-mediated post-stroke recovery is 
predominantly due to CNS resident microglia as opposed to peripheral derived macrophages 
(Kurisu et al., 2018). However, it remains unclear how TREM2-regulated processes impact 
different myeloid populations in the context of chronic vascular degenerative disease. 
Overall, the data presented in this study further demonstrate TREM2 plays a key role in 
mediating microglial responses to BCAS. Flow cytometric analysis revealed increased 
microgliosis as well as leukocyte recruitment occurs in response to BCAS suggesting CNS 
resident microglia and macrophages do not exclusively contribute to the neuroinflammatory 
response. However, it remains unclear if TREM2 regulates peripheral cell infiltration as flow 
cytometric analysis revealed only modest reductions in infiltration in TREM2-/- mice. As 
alterations in microglial cell surface protein expression were blunted this suggests TREM2 is 
required for microglial activation in response to BCAS. However, future work is required to 
obtain a broader, more detailed understanding of how TREM2 deficiency impacts microglial 
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 Summary of findings  
It was first hypothesised that chronic cerebral hypoperfusion would impact detrimentally on 
myelin integrity and induce inflammation. This was supported by data presented in chapter 5 
demonstrating induction of BCAS for 28 d caused loss of axon glial integrity across several 
white matter regions measured via MAG immunostaining (fig. 5.13 - 15). Quantification of 
microglial number by IBA1 immunostaining in chapter 5 demonstrated areas of white matter 
damage were associated with increased microglia suggesting that chronic cerebral 
hypoperfusion induced inflammation (fig. 5.16). This is further supported by flow cytometric 
data in chapter 6 showing increased numbers of microglia and peripheral leukocytes as well 
as upregulation of markers associated with microglial reactivity following chronic cerebral 
hypoperfusion (fig. 6.8 - 9).  It was further hypothesised that TREM2 deficiency would affect 
this response and exacerbate white matter damage. Data presented in chapter 5 illustrates 
white matter damage was exacerbated in TREM2 deficient mice (fig 5.14) and areas of white 
matter damage were associated with reduced numbers of microglia compared to WT mice (fig. 
5.16 - 19). Flow cytometric data in chapter 6 similarly demonstrated TREM2 deficient mice 
had reduced numbers of microglia and infiltrating leukocytes compared to WT mice following 
BCAS (fig. 6.9). In conclusion, the results presented in this thesis demonstrate optimisation of 
the BCAS model tailored to investigate the impact of TREM2 deficiency on CNS pathology 
and neuroinflammatory responses resulting from chronic cerebral hypoperfusion. In addition 
to demonstrating TREM2 plays an important role in regulating microglial responses to BCAS, 
the findings presented in this thesis suggest TREM2 confers protection against loss of myelin 
integrity following chronic cerebral hypoperfusion.  
7.2 BCAS as a suitable model of chronic cerebral hypoperfusion 
The BCAS model was utilised to mimic cerebral hypoperfusion observed in the elderly to 
obtain mechanistic insight into the contribution of TREM2 and neuroinflammation to white 
matter damage. Although previous studies have demonstrated use of 0.18 mm microcoils 
induces mild hypoperfusion leading to diffuse myelin damage after 28 d in C57BL/6J mice, 
this could not be replicated in C57BL/6Ntac mice most likely due to a combination of genetic 
 
  195 
and environmental factors. Microcoils with smaller internal diameters were therefore 
implemented in chapters 5 and 6 resulting in severe hypoperfusion (~50-60 % reduction in 
cerebral blood flow at 24 h and 28 d). Although this modification precipitated robust white 
matter pathology, select animals also demonstrated stroke-like grey matter pathology.  
Given that the elderly demonstrate much milder and gradual reductions in cerebral blood flow 
(~ 5% per decade during adult life) this questions whether the modified model accurately 
simulates hypoperfusion associated with cSVD (Marchal et al., 1992, Leenders, et al., 1990, 
Bentourkia, et al., 2000). Although it would be preferential to induce more gradual and milder 
hypoperfusion, this was not possible given that mild and moderate hypoperfusion evoked 
negligible and infrequent myelin damage as demonstrated in chapters 3-5. The GCAS or 
ACAS models described in section 1.4.2 could be implemented to avoid acute reductions in 
cerebral blood flow. However, given that substantial cerebral hypoperfusion was required to 
elicit robust neuropathology it is uncertain whether either of these models would be suitable.  
Although the extent of hypoperfusion induced by BCAS may not model age-related cerebral 
hypoperfusion accurately, pathological assessment demonstrated BCAS precipitated cSVD-
like pathology including diffuse myelin damage and focal white matter infarcts. Areas of myelin 
damage were also associated with neuroinflammation and manipulation of microglial function 
exacerbated myelin damage suggesting microglial dysfunction contributes to white matter 
damage. Therefore, the model still provides a useful platform to interrogate mechanisms by 
which cerebral hypoperfusion contributes to white matter damage warranting its future use.   
In future, it will be important to decipher whether loss of myelin integrity is also associated with 
cognitive deficits comparable to VCI patients. Given that previous preclinical studies have 
demonstrated mild white matter damage is sufficient to elicit spatial working memory defects 
it is likely animals in chapters 5 and 6 also demonstrated this as diffuse myelin damage was 
observed across multiple white matter tracts (Coltman et al., 2011). As several mice also 
demonstrated hippocampal degeneration it could be postulated mice also exhibited reference 
memory impairment. In future it will therefore be important to conduct behavioural 
assessments (e.g. barnes and radial arm maze) to characterise cognitive deficits caused by 
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BCAS. Furthermore, electrophysiology could be utilised to assess conduction velocity of white 
matter and assess whether structural impairments are also associated with functional 
impairment. 
7.3 Use of velocigene TREM2-/- C57BL6/Ntac mice 
TREM2-/- C57BL/6Ntac mice were generated by introducing a floxed velocigene ZEN-Ub1 
reporter cassette into the TREM2 locus preventing gene transcription and protein expression 
providing a useful tool to investigate the impact of TREM2 deficiency in health and disease. 
However, recent transcriptomic analysis of TREM2-/- microglia from this TREM2-/- line 
revealed reporter cassette insertion causes artificial upregulation of Treml1 (Kang, et al. 2018). 
Therefore, caution must be taken when interpreting the impact of TREM2 deficiency as the 
consequences of Treml1 upregulation on microglial function remain unknown. To circumvent 
this, Kang, et al. demonstrated removal of the floxed reporter cassette by rederivation 
abrogated artificial Treml1 upregulation (Kang, et al. 2018). While future experiments 
expanding on work described in this thesis will continue to use TREM2-/- mice containing the 
inserted reporter cassette to ensure consistency, rederived TREM2-/- mice lacking the reporter 
cassette will be utilised for new studies investigating the impact of TREM2 deficiency.  
 TREM2 and neuroinflammation in VCI  
Whilst neuroinflammation was initially believed to be a consequence of neurodegeneration, 
recent genetic studies identifying mutations in microglial-enriched genes predisposing to 
neurodegenerative disease demonstrate microglial dysfunction actively contributes to disease 
pathogenesis. However, precise understanding of microglial function within these disease 
contexts remains unclear due to the fact that both beneficial and detrimental functions have 
been reported. Studies investigating disease burden after microglial ablation report 
contradictory findings across different disease models. Elimination of microglia is associated 
with reduced neuronal loss and memory impairment in 5xFAD mice (Spangenberg et al., 
2016). Similarly, transient microglial depletion and repopulation rescues behavioural deficits 
following inducible neuronal loss (Rice et al., 2017). On the other hand, elimination of microglia 
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is associated with increased infarction and cognitive deficits in models of ischaemic injury (Jin 
et al., 2017, Szalay et al., 2016).  
In the context of VCI, preclinical studies utilising immunomodulatory drugs suggest 
suppressing microglial activation is beneficial for white matter structure and function (Manso 
et al., 2018). However, it cannot be definitively concluded that observed effects are due to 
inhibition of microglial activation as off target effects have been described on other cell types 
within the CNS including astrocytes, oligodendrocytes and neurons (Moller et al., 2016). More 
recently, elimination of microglia using a CSF1R inhibitor prior to BCAS was shown to reduce 
subsequent white matter injury and cognitive impairment suggesting microglia impact 
detrimentally on myelin integrity and cognition (Kakae et al., 2019).  
Whilst neuroinflammation is likely to contribute to aspects of VCI, treating gross inhibition of 
neuroinflammation as a therapeutic strategy may be too simplistic as not all neuroinflammation 
is damaging. Studies manipulating TREM2 function consistently demonstrate TREM2 
deficiency impairs the ability of microglia to detect and respond to CNS injury. In addition to 
reducing microglia clustering in areas of damage, TREM2 deficient microglia downregulate 
expression of genes associated with activation and demonstrate a more homeostatic-like 
profile. Interestingly, this is generally associated with worsened disease burden across 
disease models. In models of demyelination, TREM2 deficiency reduces microglial activation 
resulting in accumulation of myelin debris and worsened axonal pathology suggesting TREM2-
mediated responses are necessary for maintenance of myelin integrity and remyelination 
(Cantoni et al., 2015, Poliani et al., 2015).  
Although the role of TREM2 in cerebrovascular-mediated white matter injury remains 
understudied, the findings of this thesis provide novel insight into the impact of TREM2 
deficiency on myelin integrity and neuroinflammatory responses to cerebrovascular 
dysfunction. The results from chapter 5 and 6 demonstrate TREM2 deficiency blunted 
neuroinflammation and exacerbated myelin damage following BCAS. Therefore, although 
inhibition of microglial activation is suggested as a potential therapeutic strategy for VCI and 
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other dementia causing diseases, the findings presenting here suggest reducing microglial 
activation may in fact be detrimental. 
Although microglia secrete various inflammatory mediators which may contribute to loss of 
white matter integrity, microglia are also a source of trophic mediators and aid in the repair 
and resolution of injury. As discussed in chapter 5, clearance of myelin debris via phagocytosis 
is required for efficient remyelination (Lampron et al., 2015). Furthermore, microglia are a 
source of various trophic mediators required for OPC proliferation and maturation (Lloyd & 
Miron, 2019). Therefore, rather than complete inhibition, fine tuning of neuroinflammatory 
responses to promote regenerative processes whilst limiting damaging inflammation may 
provide a promising therapeutic strategy to enhance myelin integrity and reduce cognitive 
impairment and dementia. 
It is therefore crucial to gain a better understanding of microglial function and identify pro-
resolving and disease-associated phenotypes. Given that manipulation of TREM2 signalling 
further compromised myelin integrity following cerebral hypoperfusion it will be important to 
understand what downstream pathways are affected by TREM2 deficiency as exploitation of 
such pathways may confer resilience to myelin damage and cognitive impairment. As TREM2 
signalling modulates key genes involved in phagocytosis, lysosomal function and lipid 
metabolism, it could be postulated targeting microglial clearance and degradation of damaged 
myelin may ameliorate disease burden.  
Additional studies genetically manipulating microglial function will be crucial to establish the 
precise contribution of these processes to disease pathogenesis. Although drugs selectively 
targeting microglia are lacking, TREM2 could be considered as a potential target given that 
expression is limited to microglia and macrophages in the CNS.  However, the precise function 
of TREM2 still remains unclear, particularly as mixed effects have been observed across 
disease models. In addition to elucidating common functions across neurodegenerative 
diseases, it will be important to determine how TREM2 function evolves with disease 
progression. Whilst preclinical studies have demonstrated TREM2 function depends on 
disease progression in models of amyloidopathy, it remains unknown whether this is also 
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observed in other contexts of neurodegeneration (Jay et al. 2017). Furthermore, it remains 
unclear whether TREM2 functions reported in rodents are similarly observed in humans. Thus, 
although stimulation of TREM2 signalling may elicit protection to chronic cerebrovascular 
dysfunction, further understanding of TREM2 function is required. Despite this, the results 
presented in chapters 5 and 6 demonstrate immune dysfunction contributes to loss of myelin 
integrity following chronic cerebral hypoperfusion. Therefore, future work should continue to 
characterise the temporal cellular and molecular neuroinflammatory profile resulting from 
chronic cerebrovascular dysfunction and elucidate the contribution of microglia to disease 
pathogenesis.   
 Future work  
Future studies will continue to characterise the impact of TREM2 deficiency on microglial 
responses and disease burden following BCAS. Although TREM2 deficiency exacerbated 
myelin damage in the internal capsule, the impact of TREM2 deficiency on white matter 
function or behaviour remains unclear. As discussed in section 7.2, the barnes or radial arm 
maze could be utilised to characterise defects in working and reference memory caused by 
loss of white matter integrity or electrophysiology could be used to assess white matter 
conduction velocity. If TREM2 deficiency is also associated worsened memory function, it may 
be possible promoting aspect of TREM2 signalling will counteract this and ameliorate myelin 
damage and cognitive decline.  
Although TREM2 appears to be important for maintenance of white matter integrity the precise 
mechanisms remain unclear. Future transcriptomic analysis of microglia isolated from discrete 
brain regions following BCAS will provide insight into the impact of cerebral hypoperfusion on 
the microglial transcriptome. In addition to this, TREM2 dependant alterations in microglial 
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Whilst bulk RNA sequencing of microglia is useful for understanding how microglial phenotype 
is altered by disease, it cannot discriminate between functionally distinct subtypes within the 
same tissue. Microglia are highly complex and demonstrate functional plasticity to various 
factors including type, duration, location and severity of stimulus. The recent development of 
single cell sequencing illustrates the heterogeneity of microglia and enables more precise 
investigation of microglial function in health and disease. Identification of microglia exhibiting 
a DAM-like phenotype surrounding areas of CNS injury across models of neurodegenerative 
disease suggest microglia adopt a conserved phenotype to CNS injury (Krasemann, et al., 
2017, Keren-Shaul, et al., 2017, Hammond, et al., 2019). Although this phenotype is 
associated with neuroprotection in models of proteopathy, it remains unknown if similar 
subsets are observed in response to vascular insult. 
As VCI is characterised by a spectrum of pathologies in both the white and grey matter it is 
likely distinct microglial populations are associated with different vascular lesions (e.g. 
ischaemic and haemorrhagic). Future studies implementing single cell sequencing will be 
important for characterising microglial diversity in preclinical models of VCI. Such studies 
would establish whether microglia adopt DAM-like or functionally distinct phenotypes to those 
described in other models of neurodegenerative disease. To validate findings in mice, it will 
be crucial to assess microglial phenotype in VCI patients. Ex vivo magnetic resonance imaging 
(MRI) could be conducted on post-mortem tissue to identify vascular lesions and subsequent 
immunohistochemistry would reveal neuroinflammatory changes associated with imaged 
lesions. Furthermore, single nuclear sequencing of tissue containing vascular lesions 
identified via ex vivo MRI could be implemented to assess microglial phenotypic alterations 
associated with vascular pathology and determine whether microglia exhibit similar changes 
to those observed in preclinical models. This could also be complemented with RNAscope in 
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Given that TREM2 is suggested to be necessary for microglia to adopt a DAM-like phenotype 
it will be important to assess how TREM2 deficiency impacts the composition and spatial 
distribution of microglial subsets in response to BCAS and how this relates to function. It could 
be postulated that TREM2-deficient microglia initiate an abnormal response to hypoperfusion 
and contribute to myelin damage directly or that impaired responses to secondary events such 
as myelin debris and BBB dysfunction leads to accumulation of noxious stimuli and 
exacerbation of white matter damage following BCAS. As sequencing data provides a static 
picture of cell phenotype at a given point in time, it will be important to understand how 
microglial heterogeneity evolves over disease progression. Accumulation of data sets 
investigating the temporal response of WT and TREM2-/- microglia would identify microglial 
subpopulations associated with disease and establish how these populations develop with 
disease progression.  
As numerous stimuli are likely to influence microglial function following BCAS it will be 
important to decipher how microglia respond to such stimuli. Since completion of the work 
presented in this thesis, in vitro platforms are being developed by the McColl lab to 
characterise WT and TREM2-/- microglial responses to relevant stimuli such as hypoxia, 
inflammation and myelin debris. In addition to this, it will also be crucial to understand the 
impact of TREM2 deficiency on other cell types within the neurogliovascular unit given that 
multiple cell types contribute to VCI and dementia pathogenesis.  
As a FACS based method was optimised for isolation of microglia this could be further 
developed to enable dual isolation of additional cell types such as endothelial cells following 
BCAS. Subsequent gene expression profiling would provide a powerful tool to investigate how 
microglial and vascular cell transcriptomes are affected by BCAS and TREM2 deficiency and 
identify mechanisms by which TREM2 may increase susceptibility to CNS injury. As TREM2 
is highly enriched on microglia within the CNS, TREM2 dependant alterations in endothelial 
cell phenotype would suggest microglial perturbation also impacts endothelial function. To 
complement in vivo findings, use of mixed glial monolayer or transwell cultures in conditions 
simulating chronic cerebrovascular dysfunction (e.g. hypoxia) in combination with gene or 
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protein analyses would provide mechanistic insight into bidirectional signalling between 
microglia and other cell types. In addition to providing insight into environmental cues which 
drive cell phenotypes associated with disease, the above would elucidate how microglial 
dysfunction impacts on other cells within the neurogliovascular unit.   
 Conclusion 
In summary, the results presented in this thesis demonstrate TREM2 deficiency exacerbates 
loss of myelin integrity following BCAS lending support to the role of microglial dysfunction in 
cerebrovascular-mediated white matter injury. Given that white matter degeneration is a key 
contributor to age-related cognitive decline and dementia, development of microglial- specific 
drugs that exploit regenerative functions offers a potential strategy to limit white matter 
degeneration and cognitive impairment. Prior to this, further work is required to understand 
microglial phenotypes in VCI and other dementia causing diseases and how this relates to 
function. Use of transcriptomic approaches such as single cell sequencing will prove valuable 
for identifying microglial subsets associated with disease in rodents and human patients and 
elucidate common mechanisms across disease contexts which could be modulated to promote 
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Appendix I: Chapter 3 










Appendix II: Chapter 4Weight changes in WT mice following sham 
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Figure S8.1: Weight change (% of pre-surgery weight) 28 d following sham and BCAS 
surgeries. Sham and BCAS mice demonstrated a maximal 5.9 % and 5.3 % loss in weight 3 d 
following surgery, respectively. Data show mean ± SEM. N = 5 – 7 independent animals per group.  
Figure S8.2: Weight change (% of pre-surgery weight) following sham and BCAS surgeries 
(1 week). Sham and BCAS mice demonstrated a maximal 3.1 % and 5.6 % loss in weight 3 d 
following surgery, respectively. Data show mean ± SEM. N = 10 - 12 independent animals per 
group.  
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Figure S8.3: Weight change (% of pre-surgery weight) following sham and BCAS surgeries 
(1 month). Sham and BCAS mice demonstrated a maximal 2.8 % and 6.4 % loss in weight 3 d 
following surgery, respectively. Data show mean ± SEM. N = 8 – 10 independent animals per 
group.  
  
Figure S8.4: Weight change (% of pre-surgery weight) following sham and BCAS surgeries 
(3 months). Sham and BCAS mice demonstrated a maximal 5  % and 10.2 % loss in weight 3 d 
following surgery, respectively. Data show meanSEM.  n = 10 - 12 independent animals per group.  
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 Pathological assessment of WT and TREM2-/- mice 28 d 
after modified BCAS surgery (removal of 30 min recovery 
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Table S8.1: WT and TREM2-/- mice demonstrating neuronal pathology detected by H & E 
staining 28 d following modified BCAS surgeries. No animals demonstrated neuronal pathology 28 
d following modified BCAS surgeries. 
Table S8.2: WT and TREM2-/- mice demonstrating myelin damage detected by MAG 
immunostaining 28 d following modified BCAS surgeries. No animals demonstrated myelin 
pathology 28 d following modified BCAS surgeries. 
 
 












































































































:  Figure S8.5: Quantification of IBA1+ cells in white matter tracts of WT and TREM2-/- mice  28 d 
following BCAS surgeries. BCAS did not increase the number of IBA1+ cells in white matter tracts 
compared to sham animals.  Student’s unpaired t test. Data show mean ± SEM.  N = 3 independent 
animals per group. 
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 Apendix III: Chapter 5 
 Weight changes in WT and TREM2-/- 28 d following BCAS 
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Figure S8.7: Weight change (% of pre-surgery weight) in WT and TREM2-/- mice 28 d post  
sham and BCAS surgeries. BCAS caused a maximal 9.9 % and 12.4 % loss in weight 5 d following 
surgery in WT and TREM2-/- mice, respectively. Data show mean ± SEM. N = 6 – 9 independent 
animals per group.  
Figure S8.6: Weight change (% of pre-surgery weight) in WT and TREM2-/- mice following sham 
and BCAS surgeries (cohort 1) . BCAS caused a maximal 9.9 % and 8.9 % loss in weight in WT 
and TREM2-/- mice 3 d following surgery, respectively. Data show mean ±CAS caN = 6 - 7 
independent animals per group.  
  
 
  209 
 Appendix IV: Chapter 6: 
Weight changes in WT and TREM2-/- mice 28 d following 
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Figure S8.8: Weight change (% of pre-surgery weight) in WT and TREM2-/- mice 28 d post sham 
and BCAS surgeries. BCAS caused an average maximal 12.4 % loss of weight 8 d following surgery 
whilst TREM2-/- mice demonstrated an average maximal 12.8 % loss of weight 22 d following surgery. 
Data show mean ± SEM.  N = 7 independent animals per group.  
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 Yield and purity of RNA extracted from FACS-isolated 
microglia 
 











Total RNA yield (ng) 260/ 280 ratio 
 4.3 46.9 2.0 
 7.8 85.7 2.0 
Sham 6.0 65.3 2.1 
 7.7 84.2 2.3 
 6.6 73.1 1.9 
 13.1 144.8 1.8 
 5.3 57.9 2.5 
BCAS (WT) 14.2 156.0 1.9 
 8.7 95.4 2.0 
 9.4 103.6 2.3 
 8.6 94.6 2.3 
 5.8 63.8 1.9 
BCAS (TREM2-/-) 6.4 69.9 2.5 
 7.2 79.629 1.9 
 12.3 135.1 2.4 
Table S8.3: Yield and purity of RNA extracted from WT and TREM2-/- white matter microglia 
following sham and BCAS surgeries for future transcriptomic analysis. 
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 (ng/ μl) 
Total RNA yield (ng) 260/ 280 ratio 
 8.9 97.8 2.0 
 9.4 103.6 1.9 
Sham 6.5 72.2 2.8 
 10.6 116.3 2.1 
 19.6 215.8 2.3 
 16.6 182.1 1.9 
 7.4 81.3 1.8 
BCAS (WT) 13.5 148.8 2.1 
 14.1 155.3 2.2 
 10.9 119.4 1.9 
 12.7 139.7 1.8 
 10.7 117.5 2.1 
BCAS (TREM2-/-) 11.3 124.7 2.1 
 11.6 127.2 2.3 
 9.1 99.6 2.4 
Table S8.4: Yield and purity of RNA extracted from WT and TREM2-/- grey matter microglia 
following sham and BCAS surgeries for future transcriptomic analysis. 
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 Appendix V: Buffer constituents  
3.8% tri-sodium citrate: 3.8g tri-sodium citrate (Thermo Scientific)  in 100 ml dH20.  
4 % PFA: 40 g paraformaldehyde (Sigma) in 1 l phosphate buffer, pH 7.4 
Microglial media: DMEM/ F12 (1:1 mix) (Gibco), 10 % FBS. 
Saline: 9 g NaCl in 1 l dH20. 
Tri-sodium citrate antigen retrieval buffer: 2.94 g tri-sodium citrate in 1X PBS, pH 6 
FACS buffer: 0.5 g low endotoxin BSA (Sigma) in 500 ml PBS (-Ca2+, -Mg2+). For studies 
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